<SEC-DOCUMENT>0001104659-23-038584.txt : 20230330
<SEC-HEADER>0001104659-23-038584.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330060329
ACCESSION NUMBER:		0001104659-23-038584
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230329
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AVADEL PHARMACEUTICALS PLC
		CENTRAL INDEX KEY:			0001012477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37977
		FILM NUMBER:		23777019

	BUSINESS ADDRESS:	
		STREET 1:		BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
		STREET 2:		BALLYCOOLIN
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			15
		BUSINESS PHONE:		636-449-1830

	MAIL ADDRESS:	
		STREET 1:		16640 CHESTERFIELD GROVE ROAD
		STREET 2:		SUITE 200
		CITY:			CHESTERFIELD
		STATE:			MO
		ZIP:			63005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLAMEL TECHNOLOGIES SA
		DATE OF NAME CHANGE:	19960422
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>tm2310752d2_8ka.htm
<DESCRIPTION>FORM 8-K/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:avdl="http://avadel.com/20230329">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_avdl_avadel.com_20230329 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20230329_20230329 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001012477 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_071_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\EntityInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:EntityCentralIndexKey">0001012477</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:AmendmentFlag">true</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avdl-20230329.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-03-29to2023-03-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-29</xbrli:startDate>
        <xbrli:endDate>2023-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 5pt">&#160;</span></p>

<p style="font: 14pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_90D_edei--DocumentType_c20230329__20230329_zvGvEWZn4qPb"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:DocumentType">8-K/A</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Amendment No. 1)</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 5pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 5pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="font-size: 10pt">Pursuant
to Section 13 or Section 15(d)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="font-size: 10pt">of the Securities Exchange Act of 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Date of report
(Date of earliest event reported)</b>: <span id="xdx_900_edei--DocumentPeriodEndDate_c20230329__20230329_zEJJ0OJ05gRd"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 29, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityRegistrantName_c20230329__20230329_zlFl8pr8zpmf"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:EntityRegistrantName">AVADEL PHARMACEUTICALS PLC</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact Name of Registrant as Specified
in its Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 5pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20230329__20230329_z84gmPIJs0a9"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Ireland</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityFileNumber_c20230329__20230329_z3XssAFDrfR6"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:EntityFileNumber">001-37977</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20230329__20230329_z2cIzWiNpZK9"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:EntityTaxIdentificationNumber">98-1341933</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(Commission</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(IRS Employer</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">of incorporation)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">File Number)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_904_edei--EntityAddressAddressLine1_c20230329__20230329_zA7X12EASU48"><b><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:EntityAddressAddressLine1">10
        Earlsfort Terrace</ix:nonNumeric></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20230329__20230329_zbmmQnuRTlt"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:EntityAddressCityOrTown">Dublin 2</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCountry_c20230329__20230329_ziRetLdy1M25"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Ireland</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressPostalZipCode_c20230329__20230329_zPo6uisaPKNf"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:EntityAddressPostalZipCode">D02 T380</ix:nonNumeric></span></b></p></td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 50%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Not Applicable</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold">Registrant&#8217;s
telephone number, including area code:</span><b> +<span id="xdx_90B_edei--CityAreaCode_c20230329__20230329_zQs3REL5Fct7"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:CityAreaCode">353</ix:nonNumeric> </span></b><b><span id="xdx_90F_edei--LocalPhoneNumber_c20230329__20230329_z0d2FnFKl4J3"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:LocalPhoneNumber">1
901 5201</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Former name or former
address, if changed since last report)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation to  the registrant under any of the following provisions:</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90C_edei--WrittenCommunications_c20230329__20230329_zfYB4vj6hf1i"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20230329__20230329_zvWHmpOO25Z3"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementTenderOffer_c20230329__20230329_zWYVoYAS1vKk"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20230329__20230329_zNo2B38QwGKk"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 1pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="text-align: left; vertical-align: bottom">
    <td style="border: Black 1pt solid; padding: 2pt; vertical-align: bottom; width: 40%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; vertical-align: bottom; width: 20%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Trading<br />
 Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; vertical-align: bottom; width: 40%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Name of each exchange on which <br />
registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt; vertical-align: top; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90E_edei--Security12bTitle_c20230329__20230329_z6gfR2tq7ati"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:Security12bTitle">American
Depositary Shares*</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ordinary Shares, nominal value
$0.01 per share**</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; vertical-align: top; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90B_edei--TradingSymbol_c20230329__20230329_zpk7h5e0iAVl"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:TradingSymbol">AVDL</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20230329__20230329_zTg9qIZ8rQA8"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">*American Depositary Shares may be evidenced by American Depositary
Receipts. Each American Depositary Share represents one (1) Ordinary Share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 1pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">** Not for trading, but only in connection with the listing
of American Depositary Shares on The Nasdaq Global Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20230329__20230329_zpM6YSK4v6Vl"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Explanatory Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_906_edei--AmendmentDescription_c20230329__20230329_zNFuVTI2HSB9"><ix:nonNumeric contextRef="From2023-03-29to2023-03-29" name="dei:AmendmentDescription">March 29, 2023, Avadel Pharmaceuticals plc (the &#8220;Company&#8221;)
filed a Current Report on Form 8-K (the &#8220;Original 8-K&#8221;) to disclose that (i) the Company and Avadel Finance Cayman Limited,
a Cayman Islands exempted company (the &#8220;Issuer&#8221;) had entered into separate, privately negotiated exchange agreements (the &#8220;Exchange
Agreements&#8221;) with certain holders of its outstanding 4.50% exchangeable senior notes due October 2, 2023 and issued on April 4, 2022
(the &#8220;2023 Notes&#8221;) pursuant to which the Issuer will exchange approximately $96.2 million in aggregate principal amount of the
2023 Notes for an aggregate principal amount of new 6.00% exchangeable senior notes due April 1, 2027 (the &#8220;2027 Notes&#8221;) that
will be determined pursuant to the terms of the Exchange Agreements (the &#8220;Exchange Transactions&#8221;) as described in greater detail
in the Original 8-K and (ii) that Avadel CNS Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of the Company (&#8220;Avadel CNS&#8221;),
the Company, and each guarantor party thereto, and RTW Royalty II DAC (&#8220;RTW&#8221;) entered into a Purchase and Sale Agreement (the
&#8220;Royalty Purchase Agreement&#8221;), pursuant to which Avadel CNS sold to RTW the right to receive certain royalty payments from Avadel
CNS for a purchase price of up to $75.0 million in cash.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purpose of this Amendment No. 1 is solely to file the Royalty Purchase
Agreement as Exhibit 10.2 in a hyperlinked and text-searchable format.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 1in"><b>Item 1.01</b></td>
    <td style="font-size: 10pt"><b>Entry into a Material Definitive Agreement </b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Exchange Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On March 29, 2023, Avadel Finance Cayman
Limited, a Cayman Islands exempted company (the &#8220;<span style="text-decoration: underline">Issuer</span>&#8221;) and an indirect wholly-owned subsidiary of Avadel
Pharmaceuticals plc (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;), and the Company entered into separate, privately negotiated exchange
agreements (the &#8220;<span style="text-decoration: underline">Exchange Agreements</span>&#8221;) with certain holders of its outstanding 4.50% exchangeable senior notes
due October 2, 2023 and issued on April 4, 2022 (the &#8220;<span style="text-decoration: underline">2023 Notes</span>&#8221;) pursuant to which the Issuer will exchange
approximately $96.2 million in aggregate principal amount of the 2023 Notes for an aggregate principal amount of new 6.00%
exchangeable senior notes due April 1, 2027 (the &#8220;<span style="text-decoration: underline">2027 Notes</span>&#8221;) that will be determined pursuant to the terms of
the Exchange Agreements (the &#8220;<span style="text-decoration: underline">Exchange Transactions</span>&#8221;), in each case, pursuant to the exemption from registration
provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;). Following the
closing of the Exchange Transactions, approximately $21.2 million in aggregate principal amount of the 2023 Notes will remain
outstanding with terms unchanged. The Exchange Transactions are expected to close, subject to customary closing conditions, on or
after April 3, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The foregoing description of the Exchange
Agreements is only a summary and is qualified in its entirety by reference to the full text of the form of Exchange Agreement, which is
filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in Item 1.01 and Item 3.02.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The 2027 Notes will be issued pursuant to
an Indenture (the &#8220;<span style="text-decoration: underline">2027 Indenture</span>&#8221;), to be entered into by the Issuer, the Company and The Bank of New York Mellon,
as trustee (the &#8220;<span style="text-decoration: underline">Trustee</span>&#8221;). The 2027 Notes will be senior unsecured obligations of the Issuer and will be guaranteed
by the Company. The 2027 Notes will bear interest at a rate of 6.00% per annum from, and including, the closing date of the Exchange Transactions, payable semi-annually
in arrears on April 1 and October 1 of each year, beginning on October 1, 2023. In certain circumstances, the Issuer and the Company may
be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the
2027 Notes. The 2027 Notes will mature on April 1, 2027, unless earlier exchanged, repurchased or redeemed by the Issuer or exchanged
by the holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At any time prior to 5:00 p.m. (New York City time) on the
business day immediately preceding the maturity date, the 2027 Notes will be exchangeable at the election of holders at an initial
exchange rate (the &#8220;<span style="text-decoration: underline">Exchange Rate</span>&#8221;) equal to $1,000 divided by (i) if
the Company enters into an underwriting agreement (the &#8220;<span style="text-decoration: underline">Underwriting
Agreement</span>&#8221;) in respect of a firm commitment underwritten public offering that is broadly distributed in the reasonable
judgment of the Company acting in good faith of at least $40,000,000 of equity of the Company within five business days of the
execution of the Exchange Agreements (the &#8220;<span style="text-decoration: underline">Public Offering</span>&#8221;), (x) the
product of 1.25 and the public offering price per ADS in such Public Offering (the &#8220;ADS Public Offering Price&#8221;) to the
extent the Public Offering is marketed during market hours after a public announcement of launch or (y) the product of 1.15 and the
ADS Public Offering Price if the Public Offering is conducted as an &#8220;overnight&#8221; transaction, (ii) if the Company prices
an offering of at least $40,000,000 of equity of the Company that is not a Public Offering within five business days of the execution
of the Exchange Agreements, the product of 1.10 and the lowest of (x) the per share purchase price of the ADS, if any, in such
offering, (y) the simple average of the VWAPs for the ADS for each trading day during the five consecutive trading days ending
immediately prior to the pricing of such equity offering and (z) the simple average of the VWAPs for the ADS for each trading day
during the five consecutive trading days beginning on the first trading day following the pricing of such equity offering, or (iii)
if the Company has not entered into the Underwriting Agreement, purchase agreement or similar agreement in respect of an equity
offering described in either (i) or (ii) within five business days of the execution of the Exchange Agreements, the product of 1.10
and the simple average of the VWAPs for the ADS for each trading day during the five consecutive trading days beginning on the first
trading day following the earlier of Avadel's public announcement that the Public Offering did not price or notification to the
counterparties to the Exchange Agreements that no such equity offering shall take place, with such quotient rounded down to the
nearest 1/10,000th and subject to adjustment in accordance with the provisions of the Indenture, ADS per $1,000 principal amount of
the 2027 Notes (so long as the principal amount of such holder's 2027 Notes not exchanged is at least $200,000). If the Exchange Rate is determined pursuant to clause (iii), the Exchange Rate will be reset in connection with the maturity or
earlier repurchase, redemption or exchange of the remaining 2023 Notes in certain circumstances; provided that the 2027 Indenture
will include a limit on the issuance of ADSs, to the extent necessary for compliance with rules of The Nasdaq Global Market, above
which the Issuer would be required to settle exchanges with cash. Upon exchange, the 2027 Notes may be settled in cash, ADSs, or a
combination of cash and ADSs, at the Issuer's election.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Issuer may cause the then
outstanding principal amount of the 2027 Notes to be exchanged, in whole but not in part, at its option (the &#8220;<span style="text-decoration: underline">Mandatory
Exchange</span>&#8221;), prior to the close of business on January 15, 2027, if the last reported sale price of the ADSs has been at
least 130% of the quotient of $1,000 and the Exchange Rate then in effect on (x) each of at least 20 trading days (whether or not
consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date that the
Issuer provides notice of the Mandatory Exchange in accordance with the 2027 Indenture (the &#8220;<span style="text-decoration: underline">Mandatory
Exchange Notice Date</span>&#8221;); and (y) the trading day immediately before such Mandatory Exchange Notice Date, at the then
prevailing Exchange Rate, subject to adjustment described below. The Issuer may settle Mandatory Exchanges in cash, ADSs, or a
combination of cash and ADSs, at the Issuer&#8217;s election. Accrued and unpaid interest, if any, on 2027 Notes
subject to Mandatory Exchange to but excluding, the exchange date in respect of the Mandatory Exchange shall be paid by the Issuer
to holders of the 2027 Notes in cash concurrently with the delivery of the other exchange consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Exchange Rate will be subject to adjustment
in some events but will not be adjusted for any accrued and unpaid interest. Following a &#8220;Make-Whole Fundamental Change&#8221; (as
will be defined in the 2027 Indenture) or upon the Issuer&#8217;s issuance of a notice of redemption, the Issuer will increase the Exchange
Rate for a holder who elects to exchange its 2027 Notes in connection with such &#8220;make-whole fundamental change&#8221; or during
the related redemption period in certain circumstances. In addition, the Issuer will increase the Exchange Rate for a holder who elects
to exchange its 2027 Notes prior to January 15, 2027 or whose 2027 Notes are subject to a Mandatory Exchange in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Issuer may redeem for cash all of the 2027 Notes in connection
with certain tax-related events at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed plus accrued
and unpaid interest to, but excluding, the redemption date, but may not otherwise redeem the 2027 Notes. No sinking fund is provided for
the 2027 Notes, which means that the Company is not required to redeem or retire the 2027 Notes periodically.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">The 2027 Indenture will
include covenants that, subject to carveouts and exceptions, limit the ability of (1) the Company and the Issuer to incur secured debt,
(2) the Company&#8217;s subsidiaries (other than the Issuer) to incur unsecured debt, (3) the Company and its subsidiaries (including
the Issuer) to pay dividends and redeem equity and (4) the Company and its subsidiaries (including the Issuer) to transfer capital stock
of any subsidiary (other than the Issuer) that does not guarantee the 2027 Notes. Until such time that the Company achieves $25.0 million
in quarterly revenue from commercial sales in the United States of LUMRYZ<sup>TM</sup>, the 2027 Indenture will also require that the
Company and its subsidiaries (including the Issuer) maintain, on a consolidated basis, a minimum cash and cash equivalents balance of
at least $35.0 million, which will be reduced to $20.0 million after the first commercial sale of LUMRYZ in the United Sates after receipt
of final approval of the Company&#8217;s new drug application for LUMRYZ<sup>TM</sup> by the U.S. Food and Drug Administration (the &#8220;<span style="text-decoration: underline">FDA</span>&#8221;)
in the United States. In addition, in certain circumstances the Issuer will be required to make an offer to purchase the 2027 Notes with
cash equal to 50% of the net proceeds generated from licensing agreements, if any, with respect to research, the development or the commercialization
of LUMRYZ<sup>TM</sup> outside of the United States for a purchase price equal to 100% of the principal amount repurchased plus accrued
and unpaid interest. The 2027 Indenture will also include certain other customary covenants and events of default.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The foregoing descriptions of the 2027
Notes and the 2027 Indenture do not purport to be complete and are qualified in their entirety by reference to the 2027 Indenture
(which includes the form of the 2027 Note). A copy of the draft form of 2027 Indenture (which will include the form of the 2027
Note) is included as Exhibit C to the form of Exchange Agreement, a copy of which is filed as Exhibit 10.1 hereto and is
incorporated herein by reference. The final 2027 Indenture is expected to be attached as an exhibit to a Current Report on Form 8-K
to be filed by the Company following the closing of the Exchange Transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company offered the 2027 Notes to certain
holders of the 2023 Notes in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. The offer
and sale of the 2027 Notes to certain holders of the 2023 Notes did not involve a public offering, the solicitation of offers for the
2027 Notes was not done by any form of general solicitation or general advertising, and offers for the 2027 Notes were only solicited
from persons believed to be &#8220;qualified institutional buyers&#8221; within the meaning of Rule 144A promulgated under the Securities
Act. The 2027 Notes and any ADSs that may be issued upon exchange of the 2027 Notes will not be registered under the Securities Act,
and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration
requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Current Report on Form 8-K does not constitute
an offer to sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction
in which such offering would be unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Royalty Purchase</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On March 29, 2023, Avadel CNS
Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of the Company (&#8220;<span style="text-decoration: underline">Avadel
CNS</span>&#8221;), the Company and each guarantor party thereto, and RTW Royalty II DAC (&#8220;RTW&#8221;) entered into a Purchase
and Sale Agreement (the &#8220;<span style="text-decoration: underline">Royalty Purchase Agreement&#8221;</span>) pursuant to which
Avadel CNS sold to RTW the right to receive certain royalty payments from Avadel CNS (up to a 2.5x return on RTW&#8217;s investment) for a
purchase price of up to $75.0 million in cash. RTW will pay Avadel CNS (a) $30.0 million upon (i) amendment of the Company&#8217;s
existing convertible notes, (ii) receipt of FDA approval of LUMRYZ, (iii) the first shipment of LUMRYZ (&#8220;<span style="text-decoration: underline">Tranche
1 Payment</span>&#8221;), and (iv) other customary closing conditions and (b) $45.0 million, at Avadel CNS&#8217;s election, if the
Company&#8217;s quarterly net revenue equals or exceeds $25.0 million for any single quarter through and including the second
quarter of 2024 (&#8220;<span style="text-decoration: underline">Tranche 2 Payment</span>&#8221;), subject to customary closing
conditions. If Avadel CNS elects not to receive the Tranche 2 Payment on or prior to August 31, 2024, the option to receive the
tranche will expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under the Royalty Purchase Agreement,
RTW is entitled to receive royalties at a rate of 3.75% on net sales of LUMRYZ if the Tranche 1 Payment is made or 7.50% if
both the Tranche 1 Payment and Tranche 2 Payment are made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under the Royalty Purchase Agreement, Avadel
CNS has agreed to specified affirmative and negative covenants, including without limitation covenants regarding periodic reporting of
information by Avadel CNS to RTW, audit and inspection covenants, and certain restrictions on the ability of Avadel CNS or any of its
subsidiaries to incur indebtedness (which restrictions are eliminated after the achievement by RTW of a specified return on its investment).
The Royalty Purchase Agreement also contains representations and warranties, other covenants, indemnification obligations, and other provisions
customary for transactions of this nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The foregoing description of the Royalty Purchase
Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Royalty Purchase Agreement,
a copy of which is filed as Exhibit 10.2 hereto and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 1in"><b>Item 3.02</b></td>
    <td style="font-size: 10pt"><b>Unregistered Sales of Equity Securities</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth in Item 1.01 of this Current Report on Form
8-K is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in; font-size: 10pt"><b>Item 9.01</b></td>
    <td style="font-size: 10pt"><b>Exhibits</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 6%">10.1**</td>
    <td style="width: 94%; text-align: justify">Form of Exchange Agreement between the Issuer, the Company and certain holders of the 2023 Notes.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2310752d2_ex10-2.htm" style="-sec-extract: exhibit">10.2</a></td>
    <td style="text-align: justify"><a href="tm2310752d2_ex10-2.htm" style="-sec-extract: exhibit">Purchase and Sale Agreement, dated
March 29, 2023, between Avadel CNS Pharmaceuticals, LLC, the Company, Flamel Ireland Ltd., and RTW Royalty II DAC*</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>104</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Certain identified information has been excluded from this exhibit
because it is not material and is the type of information that the Company customarily and actually treats as private and confidential.
Certain exhibits and schedules to this exhibit have been omitted pursuant to Item 601 of Regulation S-K. The registrant will furnish copies
of any of the exhibits and schedules to the Securities and Exchange Commission upon request.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">** Previously filed as an exhibit to the Original 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Forward-Looking Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Current Report on Form 8-K contains
forward-looking statements concerning the Company&#8217;s expectations, anticipations, intentions, beliefs or strategies regarding the
proposed Exchange Transactions, the principal amount of the 2023 Notes subject to the exchange, the closing date for the Exchange Transactions,
the resulting allocation of principal between the 2023 Notes and 2027 Notes the Royalty Purchase Agreement. These forward-looking statements
are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to
differ materially from those described or projected herein are the following: financial market conditions and global economic uncertainty.
A further list and description of these risks, uncertainties and other risks associated with an investment in the Company can be found
in Company&#8217;s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and
subsequent filings. Existing and prospective investors are cautioned not to place&#8239;undue reliance on these forward-looking statements,
which speak only as of the date hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has&#8239;duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March&#160;30,&#8239;2023</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AVADEL PHARMACEUTICALS PLC</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerad G. Seurer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td><td style="width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerad G. Seurer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Counsel&#160;&amp; Corporate Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxVjtFKAzEQRb9g/2HIc2mTFCnkrS5ailuVtYivaXeqoZvMMkmr/ST/0jSLiGEghHtPzggxESu6dz0yvN22DWzRD71NCC0ekDHsMTfq9YOBfLf47mJiG1J5/oI1ZQYzczNVepeDUj27iJ0BOZ+pxUxrkMrMF7DciOqa1xQOrsOQnO3Bhg6emQZ2mCxfxh+29osC+UtRvSJHR8GAmsox/gYtlYZHOttP4mOEpqlFNSmnEium03DVnGIiD3c9+uyKI/o3ZZV96Zgn7lzI9pcPyxg36HfIOVVSZ9FS/ud+ABOzWJ4= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>tm2310752d2_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; margin: 0"><b>Exhibit 10.2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">Purchase
and Sale Agreement</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">By and
Between</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">RTW Royalty
II DAC, on the one hand</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><font style="font-variant: small-caps">And</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">Avadel
CNS Pharmaceuticals, LLC,</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">Solely
for the Limited Purposes Provided for Herein,</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">Avadel
Pharmaceuticals plc and each other Guarantor party hereto, on the other hand</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-variant: small-caps">Dated as
of March&nbsp;</font><font style="text-transform: uppercase">29</font><font style="font-variant: small-caps">, 2023</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 17%">&nbsp;</td>
    <td style="width: 77%; text-align: center">&nbsp;</td>
    <td style="width: 6%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Page</u></b></font></td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;1
    </font><font style="text-transform: uppercase">DEFINITIONS</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Definitions</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Certain Interpretations</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;2
    </font><font style="text-transform: uppercase">PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">23</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Purchase, Sale and Assignment</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Purchase Price</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>No Assumed Obligations, Etc.</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;3
    </font><font style="text-transform: uppercase">CLOSING</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">25</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Tranche 1 Closing</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Payment of Purchase Price</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;4
    </font><font style="text-transform: uppercase">REPRESENTATIONS AND WARRANTIES</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">26</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Parent&rsquo;s and Seller&rsquo;s Representations
    and Warranties</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Buyer&rsquo;s Representations and Warranties</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>No Implied Representations and Warranties</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;5
    </font><font style="text-transform: uppercase">CONDITIONS TO CLOSING</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">33</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Effective Date Actions</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Conditions to the Tranche 1 Closing Date</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.3</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Conditions to the Tranche 2 Closing Date</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;6
    </font><font style="text-transform: uppercase">COVENANTS</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">36</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Reporting</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Royalty Payments; Royalty Reports; Put/Call Option</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Disclosures</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.4</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Inspections and Audits of the Seller</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.5</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Intellectual Property Matters</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.6</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>In-Licenses</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.7</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Out-Licenses</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.8</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Restricted Indebtedness</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.9</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Diligence</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.10</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Efforts to Consummate Transactions</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.11</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Further Assurances</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.12</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Back-Up Security Interest</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.13</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Certain Tax Matters</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.14</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Collateral Covenants</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;7
    </font><font style="text-transform: uppercase">INDEMNIFICATION</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">47</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>General Indemnity</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Notice of Claims</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Limitations on Liability</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Exclusive Remedy</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Tax Treatment of Indemnification Payments</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;8
    </font><font style="text-transform: uppercase">CONFIDENTIALITY</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">48</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Confidentiality</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Authorized Disclosure</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;9
    </font><font style="text-transform: uppercase">TERMINATION</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">50</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Mutual Termination</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Automatic Termination</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</font></td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->)</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in; width: 17%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.3</font></td>
    <td style="width: 77%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Survival</u></font></td>
    <td style="text-align: right; width: 6%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;10
    </font><font style="text-transform: uppercase">EVENTS OF DEFAULT REMEDIES</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">51</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Remedies Upon Event of Default</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE&nbsp;11
    </font><font style="text-transform: uppercase">MISCELLANEOUS</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">51</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Headings</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Notices</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.3</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Expenses</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.4</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Assignment</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.5</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Amendment and Waiver</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.6</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Entire Agreement</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.7</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>No Third Party Beneficiaries</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.8</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Governing Law</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.9</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Jurisdiction; Venue</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.10</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Severability</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.11</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Specific Performance</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.12</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Counterparts</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.13</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Relationship of the Parties</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.14</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Guaranty</u></font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.15</Font></td>
    <td><u>Section 409 Authorisation</u></td>
    <td style="text-align: right">57</td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Index of Exhibits, Schedules and
    Annexes</u></b></font></td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;A:</font></td>
    <td style="width: 84%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LUMRYZ</font></td>
    <td style="text-align: right; width: 6%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;B:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Bill of Sale</font></td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;C:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller Opinions</font></td>
    <td style="text-align: right">&nbsp;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->)</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">PURCHASE
AND SALE AGREEMENT</font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This <font style="font-variant: small-caps">Purchase
and Sale Agreement</font> (this &ldquo;<u>Agreement</u>&rdquo;), dated as of March&nbsp;29, 2023 (the &ldquo;<u>Effective Date</u>&rdquo;),
is made and entered into by and between RTW Royalty II DAC, a designated activity company incorporated under the laws of Ireland with
registered number 729563 and registered office at 2nd Floor, Palmerston House, Denzille Lane, Dublin 2, D02 WD37,&nbsp;Ireland (the &ldquo;<u>Buyer</u>&rdquo;),
on the one hand, and Avadel CNS Pharmaceuticals, LLC, a Delaware limited liability company (the &ldquo;Seller&rdquo;), and, solely for
the limited purposes provided for herein, Avadel Pharmaceuticals plc, an Irish incorporated public limited company (the &ldquo;<u>Parent</u>&rdquo;)
and each other Guarantor party hereto (as defined below), on the other hand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase"><u>W I
T N E S S E T H</u>:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Seller, a wholly-owned, indirect
Subsidiary of Parent, is in the business of, among other things, developing and commercializing the Product;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Seller and Flamel Ireland Ltd, a
private company limited by shares incorporated under the laws of Ireland (&ldquo;<u>Avadel Ireland</u>&rdquo;, together with the
Seller and each Guarantor, the &ldquo;<u>Seller Group</u>&rdquo;), which are wholly-owned direct or indirect Subsidiaries of Parent,
own or are otherwise vested in rights in or to the Product Rights; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Buyer desires to purchase the Revenue
Participation Right from the Seller in exchange for payment of the Purchase Price, and the Seller desires to sell the Revenue Participation
Right to the Buyer in exchange for the Buyer&rsquo;s payment of the Purchase Price, in each case on the terms and conditions set forth
in this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW THEREFORE, in consideration of the representations,
warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, the Seller and the Buyer hereby agree as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">ARTICLE&nbsp;1</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000"></font>DEFINITIONS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">Section&nbsp;1.1</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>Definitions</u>.
The following terms, as used herein, shall have the following meanings:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>2023 Notes Indenture</u>&rdquo; means
that certain Indenture by and among Notes Issuer, as issuer, the Parent, as guarantor, and The Bank of New York Mellon, as trustee, dated
April&nbsp;4. 2022, as amended in accordance with the terms thereof so long as any such amendment is not materially adverse to the Buyer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>2027 Notes Indenture</u>&rdquo; means
that certain Indenture by and among Notes Issuer, as issuer, the Parent, as guarantor, and The Bank of New York Mellon, as trustee, anticipated
to be entered into on or before April&nbsp;3, 2023, as amended in accordance with the terms thereof so long as any such amendment is
not materially adverse to the Buyer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Acceptable Intercreditor Agreement</u>&rdquo;
means an intercreditor agreement establishing the rights and priorities in respect of common Liens on the Product Collateral on terms
acceptable to Buyer acting reasonably and in good faith among the Buyer, each Grantor and the holders of any Indebtedness incurred pursuant
to clause (b)&nbsp;of the definition of Restricted Indebtedness or any agent, representative or trustee acting on behalf of such holders,
to be mutually agreed by the parties thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Affiliate</u>&rdquo; means, (a)&nbsp;with
respect to any particular Person, any other Person directly or indirectly controlling, controlled by or under common control with such
particular Person and (b)&nbsp;with respect to the Buyer, any Person now or hereafter existing that is managed or controlled by RTW Investments,
LP or of which RTW Investments, LP serves as investment manager. For purposes of the foregoing sentence, the term &ldquo;control&rdquo;
means direct or indirect ownership of (x)&nbsp;fifty percent (50%) or more, including ownership by trusts with substantially the same
beneficial interests, of the voting and equity rights of such Person, firm, trust, corporation, partnership or other entity or combination
thereof, or (y)&nbsp;the power to direct the management of such person, firm, trust, corporation, partnership or other entity or combination
thereof, by contract or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Agreement</u>&rdquo; is defined in the
preamble.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Avadel Ireland</u>&rdquo; is defined
in the preamble.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Back-Up Security Interest</u>&rdquo;
is defined in &lrm;Section&nbsp;2.1(c).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Bankruptcy Laws</u>&rdquo; means, collectively,
bankruptcy, insolvency, reorganization, examinership, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting
the enforcement of creditors&rsquo; rights generally.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Business Day</u>&rdquo; means any day
other than (a)&nbsp;a Saturday or Sunday or (b)&nbsp;a day on which banking institutions located in New York are permitted or required
by applicable law or regulation to remain closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Buyer</u>&rdquo; is defined in the preamble.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Buyer Indemnified Parties</u>&rdquo;
is defined in &lrm;Section&nbsp;7.1(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Calendar Quarter</u>&rdquo; means, (a)&nbsp;for
the calendar quarter in which the Tranche 1 Closing occurs, the period beginning on the first day of such calendar quarter and ending
on the last day of such calendar quarter, (b)&nbsp;for the calendar quarter in which the Tranche 2 Closing occurs, the period beginning
on the first day of such calendar quarter and ending on the last day of such calendar quarter and thereafter, in each case, each successive
period of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 or December&nbsp;31.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Call Option</u>&rdquo; means the Tranche
1 Call Option, the Tranche 2 Call Option, or the Pre-Funding Call Option, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Capital Lease</u>&rdquo; means any lease
that is required to be capitalized for financial reporting purposes in accordance with GAAP (with the amount of any indebtedness in respect
of a capital lease being the capitalized amount of the obligations under such capital lease determined in accordance with GAAP); provided,
notwithstanding anything herein to the contrary, in no event shall any lease that would have been categorized as an operating lease as
determined in accordance with GAAP prior to giving effect to the Financial Accounting Standards Board Accounting Standard Update 2016-02,
Leases (Topic 842), issued in February&nbsp;2016, or any other changes in GAAP subsequent to the date hereof be considered a &ldquo;Capital
Lease&rdquo;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Capital Lease Obligations</u>&rdquo;
of any Person means the obligations of such Person to pay rent or other amounts under any lease of (or other arrangement conveying the
right to use) real or personal property, or a combination thereof, which obligations are required to be classified and accounted for
as Capital Leases, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Change of Control</u>&rdquo; means the
occurrence of any one or more of the following: (a)&nbsp;the acquisition, whether directly, indirectly, beneficially or of record, whether
by merger, scheme of arrangement, consolidation, sale or other transfer of securities in a single transaction or series of related transactions,
by any Person of any voting securities of Parent, or if the percentage ownership of any Person in the voting securities of the Parent
is increased through stock redemption, cancellation, or other recapitalization, and immediately after such acquisition or increase such
Person is, directly or indirectly, the beneficial owner of voting securities representing fifty percent (50%) or more of the total voting
power of all of the then outstanding voting securities of Parent; (b)&nbsp;a merger, scheme of arrangement, consolidation, recapitalization,
or reorganization of Parent is consummated that would result in shareholders or equity holders of Parent immediately prior to such transaction
that did not own more than fifty percent (50%) of the outstanding voting securities of Parent immediately prior to such transaction,
owning more than fifty percent (50%) of the outstanding voting securities of the surviving entity (or its parent entity) immediately
following such transaction; and (c)&nbsp;the sale, lease, transfer, license or other disposition, in a single transaction or series of
related transactions, by Parent or any Subsidiary of Parent of all or substantially all the assets of the Parent and its Subsidiaries
taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more Subsidiaries of Parent if
substantially all of the assets of the Parent and its Subsidiaries taken as a whole are held by such Subsidiary or Subsidiaries, except
where such sale, lease, transfer, license or other disposition is to a wholly owned Subsidiary of Parent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Clinical Trial</u>&rdquo; means a clinical
trial intended to support the Marketing Approval or Commercialization of a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Clinical Updates</u>&rdquo; means (a)&nbsp;a
summary of any material updates with respect to the Clinical Trials, including the number of patients currently enrolled in each such
Clinical Trial, the number of sites conducting each such Clinical Trial, the material progress of each such Clinical Trial, any material
modifications to each such Clinical Trial, any adverse events in the Clinical Trials, (b)&nbsp;written plans to start new Clinical Trials,
and (c)&nbsp;investigator brochures for the Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Closing</u>&rdquo; means the Tranche
1 Closing and/or the Tranche 2 Closing, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Closing Date</u>&rdquo; means the date
on which the Tranche 1 Closing occurs pursuant to &lrm;Section&nbsp;3.1(a)&nbsp;and/or the Tranche 2 Closing occurs pursuant to &lrm;Section&nbsp;3.1(b),
as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>CMC</u>&rdquo; means chemistry, manufacturing
and controls with respect to a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<u>CoC Agreement</u>&rdquo;
is defined in &lrm;Section&nbsp;6.2(c).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<u>Combination Product</u>&rdquo;
means:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">a
single pharmaceutical formulation (whether co-formulated or administered together via the same administration route) containing as its
active ingredients both a Product and one or more other therapeutically or prophylactically active pharmaceutical or biologic ingredients
(each an &ldquo;<u>Other Component</u>&rdquo;), or</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">a
combination therapy comprised of a Product and one or more Other Component(s), whether priced and sold in a single package containing
such multiple products, packaged separately but sold together for a single price, or sold under separate price points but labeled for
use together,</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">in each case, including all dosage forms,
formulations, presentations, and package configurations. Drug delivery vehicles, adjuvants and excipients will not be deemed to be &ldquo;active
ingredients&rdquo;, except in the case where such delivery vehicle, adjuvant or excipient is recognized by the FDA as an active ingredient
in accordance with 21 C.F.R. 210.3(b)(7). All references to Products in this Agreement shall be deemed to include Combination Products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Commercial Updates</u>&rdquo; means
a summary of material updates with respect to the Seller&rsquo;s and its Affiliates&rsquo; and any Licensee&rsquo;s sales and marketing
activities and, if material, commercial manufacturing matters with respect to a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Commercialization</u>&rdquo; means any
and all activities directed to the distribution, marketing, detailing, promotion, selling and securing of reimbursement of a Product
(including the using, importing, selling and offering for sale of such Product), and shall include post-Marketing Approval studies to
the extent required by a Regulatory Authority, post-launch marketing, promoting, detailing, distributing, selling such Product, importing,
exporting or transporting such Product for sale, and regulatory compliance with respect to the foregoing. When used as a verb, &ldquo;Commercialize&rdquo;
shall mean to engage in Commercialization. Except with respect to post-Marketing Approval studies required by a Regulatory Authority,
Commercialization shall not include any activities directed to the research or development (including pre-clinical and clinical development)
or manufacture of a Product (and &ldquo;Commercialize&rdquo; shall be construed accordingly).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Commercially Reasonable Efforts</u>&rdquo;
means the level of efforts and resources (measured as of the time that such efforts and resources are required to be used under this
Agreement) that are commonly used by a commercial-stage public biotechnology company of similar size and resources to Parent, to develop,
manufacture or commercialize, as the case may be, a comparable product for a comparable clinical indication (with respect to market size
and commercial opportunity) at a similar stage in its development or product life and of a similar market and potential to the Product,
but without regard to the Seller&rsquo;s financial obligations under this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Confidential Information</u>&rdquo;
is defined in &lrm;Section&nbsp;8.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Convertible Bond Indebtedness</u>&rdquo;
means (1)&nbsp;Existing Exchangeable Notes, (2)&nbsp;the New Exchangeable Notes, (3)&nbsp;any Indebtedness of Parent or any of its Subsidiaries
having a feature which entitles the holder thereof to convert or exchange all or a portion of such Indebtedness into ordinary shares
or a defined American Depositary Share of Parent (or other securities or property following a merger event or other change of the common
capital stock or ordinary shares of Parent), cash or any combination of cash and such common capital stock or ordinary shares (or such
other securities or property) based on the market price of such common capital stock or ordinary shares (or such other securities or
property); provided, that, with respect to this clause (3), (a)&nbsp;the principal amount (or accreted value, if applicable) of such
Convertible Bond Indebtedness does not exceed $[***], (b)&nbsp;such Convertible Bond Indebtedness shall be unsecured, (c)&nbsp;no Subsidiary
shall Guarantee such Convertible Bond Indebtedness, and (d)&nbsp;such Convertible Bond Indebtedness shall include conversion or exchange,
redemption, mandatory conversion and fundamental change provisions that are customary for public market convertible indebtedness (pursuant
to a public offering or an offering under Rule&nbsp;144A or Regulation S of the Securities Act) or are otherwise not materially different
than the Existing Exchangeable Notes or the New Exchangeable Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Credit Facilities</u>&rdquo; means,
one or more debt facilities, letter of credit facilities or commercial paper facilities providing for revolving credit loans, term loans,
receivables financing (including through the sale of receivables to such lenders or to special purpose entities formed to borrow from
such lenders against such receivables), letters of credit or other extensions of credit or other Indebtedness, in each case, including
any notes, mortgages, guarantees, collateral documents, instruments and agreements executed in connection therewith and, in each case,
as amended, extended, renewed, restated, supplemented or otherwise modified (in whole or in part, and without limitation as to amount,
terms, conditions, covenants and other provisions) from time to time, and any agreement or instrument (and related documents) governing
Indebtedness incurred to refinance or replace, in whole or in part, the borrowings and commitments then outstanding or permitted to be
outstanding under such facilities or a successor facility, whether by the same or any other bank, institutional lender, purchaser, investor,
trustee or agent or group thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Disclosing Party</u>&rdquo; is defined
in &lrm;Section&nbsp;8.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Disclosure Schedule</u>&rdquo; means
the Disclosure Schedule, dated as of the Effective Date, delivered to the Buyer by the Seller concurrently with the execution of this
Agreement, and as may be updated solely with respect to the representations and warranties set forth in Section&nbsp;4.1(h), 4.1(k)&nbsp;and
4.1(l)&nbsp;(provided that such Disclosure Schedule may not be updated to the extent any updates would qualify any such representation
and warranty in a manner that would be materially adverse to the Buyer&rsquo;s interests under this Agreement) and delivered to the Buyer
by the Seller as of each Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Distributor</u>&rdquo;
means a Third Party that (a)&nbsp;purchases or has the option to purchase any Product in finished form from or at the direction of the
Seller or any of its Affiliates, (b)&nbsp;has the right, option or obligation to distribute, market and sell such Product (with or without
packaging rights) in one or more regions, and (c)&nbsp;does not otherwise make any royalty, milestone, profit share or other similar
payment to the Seller or its Affiliate based on such Third Party&rsquo;s sale of the Product. The term &ldquo;packaging rights&rdquo;
in this definition will mean the right for the Distributor to package or have packaged Product supplied in unpackaged bulk form into
individual ready-for-sale packs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Domestic Subsidiary</u>&rdquo;
is defined in 6.14(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>EMA</u>&rdquo; means the European Medicines
Agency, or any successor agency thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>ERISA</u>&rdquo; means the Employee
Retirement Income Security Act of 1974.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Event of Default</u>&rdquo; means any
of the events set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Non-Payment</u>.
The Seller fails to pay any amounts to the Buyer hereunder when and as the same shall become due and payable; provided that the Seller
shall have the right to cure such failure within [***] Business Days;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Covenants</u>.
If (i)&nbsp;the Parent or the Seller fails to perform or observe any covenant or agreement (not specified in subsection (a)&nbsp;above)
contained in this Agreement on its part to be performed or observed, and, in the case of any failure that is capable of cure, such failure
continues unremedied for a period of [***] or more days; and (ii)&nbsp;such failure (without giving effect to any qualifications as to
 &ldquo;materiality&rdquo; &ldquo;Material Adverse Effect&rdquo; or any words of similar meaning) could reasonably be expected to have
a Material Adverse Effect;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Representations
and Warranties</u>. If (i)&nbsp;any representation or warranty made or deemed made by or on behalf of the Parent or the Seller in or
in connection with this Agreement or any amendment or modification hereof, or in any report, certificate, financial statement or other
document furnished pursuant to or in connection with this Agreement or any amendment or modification hereof, shall: (A)&nbsp;prove to
have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material
Adverse Effect qualifier; or (B)&nbsp;prove to have been incorrect in any material respect when made or deemed made to the extent that
such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier; and (ii)&nbsp;such inaccuracy
(without giving effect to any qualifications as to &ldquo;materiality&rdquo; &ldquo;Material Adverse Effect&rdquo; or any words of similar
meaning) could reasonably be expected to have a Material Adverse Effect;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Bankruptcy
Event</u>. (i)&nbsp;Parent or any of its Significant Subsidiaries shall commence a voluntary case or other proceeding seeking liquidation,
reorganization or other relief with respect to the Parent, any Significant Subsidiaries or their respective debts under any bankruptcy,
insolvency, examinership or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, examiner,
liquidator, custodian or other similar official of Parent or any Significant Subsidiary or any substantial part of its property, or shall
consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding
commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they
become due; or (ii)&nbsp;an involuntary case or other proceeding shall be commenced against Parent or any Significant Subsidiary seeking
liquidation, reorganization or other relief with respect to Parent or any Significant Subsidiary or its debts under any bankruptcy, insolvency,
examinership or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, examiner, liquidator,
custodian or other similar official of the Parent or any Significant Subsidiary or any substantial part of its property, and such involuntary
case or other proceeding shall remain undismissed and unstayed for a period of [***] consecutive days; or</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(e)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Indebtedness</u>.
Default by Parent or any of its Subsidiaries with respect to any mortgage, agreement or other instrument under which there may be outstanding,
or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $[***] (or its foreign currency equivalent)
in the aggregate of Parent and its Subsidiaries, whether such indebtedness now exists or shall hereafter be created (i)&nbsp;resulting
in such indebtedness becoming or being declared due and payable or (ii)&nbsp;constituting a failure to pay the principal of any such
debt when due and payable (after the expiration of all applicable grace periods) at its stated maturity, upon required repurchase, upon
declaration of acceleration or otherwise.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(f)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Judgment</u>.
a final judgment or judgments for the payment of $[***] (or its foreign currency equivalent) or more (excluding any amounts covered by
insurance) in the aggregate rendered against Parent or any of its Subsidiaries which judgment is not discharged, bonded, paid, waived
or stayed within sixty (60) days after (i)&nbsp;the date on which the right to appeal thereof has expired if no such appeal has commenced,
or (ii)&nbsp;the date on which all rights to appeal have been extinguished.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Existing Exchangeable Notes</u>&rdquo;
means the 4.50% Exchangeable Senior Notes due 2023 issued and outstanding under the 2023 Notes Indenture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Existing Out-License</u>&rdquo; is defined
in &lrm;Section&nbsp;4.1(h)(ii).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Existing Patent Rights</u>&rdquo; is
defined in &lrm;Section&nbsp;4.1(k)(i).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>FD&amp;C Act</u>&rdquo;
means the United States Federal Food, Drug, and Cosmetic Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>FDA</u>&rdquo; means the U.S. Food and
Drug Administration, or any successor agency thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>First Shipment</u>&rdquo; means, with
respect to a Product, the first shipment of such properly prescribed Product from a specialty pharmacy within Seller&rsquo;s distribution
network to a patient in the United States after U.S. Marketing Approval of such Product has been granted, or such marketing and sale
is otherwise permitted, by the FDA. For clarity, First Shipment shall not include any Net Sales Exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>GAAP</u>&rdquo;
means generally accepted accounting principles in the United States in effect from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Governmental Entity</u>&rdquo; means
any: (a)&nbsp;nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (b)&nbsp;U.S. federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or quasi-governmental
authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council,
board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other
tribunal); (d)&nbsp;multi-national organization or body; or (e)&nbsp;individual, body or other entity exercising, or entitled to exercise,
any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Grantors</u>&rdquo; means the Seller
and each Guarantor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Gross Sales</u>&rdquo; is defined in
the definition of &ldquo;Net Sales&rdquo;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Guarantee</u>&rdquo; means, as to any
Person, (a)&nbsp;any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any
indebtedness or other obligation payable or performable by another Person (the &ldquo;primary obligor&rdquo;) in any manner, whether
directly or indirectly, and including any obligation of such Person, direct or indirect, (i)&nbsp;to purchase or pay (or advance or supply
funds for the purchase or payment of) such indebtedness or other obligation, (ii)&nbsp;to purchase or lease property, securities or services
for the purpose of assuring the obligee in respect of such indebtedness or other obligation of the payment or performance of such indebtedness
or other obligation, (iii)&nbsp;to maintain working capital, equity capital or any other financial statement condition or liquidity or
level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such indebtedness or other obligation,
or (iv)&nbsp;entered into for the purpose of assuring in any other manner the obligee in respect of such indebtedness or other obligation
of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), (b)&nbsp;any
lien on any assets of such Person securing any indebtedness or other obligation of any other Person, whether or not such indebtedness
or other obligation is assumed by such Person (or any right, contingent or otherwise, of any holder of such indebtedness to obtain any
such lien) or (c)&nbsp;any direct or indirect liability, contingent or not, of that Person for (i)&nbsp;any obligations for undrawn letters
of credit for the account of that Person or (ii)&nbsp;all obligations from any interest rate, currency or commodity swap agreement, interest
rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates,
currency exchange rates or commodity prices. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable
amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable,
the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term &ldquo;Guarantee&rdquo;
as a verb has a corresponding meaning.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Guarantors</u>&rdquo; means the Parent,
Avadel Ireland, and each Joining Subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Guaranty</u>&rdquo; is defined in &lrm;Section&nbsp;11.14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Improvements</u>&rdquo; means any improvement,
invention or discovery relating to a Product (other than with respect to a new composition of matter), including the formulation, or
the method of manufacture of a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>In-License</u>&rdquo; means any license,
settlement agreement or other agreement or arrangement between the Seller or any of its Affiliates and any Third Party pursuant to which
the Seller or any of its Affiliates obtains a license or a covenant not to sue or similar grant of rights to any Patents or other intellectual
property rights of such Third Party that is necessary for the research, development, manufacture, use or Commercialization of a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Indebtedness</u>&rdquo; of any Person
means any indebtedness for borrowed money, any obligation evidenced by a note, bond, debenture or similar instrument, or any guarantee
of any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Indemnified Party</u>&rdquo; is defined
in &lrm;Section&nbsp;7.2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Indemnifying Party</u>&rdquo; is defined
in &lrm;Section&nbsp;7.2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Intellectual Property Product Rights</u>&rdquo;
means any and all of the following as they exist throughout the world at any time: (a)&nbsp;the Patent Rights; (b)&nbsp;rights in registered
and unregistered trademarks, service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names, and
registrations and applications for registration of any of the foregoing, in each case, with respect to any Product; (c)&nbsp;rights in
all Know-How necessary for the development, manufacture or Commercialization of any Product; and (d)&nbsp;any and all other intellectual
property rights and/or proprietary rights, whether or not patentable, specifically relating to any of the foregoing, as necessary for
the development, manufacture or Commercialization of a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Intellectual Property Rights</u>&rdquo;
means any and all of the following as they exist throughout the world at any time: (a)&nbsp;the Patent Rights and (b)&nbsp;the Know-How
Rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Intellectual Property Updates</u>&rdquo;
means an updated list of the Patent Rights, including any new Patents issued or filed, amended or supplemented, relating to a Product
in any country or any abandonments or other termination of prosecution with respect to any of the Patent Rights, and any other material
information or developments with respect to the Intellectual Property Rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Irish Obligor</u>&rdquo;
is defined in &lrm;Section&nbsp;6.14(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Joining Subsidiary</u>&rdquo; means
any Subsidiary of the Parent that executes and delivers a joinder agreement pursuant to &lrm;Section&nbsp;6.14(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Judgment</u>&rdquo; means any judgment,
order, writ, injunction, citation, award or decree of any nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Know-How</u>&rdquo; means any and all
proprietary or confidential information, know-how and trade secrets, including processes, formulae, models and techniques (but excluding
rights in research in progress, algorithms, data, databases, data collections, chemical and biological materials and the results of experimentation
and testing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Know-How Rights</u>&rdquo; means any
and all Know-How owned or in-licensed by the Seller or any of its Affiliates or under which the Seller or any of its Affiliates is or
may become empowered to grant licenses necessary or used in the development, manufacture, or Commercialization of a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Knowledge of the Parent</u>&rdquo; means
the actual knowledge of the Parent Knowledge Parties, after reasonable inquiry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Licensee</u>&rdquo;
means, with respect to any Product, a Third Party to whom the Seller or any Affiliate of the Seller has granted a license or sublicense
to Commercialize such Product. For clarity, a Distributor shall not be deemed to be a &ldquo;Licensee.&rdquo;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Lien</u>&rdquo; means any mortgage,
lien, pledge, participation interest, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any
restriction on use, transfer or exercise of any other attribute of ownership of any kind.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Loss</u>&rdquo; means any and all Judgments,
damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Loss of Market Exclusivity</u>&rdquo;
shall mean, on a Product-by-Product and country-by-country basis, the later to occur of: (a)&nbsp;the expiration of the last-to-expire
Valid Claim of a Patent Right covering such Product in such country; and (b)&nbsp;the expiry of all Regulatory Exclusivity Periods for
such Product in such country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Losses Cap</u>&rdquo; means [***] of
the amount of the Purchase Price actually paid to the Seller as of the date any claim for Losses is made against Seller pursuant to &lrm;ARTICLE&nbsp;7.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>LUMRYZ</u>&rdquo; means the product
known as LUMRYZ&trade; (sodium oxybate), the active pharmaceutical ingredient of which (i.e., sodium oxybate) is described on <u>Exhibit&nbsp;A</u>
hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Marketing Approval</u>&rdquo; means,
an NDA approved by the FDA, a Marketing Authorization Application approved by the EMA under the centralized European procedure, or any
corresponding non-U.S. or non-EMA application, registration or certification in the Territory, necessary or reasonably useful to market
a Product approved by the corresponding Regulatory Authority, including pricing and reimbursement approvals where required. For clarity,
notwithstanding the foregoing, solely with respect to &lrm;Section&nbsp;5.2(a), &ldquo;Marketing Approval&rdquo; shall not include pricing
and reimbursement approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Material Adverse Effect</u>&rdquo; means
(a)&nbsp;an adverse effect in any material respect on the timing, duration or amount of the Royalty Payments, (b)&nbsp;a material adverse
effect on (i)&nbsp;a Product, (ii)&nbsp; the Intellectual Property Rights, including the Seller&rsquo;s or any of its Affiliate&rsquo;s
rights in or to such Intellectual Property Rights, (iii)&nbsp;any Marketing Approval of a Product or the timing thereof, (iv)&nbsp;the
legality, validity or enforceability of any provision of this Agreement, (v)&nbsp;the ability of the Seller or the Parent to perform
any of its obligations under this Agreement, (vi)&nbsp;the rights or remedies of the Buyer under this Agreement, or (vii)&nbsp;the business
of the Seller or its Affiliates or (c)&nbsp;an adverse effect in any material respect on the Revenue Participation Rights, the Product
Collateral, or the Back-Up Security Interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Maturity Date</u>&rdquo;
shall have the meaning set forth in Section&nbsp;1.01 of the 2023 Notes Indenture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Minimum Return Date</u>&rdquo; means
the date on which the Buyer has received [***] of (a)&nbsp;the Purchase Price, if the Buyer receives a valid Tranche 2 Election prior
to or on August&nbsp;31, 2024 or (b)&nbsp;the Tranche 1 Purchase Price, if the Buyer does not receive a valid Tranche 2 Election prior
to or on August&nbsp;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>NDA</u>&rdquo;
means a New Drug Application submitted to the FDA in the United States in accordance with the FD&amp;C Act with respect to a pharmaceutical
product or any analogous application or submission with any Regulatory Authority outside of the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Net Sales</u>&rdquo; means, with respect
to each Product, the gross amount invoiced, billed or otherwise recorded for sales of such Product anywhere in the world by or on behalf
of the Seller, its Affiliates, any Distributor, or any Licensee of the Seller or any of the Seller&rsquo;s Affiliates (each of the foregoing
Persons, for purposes of this definition, shall be considered a &ldquo;<u>Related Party</u>&rdquo;) to a Third Party in an arms-length
transaction (&ldquo;<u>Gross Sales</u>&rdquo;) less the following amounts, to the extent actually incurred or accrued in accordance with
generally accepted accounting principles consistently applied, and not reimbursed by such Third Party (other than as result of being
included in the gross amount invoiced), provided, that any given amount may be taken as a permitted deduction only once:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">reasonable
and customary rebates, chargebacks, quantity, trade and similar discounts, credits and allowances and other price reductions reasonably
granted, allowed, incurred or paid in so far as they are applied to sales of a Product;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">discounts
(including cash, quantity, trade, governmental, and similar discounts), coupons, retroactive price reductions, charge back payments and
rebates granted to managed care organizations or to federal, state and local governments, or to their agencies (including payments made
under the new &ldquo;Medicare Part&nbsp;D Coverage Gap Discount Program&rdquo; and the &ldquo;Annual Fee for Branded Pharmaceutical Manufacturers&rdquo;
specific to the Product), in each case, as applied to sales of the Product and actually given to customers;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(c)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">reasonable
and customary credits, adjustments, and allowances, including those granted on account of price adjustments, billing errors, and damage,
Product otherwise not in saleable condition, and rejection, return or recall of a Product;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(d)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">reasonable
and customary freight and insurance costs incurred with respect to the shipment of a Product to customers, in each case if charged separately
and invoiced to the customer;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt; color: #010000">(e)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">customs
duties, surcharges and other similar governmental charges incurred in connection with the exportation or importation of a Product to
the extent included in the gross amount invoiced;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt; color: #010000">(f)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">sales,
use, value-added, excise, turnover, inventory and other similar Taxes (excluding income Taxes), and that portion of annual fees due under
Section&nbsp;9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No.&nbsp;111-48) and any other fee
imposed by any equivalent applicable law, in each of the foregoing cases, that Seller allocates to sales of a Product in accordance with
Seller&rsquo;s standard policies and procedures consistently applied across its products, as adjusted for rebates and refunds, imposed
in connection with the sales of the Product to any Third Party, to the extent such Taxes are not paid by the Third Party (other than
as result of such Taxes being included in the gross amount invoiced);</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(g)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">actual
copayment waiver amounts uncollected or uncollectible debt amounts with respect to sales of a Product, provided that if the debt is thereafter
paid, the corresponding amount shall be added to the Net Sales of the period during which it is paid;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(h)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">reasonable,
customary and documented out of pocket amounts directly relating to co-pay programs, bridging programs or other similar patient assistance
programs which may be implemented from time to time by the Seller; and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(i)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">other
similar or customary deductions taken in the ordinary course of business as permitted in calculating net sales or net revenue (as applicable)
under generally accepted accounting principles consistently applied.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For clarity, &ldquo;Net Sales&rdquo; will not
include (i)&nbsp;sales or dispositions for charitable, promotional, pre-clinical, clinical, regulatory, compassionate use, named patient
use or indigent or other similar programs, reasonable quantities of Products used as samples, and Products used in the development of
Products, (ii)&nbsp;sales or dispositions between any of the Related Parties (unless a Related Party is the final end-user of such Product),
but will include subsequent sales or dispositions of Products to a non-Related Party, or (iii)&nbsp;any amounts or other consideration
received by a Related Party from a Licensee, Distributor, or a non-Related Party in consideration of the grant of a (sub)license or co-promotion
or distribution right to such non-Related Party (the &ldquo;<u>Net Sales Exceptions</u>&rdquo;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to sales of a Product invoiced in
U.S. dollars, Net Sales shall be determined in U.S. dollars. With respect to sales of a Product invoiced in a currency other than U.S.
dollars, Net Sales shall be determined by converting the currencies at which the sales are made into U.S. dollars, at rates of exchange
determined in a manner consistent with the Seller&rsquo;s or a Licensee&rsquo;s, as applicable, method for calculating rates of exchange
in the preparation of the Seller&rsquo;s or such Licensee&rsquo;s annual financial statements in accordance with generally accepted accounting
principles consistently applied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net Sales for any Combination Product shall be
calculated on a country-by-country basis by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where &ldquo;A&rdquo;
is the weighted average invoice price of the Product contained in such Combination Product when sold separately in such country during
the applicable accounting period in which the sales of the Combination Product were made, and &ldquo;B&rdquo; is the combined weighted
average invoice prices of all of the Other Components contained in such Combination Product sold separately in such country during such
same accounting period. If a Product contained in such Combination Product is not sold separately in finished form in such country, the
Seller and the Buyer shall determine Net Sales for such Product by mutual agreement based on the relative contribution of such Product
and each such other active ingredient in such Combination Product in accordance with the above formula, and shall take into account in
good faith any applicable allocations and calculations that may have been made for the same period in other countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Net Sales Exceptions</u>&rdquo; is defined
in the definition of &ldquo;Net Sales&rdquo;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>New Exchangeable Notes</u>&rdquo; means
the 6.00% Exchangeable Senior Notes due 2027 issued and outstanding under the 2027 Notes Indenture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Notes Issuer</u>&rdquo; means Avadel
Finance Cayman Limited, a Cayman Islands exempted company limited by shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Orange Book</u>&rdquo; means the FDA
publication &ldquo;Approved Drug Products with Therapeutic Equivalence Evaluations,&rdquo; as may be amended from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Orange Book Patent</u>&rdquo; means
the Patents listed in the Orange Book by Seller, its Affiliates or Licensees in connection with any Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Other Component</u>&rdquo; is defined
in the definition of &ldquo;Combination Products&rdquo;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Out-License</u>&rdquo; means each license
or other agreement between the Seller or any of its Affiliates and any Third Party (other than Distributors) pursuant to which the Seller
or any of its Affiliates grants a license or sublicense of any Intellectual Property Right to market, detail, promote, sell or secure
reimbursement of a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in; background-color: white">&ldquo;<u>Parent</u>&rdquo;
is defined in the preamble.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Parent Knowledge Parties</u>&rdquo;
means the Chief Executive Officer, Chief Financial Officer, Chief Commercial Officer and General Counsel of Parent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Patents</u>&rdquo; means any and all
patents and patent applications existing as of the date of this Agreement and all patent applications filed hereafter, including any
continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any of the
foregoing patent applications, any certificate, reissue, reexamination, renewal or patent term extension or adjustment (including any
supplementary protection certificate) of any such patent or other governmental actions which extend any of the subject matter of a patent,
and any substitution patent, confirmation patent or registration patent or patent of addition based on any such patent, and all foreign
counterparts of any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Patent Rights</u>&rdquo; means any and
all Patents owned or in-licensed by the Seller or any of its Affiliates or under which the Seller or any of its Affiliates is or may
become empowered to grant licenses necessary or used in the development, manufacture, use, marketing, promotion, sale or distribution
of a Product, as well as existing or future Patents covering any Improvements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Payment Term</u>&rdquo; means the time
period commencing on the Tranche 1 Closing Date and expiring on the Royalty Termination Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Permitted Indebtedness</u>&rdquo; is
defined in the definition of &ldquo;Restricted Indebtedness&rdquo;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Permitted License</u>&rdquo; is defined
in &lrm;Section&nbsp;6.7(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Permitted Licensee</u>&rdquo; means
any counterparty to a Permitted License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Permitted Liens</u>&rdquo; means the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Liens
for Taxes, assessments or governmental charges or levies not yet due or which are being contested in good faith and by appropriate proceedings
diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with
GAAP;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">statutory
Liens of landlords and Liens of carriers, warehousemen, mechanics, materialmen and suppliers and other Liens imposed by law or pursuant
to customary reservations or retentions of title arising in the ordinary course of business, provided, that, such Liens secure only amounts
not yet due and payable or, if due and payable, are unfiled and no other action has been taken to enforce the same or are being contested
in good faith by appropriate proceedings for which adequate reserves determined in accordance with GAAP have been established;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Liens
on property existing at the time of acquisition of such property provided that such liens were in existence prior to such acquisition
and not incurred in contemplation thereof;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Permitted
Licenses, including any interest or title of a licensee under a Permitted License;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(e)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">subject
to the requirements of the second sentence of </font>&lrm;<font style="font-size: 10pt">Section&nbsp;6.8, Liens securing Indebtedness
described in clause (b)&nbsp;of the definition of Restricted Indebtedness;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(f)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">pledges
or deposits in the ordinary course of business in connection with workers&rsquo; compensation, unemployment insurance and other social
security legislation, other than any Lien imposed by ERISA;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(g)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">deposits
to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety and appeal bonds,
indemnity and performance bonds and other obligations of a like nature incurred in the ordinary course of business;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(h)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">easements,
rights-of-way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount,
and which do not materially interfere with the ordinary conduct of the business of the applicable Person;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">licenses,
sublicenses, leases or subleases granted to others in the ordinary course of business or otherwise and not interfering in any material
respect with the Revenue Participation Right, the Product Rights, the Product Collateral, or the Back-Up Security Interest;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(j)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">any
interest of title of a lessor under, and Liens arising from UCC financing statements (or equivalent filings, registrations or agreements
in foreign jurisdictions) relating to, leases permitted by this Agreement</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><font style="font-size: 10pt">(k)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">normal
and customary banker&rsquo;s liens and rights of setoff upon deposits of cash in favor of banks or other depository institutions;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-size: 10pt">(l)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Liens
of a collection bank arising under Section&nbsp;4-210 of the UCC on items in the course of collection;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-size: 10pt">(m)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Liens
of sellers of goods to the Seller and any of its Subsidiaries arising under Article&nbsp;2 of the UCC or similar provisions of applicable
law in the ordinary course of business, covering only the goods sold and securing only the unpaid purchase price for such goods and related
expenses; and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-size: 10pt">(n)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">cash
collateral securing letters of credit permitted under clause (h)&nbsp;of the definition of Restricted Indebtedness.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Person</u>&rdquo; means any individual,
firm, corporation, company, partnership, limited liability company, trust, joint venture, association, estate, trust, Governmental Entity
or other entity, enterprise, association or organization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Prime Rate</u>&rdquo; means <font style="font-family: Times New Roman, Times, Serif">the
prime rate published by The Wall Street Journal, from time to time, as the prime&nbsp;rate.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&ldquo;<u>Product</u>&rdquo;
means all current and future </font>pharmaceutical <font style="font-family: Times New Roman, Times, Serif">products developed or to
be developed by the Seller or any of its Affiliates containing or comprising: </font>(a)&nbsp;LUMRYZ; (b)&nbsp;oxybate; (c)&nbsp;any
future products developed or to be developed by the Seller or any of its Affiliates approved through 505(b)(2)&nbsp;referencing [***] or Lumryz; (c)&nbsp;any
(i)&nbsp;[***], or (ii)&nbsp;other derivative compounds that (x)&nbsp;can be derived from an oxybate by way of a [***] and (y)&nbsp;provide
a similar pharmacologic effect to oxybate, in each case of clauses (i)&nbsp;and (ii), of the foregoing clauses ((a), (b), and (c)); or
(d)&nbsp;any pharmaceutical product that contains any of the foregoing, in each case [***]<font style="font-family: Times New Roman, Times, Serif">.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Product Collateral</u>&rdquo;
means Parent&rsquo;s and its Subsidiaries&rsquo; rights, title and interests in (a)&nbsp;the Royalty Payments; (b)&nbsp;the Products
(including all inventory of the Products), (c)&nbsp;the Product Rights owned, licensed or otherwise held by the Parent of any of its
Subsidiaries, and (d)&nbsp;any proceeds from either (a), (b), or (c)&nbsp;above, including all accounts receivable and general intangibles
resulting from the sale, license or other disposition of Products by the Seller, its Affiliates, or its Licensees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Product Rights</u>&rdquo;
means any and all of the following, as they exist throughout the world: (a)&nbsp;Intellectual Property Product Rights, (b)&nbsp;regulatory
filings, submissions and approvals, including Marketing Approvals, with or from any Regulatory Authorities with respect to any of the
Products, (c)&nbsp;In-Licenses and (d)&nbsp;Out-Licenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Purchase Price</u>&rdquo; is defined
in &lrm;Section&nbsp;2.2(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Put/Call Payment</u>&rdquo; means the
Tranche 1 Put/Call Payment, the Tranche 2 Put/Call Payment, or the Pre-Funding Put/Call Payment, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Put Option</u>&rdquo; means the Tranche
1 Put Option, the Tranche 2 Put Option or the Pre-Funding Put Option, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Receiving Party</u>&rdquo; is defined
in &lrm;Section&nbsp;8.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Recharacterization Event</u>&rdquo;
is defined in &lrm;Section&nbsp;2.1(c).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Regulatory Authority</u>&rdquo; means
any national or supranational governmental authority, including the FDA, the EMA or such other equivalent regulatory authority, or any
successor agency thereto, that has responsibility in granting a Marketing Approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Regulatory Exclusivity Period</u>&rdquo;
shall mean, with respect to each Product in any country, any period of data, market or other regulatory exclusivity (other than Patent
exclusivity) granted or afforded by law or by a Regulatory Authority in such country that confers exclusive marketing rights with respect
to such Product in such country or prevents another party from using or otherwise relying on any data supporting the Marketing Approval
for such Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Regulatory Updates</u>&rdquo; means
a summary of any and all material information and developments that materially impact a Product with respect to any regulatory filings
or submissions made to any Regulatory Authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Related Party</u>&rdquo; is defined
in the definition of &ldquo;Net Sales&rdquo;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Report</u>&rdquo; is defined in &lrm;Section&nbsp;6.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Representative</u>&rdquo; means, with
respect to any Person, (a)&nbsp;any direct or indirect member or partner of such Person and (b)&nbsp;any manager, director, trustee,
officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, contractors, actual and potential
lenders, investors, co-investors and assignees, bankers and financial advisers) of such Person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Restricted Indebtedness</u>&rdquo; means
any financing, sale, or loan of royalties on the Products, or any Indebtedness, in each case other than in respect of this Agreement,
with the Buyer&rsquo;s consent or the following (collectively, &ldquo;<u>Permitted Indebtedness</u>&rdquo;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">[Reserved];</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">[Reserved];</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(c)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Convertible
Bond Indebtedness and any Refinancing Indebtedness thereof;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(d)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Swap
Contracts entered into in the ordinary course of business or consistent with past practice (and not for speculative purposes) to hedge
or mitigate commercial risk pertaining to interest rates or currency exchange rates;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(e)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">(i)&nbsp;Indebtedness
existing on the date of this Agreements (other than the Convertible Bond Indebtedness) (&ldquo;<u>Existing Indebtedness</u>&rdquo;) and
(ii)&nbsp;any Indebtedness issued in exchange for, or the net proceeds of which are promptly used to extend, refinance, renew, replace,
exchange for, defease or refund (x)&nbsp;any Existing Indebtedness, (y)&nbsp;Indebtedness incurred pursuant to clause (c), (l), (n)&nbsp;or
(p)&nbsp;(other than intercompany Indebtedness) of this definition of Permitted Indebtedness or (z)&nbsp;Indebtedness incurred pursuant
to this clause (e)&nbsp;(any such Indebtedness issued in exchange for, or the net proceeds of which are promptly used to extend, refinance,
renew, replace, exchange for, defease or refund the Indebtedness referred to in the foregoing clauses (x), (y)&nbsp;and (z), &ldquo;<u>Refinancing
Indebtedness</u>&rdquo;), provided that (1)&nbsp;if secured, the Liens securing such Refinancing Indebtedness encumber only the assets
subject to the Liens securing such Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged, (2)&nbsp;the principal
amount (or accreted value, if applicable) of such Refinancing Indebtedness does not exceed the principal amount (or accreted value, if
applicable) of the Indebtedness renewed, refunded, refinanced, replaced, defeased or discharged (plus all accrued interest on the Indebtedness
and the amount of all fees, commissions and expenses, including reasonable and customary premiums, underwriting discounts defeasance
costs, original issue discount, incurred in connection therewith) and (3)&nbsp;in the case of any Convertible Bond Indebtedness that
is extended, refinanced, renewed, replaced, exchanged for, defeased or refunded, the Refinancing Indebtedness therefor shall be Convertible
Bond Indebtedness that satisfies the requirements of Sections (3)(b)&nbsp;through (d)&nbsp;of the definition thereof;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(f)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
secured by any Lien imposed by law, such as carriers&rsquo;, warehousemen&rsquo;s, landlord&rsquo;s, mechanics&rsquo; Liens and other
like Liens, and customary Liens retained by or granted to carriers, landlords and mechanics under the terms of agreements pursuant to
which services are rendered or property is leased by such Persons to Parent or any of its Subsidiaries, in each case, either (a)&nbsp;incurred
or arising in the ordinary course of business or consistent with past practice or (b)&nbsp;for sums not overdue for a period of more
than [***] days or being contested in good faith by appropriate proceedings;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(g)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
relating to pooled deposit or sweep accounts to permit satisfaction of overdraft, cash pooling or similar obligations incurred in the
ordinary course of business or consistent with past practice;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(h)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
in respect of letters of credit issued in the ordinary course of business for the account of Parent or any of its Subsidiaries;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(i)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
in respect of bank guarantees, statutory obligations, surety or performance bonds and similar instruments incurred in the ordinary course
of business or consistent with past practice;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(j)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
incurred by Parent or any of its Subsidiaries (i)&nbsp;consisting of the financing of insurance premiums in the ordinary course of business
or consistent with past practice; (ii)&nbsp;in respect of workers&rsquo; compensation claims, health, disability and other types of employee
benefits, social security benefits, unemployment and other self-insurance obligations, vehicle, property, casualty or liability insurance
or other similar bonds; or (iii)&nbsp;arising from the honoring by a bank or other financial institution of a check, draft or similar
instrument drawn against insufficient funds, so long as such Indebtedness is covered within [***] Business Days of notification to Parent
or any of its Subsidiaries of its incurrence;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(k)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
incurred by Parent or any of its Subsidiaries in the ordinary course of business or consistent with past practice arising from business
credit card programs, treasury, payment processing services, depository, over-draft and cash management services;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(l)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
of Parent or any of its Subsidiaries in respect of purchase money indebtedness or Capital Lease Obligations in an aggregate principal
amount, including all Refinancing Indebtedness issued in exchange for, or the net proceeds of which are promptly used to extend, refinance,
renew, replace, defease or refund any Indebtedness incurred pursuant to this clause (l), not to exceed $[***] at any one time outstanding;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(m)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
representing any taxes, assessments or governmental charges to the extent such taxes are being contested in good faith and adequate reserves
have been provided therefor in conformity with GAAP;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(n)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Indebtedness
of a Person existing at the time such Person was acquired by Parent or its Subsidiary, or became a direct or indirect Subsidiary of Parent
or assets were acquired from such Person; provided that: (i)&nbsp;such Indebtedness was not incurred in connection with, or in contemplation
of, such Person becoming a Subsidiary of Parent or its Subsidiary or the acquisition of such assets; (ii)&nbsp;neither Parent nor any
of its Subsidiaries, other than the Person acquired (and its Subsidiaries) or the Person who acquired such assets has liability or obligation
with respect to such Indebtedness (and in the case of an acquisition of assets, any Liens securing such Indebtedness do not extend beyond
the assets so acquired and any improvements, additional or accessions thereto, or any casualty proceeds thereof); and (iii)&nbsp;such
Indebtedness, together with all other Indebtedness constituting Indebtedness incurred pursuant to this clause (n), and all Refinancing
Indebtedness issued in exchange for, or the net proceeds of which are promptly used to extend, refinance, renew, replace, defease or
refund any Indebtedness incurred pursuant to this clause (n), does not exceed $[***] at any one time outstanding;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(o)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">any
bona fide intercompany Indebtedness entered into in the good faith business judgment of the Parent; provided that no Indebtedness owed
by Parent to any Subsidiary of Parent shall be secured by the Product Collateral;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(p)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">additional
Indebtedness incurred by Parent or any Subsidiary of Parent in an aggregate principal amount, including all Refinancing Indebtedness
issued in exchange for, or the net proceeds of which are promptly used to extend, refinance, renew, replace, defease or refund any Indebtedness
incurred pursuant to this clause (p), not to exceed $[***] at any one time outstanding;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(q)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">customer
deposits and advance payments received in the ordinary course of business or consistent with past practice from customers for goods or
services purchased in the ordinary course of business or consistent with past practice; and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><font style="font-size: 10pt; color: #010000">(r)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">the
incurrence of Indebtedness arising from agreements of Parent or any Subsidiary of Parent providing for indemnification, adjustment of
purchase price, working capital adjustments, holdback, earn-outs or similar obligations of Parent or any Subsidiary of Parent pursuant
to such agreements, in each case, incurred in connection with the acquisition or disposition of any Subsidiary, investment, business,
property or asset.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that an item of Indebtedness meets the criteria of more
than one of the categories of Permitted Indebtedness, the Parent may, in its sole discretion, classify, reclassify or divide such item
of Indebtedness and will only be required to include the amount and type of such Indebtedness in one of the above clauses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Revenue Participation Right</u>&rdquo;
means the Tranche 1 Revenue Participation Right and the Tranche 2 Revenue Participation Right, in each case, individually or collectively
as the context requires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Royalty Cap</u>&rdquo; means [***] of
(a)&nbsp;the Purchase Price, if the Buyer receives a valid Tranche 2 Election prior to or on August&nbsp;31, 2024 or (b)&nbsp;the Tranche
1 Purchase Price, if the Buyer does not receive a valid Tranche 2 Election prior to or on August&nbsp;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Royalty Payments</u>&rdquo; means, for
the period during the Payment Term, the Tranche 1 Royalty Payments and, upon consummation of the Tranche 2 Closing Date, the Tranche
2 Royalty Payments, in each case, individually or collectively as the context requires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Royalty Report</u>&rdquo; is defined
in &lrm;Section&nbsp;6.2(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Royalty Termination Date</u>&rdquo;
means the earlier of (a)&nbsp;the date on which aggregate payments of the Royalty Payments actually received by the Buyer equal the Royalty
Cap or (b)&nbsp;(i)&nbsp;if the Tranche 2 Closing has occurred, the date the Buyer has received the Tranche 1 Put/Call Payment and the
Tranche 2 Put/Call Payment or (ii)&nbsp;if after August&nbsp;31, 2024, the Tranche 2 Closing has not occurred, the date the Buyer has
received the Tranche 1 Put/Call Payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Safety Notices</u>&rdquo; means any
recalls, field notifications, market withdrawals, warnings, &ldquo;dear doctor&rdquo; letters, investigator notices, safety alerts or
other notices of action issued or instigated by the Seller, any of its Affiliates or any Regulatory Authority relating to an alleged
lack of safety or regulatory compliance of any Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>SEC</u>&rdquo; means the Securities
and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Securities Act</u>&rdquo; means the
Securities Act of 1933.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Seller</u>&rdquo; is defined in the
preamble.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Seller Certificate</u>&rdquo; is defined
in Section&nbsp;5.1(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Seller Group</u>&rdquo;
is defined in the preamble.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&ldquo;<u>Seller Indemnified
Parties</u>&rdquo; is defined in &lrm;Section&nbsp;7.1(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Significant Subsidiary</u>&rdquo; means
a Subsidiary of the Parent that meets the definition of &ldquo;significant subsidiary&rdquo; in Article&nbsp;1, Rule&nbsp;1-02 of Regulation
S-X under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Specified Delivery Date</u>&rdquo; means
[***] Business Days after the earlier of (i)&nbsp;the date that the Parent has filed with the SEC its Form&nbsp;10-Q or Form&nbsp;10-K,
as applicable, for the immediately preceding Calendar Quarter, and (ii)&nbsp;the filing due date for such Form&nbsp;10-Q or Form&nbsp;10-K,
as applicable, taking into account any extensions under SEC Form&nbsp;12b-25.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Subsidiary</u>&rdquo; means any and
all corporations, partnerships, limited liability companies, joint ventures, associations and other entities controlled (by contract
or otherwise) by the Parent directly or indirectly through one or more intermediaries. For purposes hereof, the Seller or Parent, as
the case may be, shall be deemed to control a partnership, limited liability company, association or other business entity if the Seller
or Parent, as applicable, directly or indirectly through one or more intermediaries, shall be allocated a majority of partnership, limited
liability company, association or other business entity gains or losses or shall be or control the managing director or general partner
of such partnership, limited liability company, association or other business entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Swap Contract</u>&rdquo; means (a)&nbsp;any
and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options,
forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond
or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions,
floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts,
or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing),
whether or not any such transaction is governed by or subject to any master agreement, and (b)&nbsp;any and all transactions of any kind,
and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published
by the International Swaps and Derivatives Association,&nbsp;Inc., any International Foreign Exchange Master Agreement, or any other
master agreement (any such master agreement, together with any related schedules, a &ldquo;Master Agreement&rdquo;), including any such
obligations or liabilities under any Master Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tax</u>&rdquo; or &ldquo;<u>Taxes</u>&rdquo;
means any U.S. federal, state, local,&nbsp;Irish or foreign income, gross receipts, license, payroll, employment, excise, severance,
occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security,
unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated
or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>Territory</u>&rdquo;
means [***].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Third Party</u>&rdquo; means any Person
that is not the Parent or the Parent&rsquo;s Affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 1 Call Option</u>&rdquo; is
defined in &lrm;&lrm;Section&nbsp;6.2(c).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>Tranche 1 Closing</u>&rdquo;
is defined in &lrm;Section&nbsp;3.1(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><u>&ldquo;Tranche 1 Closing Date</u>&rdquo; means
the date on which the Tranche 1 Closing occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 1 Purchase Price</u>&rdquo;
is defined in &lrm;&lrm;Section&nbsp;2.2(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 1 Put/Call Date</u>&rdquo; is
defined in &lrm;&lrm;Section&nbsp;6.2(c)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 1 Put/Call Payment</u>&rdquo;
is defined in &lrm;&lrm;Section&nbsp;6.2(c).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 1 Put Option</u>&rdquo; is defined
in &lrm;&lrm;Section&nbsp;6.2(c).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 1 Revenue Participation Right</u>&rdquo;
means, for the period during the Payment Term, the right to receive the Tranche 1 Royalty Payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 1 Royalty Payments</u>&rdquo;
means, for each Calendar Quarter, an amount equal to the amount of worldwide aggregate Net Sales during such Calendar Quarter, multiplied
by 3.75%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 2 Call Option</u>&rdquo; is
defined in &lrm;Section&nbsp;6.2(c)(i).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>Tranche 2 Closing</u>&rdquo;
is defined in &lrm;Section&nbsp;3.1(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><u>&ldquo;Tranche 2 Closing
Date</u>&rdquo; means the date on which the Tranche 2 Closing occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>Tranche 2 Election</u>&rdquo;
is defined in &lrm;Section&nbsp;3.1(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>Tranche 2 Purchase
Price</u>&rdquo; is defined in &lrm;Section&nbsp;2.2(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 2 Put/Call Date</u>&rdquo; is
defined in &lrm;Section&nbsp;6.2(c)(i).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>Tranche 2 Put/Call
Payment</u>&rdquo; is defined in &lrm;&lrm;Section&nbsp;6.2(c).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<u>Tranche 2 Put Option</u>&rdquo; is defined
in &lrm;Section&nbsp;6.2(c)(i).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<u>Tranche 2 Revenue
Participation Right</u>&rdquo; means, upon consummation of the Tranche 2 Closing and for the period during the Payment Term, the
right to receive the Tranche 2 Royalty Payments.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<u>Tranche 2 Royalty
Payments</u>&rdquo; means, for each Calendar Quarter, an amount equal to the amount of worldwide aggregate Net Sales during such Calendar
Quarter, multiplied by 3.75%.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<u>Transaction Documents</u>&rdquo;
means this Agreement and any other ancillary agreement or transaction document contemplated by this Agreement.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<u>Transaction Expenses</u>&rdquo;
means the aggregate amount of any and all documented out-of-pocket fees and expenses reasonably incurred by or on behalf of, or paid
directly by, the Buyer in connection with the transactions contemplated hereby, including diligence and the negotiation, preparation,
and execution of the Transaction Documents, and the consummation of the transactions contemplated hereby; provided, however, that such
fees and expenses shall not exceed $[***], subject to increase upon mutual agreement of the Buyer and the Seller.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>U.S.-Ireland Treaty</u>&rdquo;
is defined in &lrm;Section&nbsp;6.13(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<u>U.S. Marketing
Approval</u>&rdquo; is defined in &lrm;Section&nbsp;5.2(a)(i).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<u>UCC</u>&rdquo;
means the Uniform Commercial Code as in effect from time to time in the State of New York; provided, that, if, with respect to any financing
statement or by reason of any provisions of applicable law, the perfection or the effect of perfection or non-perfection of the back-up
security interest or any portion thereof granted pursuant to &lrm;Section&nbsp;2.1(c)&nbsp;is governed by the Uniform Commercial Code
as in effect in a jurisdiction of the United States other than the State of New York, then &ldquo;UCC&rdquo; means the Uniform Commercial
Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement
relating to such perfection or effect of perfection or non-perfection.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<u>Valid Claim</u>&rdquo;
shall mean: (a)&nbsp;any claim of an issued and unexpired Patent included within the Patent Rights, that shall not have been withdrawn,
lapsed, abandoned, revoked, canceled or disclaimed, or held invalid or unenforceable by a court, Governmental Entity, national or regional
patent office or other appropriate body that has competent jurisdiction in a decision being final and unappealable or unappealed within
the time allowed for appeal; and (b)&nbsp;a claim of a pending Patent application included within the Patent Rights that is filed and
being prosecuted in good faith and that has not been finally abandoned or finally rejected and which has been pending for no more than
[***] years from the date of filing of the earliest Patent application to which such pending Patent application claims priority.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">Section&nbsp;1.2</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>Certain
Interpretations</u>. Except where expressly stated otherwise in this Agreement, the following rules&nbsp;of interpretation apply to this
Agreement:</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">&ldquo;either&rdquo;
and &ldquo;or&rdquo; are not exclusive and &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo; are not limiting
and shall be deemed to be followed by the words &ldquo;without limitation&rdquo;;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">&ldquo;extent&rdquo;
in the phrase &ldquo;to the extent&rdquo; means the degree to which a subject or other thing extends, and such phrase does not mean simply
 &ldquo;if&rdquo;;</font></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(c)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">&ldquo;hereof,&rdquo;
 &ldquo;hereto,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement refer
to this Agreement as a whole and not to any particular provision of this Agreement;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(d)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">references
to a Person are also to its permitted successors and assigns;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(e)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">definitions
are applicable to the singular as well as the plural forms of such terms;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(f)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">references
to an &ldquo;Article&rdquo;, &ldquo;Section&rdquo; or &ldquo;Exhibit&rdquo; refer to an Article&nbsp;or Section&nbsp;of, or an Exhibit&nbsp;to,
this Agreement, and references to a &ldquo;Schedule&rdquo; refer to the corresponding part of the Disclosure Schedule;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(g)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">references
to &ldquo;$&rdquo; or otherwise to dollar amounts refer to the lawful currency of the United States; and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(h)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">references
to a law include any amendment or modification to such law and any rules&nbsp;and regulations issued thereunder, whether such amendment
or modification is made, or issuance of such rules&nbsp;and regulations occurs, before or after the date of this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">ARTICLE&nbsp;2</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000"></font>PURCHASE,
SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">Section&nbsp;2.1</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>Purchase,
Sale and Assignment</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">At
the Tranche 1 Closing and upon the terms and subject to the conditions of this Agreement, the Seller shall sell, transfer, assign and
convey to the Buyer, without recourse (except as expressly provided herein), and the Buyer shall purchase, acquire and accept from the
Seller, the Tranche 1 Revenue Participation Right, free and clear of all Liens, except for any Lien contemplated under subparts (a),
(b), (f), (g), and (k)&nbsp;of the definition of &ldquo;Permitted Liens&rdquo;. Immediately upon the sale to the Buyer by the Seller
of the Tranche 1 Revenue Participation Right pursuant to this &lrm;Section&nbsp;2.1(a), all of the Seller&rsquo;s right, title and interest
in and to the Tranche 1 Revenue Participation Right shall terminate, and all such right, title and interest shall vest in the Buyer.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">At
the Tranche 2 Closing and upon the terms and subject to the conditions of this Agreement, the Seller shall sell, transfer, assign and
convey to the Buyer, without recourse (except as expressly provided herein), and the Buyer shall purchase, acquire and accept from the
Seller, the Tranche 2 Revenue Participation Right, free and clear of all Liens, except for any Lien contemplated under subparts (a),
(b), (f), (g), and (k)&nbsp;of the definition of &ldquo;Permitted Liens&rdquo;. Immediately upon the sale to the Buyer by the Seller
of the Tranche 2 Revenue Participation Right pursuant to this &lrm;Section&nbsp;2.1(b), all of the Seller&rsquo;s right, title and interest
in and to the Tranche 2 Revenue Participation Right shall terminate, and all such right, title and interest shall vest in the Buyer.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(c)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">It
is the intention of the parties hereto that the sale, transfer, assignment and conveyance contemplated by this Agreement be, and is,
a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller to the Buyer of all of the Seller&rsquo;s
right, title and interest in and to the Revenue Participation Right. Neither the Seller nor the Buyer intends the transactions contemplated
by this Agreement to be, or for any purpose characterized as, a loan from the Buyer to the Seller or a pledge, a security interest, a
financing transaction or a borrowing. It is the intention of the parties hereto that the beneficial interest in and title to the Revenue
Participation Right and any &ldquo;proceeds&rdquo; (as such term is defined in the UCC) thereof shall not be part of the Seller&rsquo;s
estate in the event of the filing of a petition by or against the Seller under any Bankruptcy Laws. Each of the Seller and the Buyer
hereby waives (each on behalf of itself and its Affiliates), to the maximum extent permitted by applicable law, any right to contest
or otherwise assert that this Agreement does not constitute a true, complete, absolute and irrevocable sale, transfer, assignment and
conveyance by the Seller to the Buyer of all of the Seller&rsquo;s right, title and interest in and to the Revenue Participation Right
under applicable law, which waiver shall, to the maximum extent permitted by applicable law, be enforceable against the Seller in any
bankruptcy or insolvency proceeding relating to any Grantor. Accordingly, the Seller shall treat the sale, transfer, assignment and conveyance
of the Revenue Participation Right as a sale of an &ldquo;account&rdquo; or a &ldquo;payment intangible&rdquo; (as appropriate) in accordance
with the UCC, and the Seller hereby authorizes the Buyer to file financing statements (and continuation statements with respect to such
financing statements when applicable) naming the Seller as the debtor/Seller and the Buyer as the secured party/Buyer in respect to the
Revenue Participation Right. Not in derogation of the foregoing statement of the intent of the parties hereto in this regard, and for
the purposes of providing additional assurance to the Buyer in the event that, despite the intent of the parties hereto, the sale, transfer,
assignment and conveyance contemplated hereby is hereafter held by a court of competent jurisdiction not to be a sale (any such event,
a &ldquo;<u>Recharacterization Event</u>&rdquo;), each Grantor does hereby grant to the Buyer, as security for the payment of amounts
to the Buyer equal to the Purchase Price (including a market rate of return thereon) less all Royalty Payments received by the Buyer
pursuant to this Agreement, a security interest in and to all right, title and interest in, to and under the Revenue Participation Right,
the Royalty Payments (excluding, for the avoidance of doubt, accounts (as defined in the UCC) of the Grantor) and the Product Collateral
and any &ldquo;proceeds&rdquo; (as defined in the UCC) thereof, and each Grantor does hereby authorize the Buyer, from and after each
Closing, to file such security filings and/or financing statements (and continuation statements with respect to such financing statements
when applicable) in such manner and such jurisdictions as are necessary or appropriate to perfect such security interest (the &ldquo;<u>Back-Up
Security Interest</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">Section&nbsp;2.2</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>Purchase
Price</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">At
the Tranche 1 Closing and upon the terms and subject to the conditions of this Agreement, the purchase price to be paid as consideration
to the Seller for the sale, transfer, assignment and conveyance of the Tranche 1 Revenue Participation Right to the Buyer is Thirty Million
Dollars ($30,000,000) in cash (the &ldquo;<u>Tranche 1 Purchase Price</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">At
the Tranche 2 Closing and upon the terms and subject to the conditions of this Agreement, the purchase price to be paid as consideration
to the Seller for the sale, transfer, assignment and conveyance of the Tranche 2 Revenue Participation Right to the Buyer is Forty-Five
Million Dollars ($45,000,000) in cash (the &ldquo;<u>Tranche 2 Purchase Price</u>&rdquo;, and collectively with the Tranche 1 Purchase
Price, the &ldquo;<u>Purchase Price</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">Section&nbsp;2.3</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>No
Assumed Obligations, Etc.</u> Notwithstanding any provision in this Agreement to the contrary, the Buyer is only agreeing, on the terms
and conditions set forth in this Agreement, to purchase, acquire and accept the Revenue Participation Right and is not assuming any liability
or obligation of the Seller or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">ARTICLE&nbsp;3</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000"></font>CLOSING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">Section&nbsp;3.1</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>Tranche
1 Closing; Tranche 2 Closing</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Subject
to the satisfaction of the conditions set forth in <u>Section&nbsp;5.2</u>, the purchase and sale of the Tranche 1 Revenue Participation
Right shall take place remotely via the exchange of documents and signatures after July&nbsp;1, 2023 on the date that is [***] calendar
days after the Buyer&rsquo;s receipt of written notice from the Seller of the satisfaction of the conditions set forth in &lrm;Section&nbsp;5.2(a)&nbsp;(other
than those conditions that by their nature are to be satisfied at such closing or those conditions that have been waived by the Buyer)
(the &ldquo;<u>Tranche 1 Closing</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">If
the Seller&rsquo;s quarterly net revenue is at least Twenty-Five Million Dollars ($25,000,000) for any single Calendar Quarter through
and including the second Calendar Quarter of 2024, the Seller may elect to receive the Tranche 2 Purchase Price (defined below) by delivering
a written notice of such election to the Buyer prior to or on August&nbsp;31, 2024 (the &ldquo;<u>Tranche 2 Election</u>&rdquo;). Subject
to the Tranche 1 Closing and the Buyer&rsquo;s receipt of a valid Tranche 2 Election prior to or on August&nbsp;31, 2024, the purchase
and sale of the Tranche 2 Revenue Participation Right shall take place remotely via the exchange of documents and signatures on the date
that is [***] calendar days after the Buyer&rsquo;s receipt of the valid Tranche 2 Election, which shall include written notice from
the Seller of the satisfaction of the conditions set forth in &lrm;Section&nbsp;5.3 (other than those conditions that by their nature
are to be satisfied at such closing or those conditions that have been waived by the Buyer) (the &ldquo;<u>Tranche 2 Closing</u>&rdquo;).
If the Buyer does not receive a valid Tranche 2 Election prior to or on August&nbsp;31, 2024, the Seller will make a one-time payment
to the Buyer of [***] on the first Business Day following August&nbsp;31, 2024.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt; color: #010000">Section&nbsp;3.2</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>Payment
of Purchase Price</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">At
the Tranche 1 Closing, (i)&nbsp;the Buyer shall deliver (or cause to be delivered) payment of the Tranche 1 Purchase Price to the Seller
by electronic funds transfer or wire transfer of immediately available funds to one or more accounts specified by the Seller and (ii)&nbsp;upon
confirmation of the receipt of the Tranche 1 Purchase Price, the Seller shall deliver to the Buyer a duly executed bill of sale evidencing
the sale, transfer, assignment and conveyance of the Tranche 1 Revenue Participation Right in the form attached hereto as Exhibit&nbsp;B;
provided, that the Buyer shall have the right to, at its option, fund the Tranche 1 Purchase Price on a net basis less the reimbursement
owed by the Seller pursuant to &lrm;Section&nbsp;11.3.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">At
the Tranche 2 Closing, (i)&nbsp;the Buyer shall deliver (or cause to be delivered) payment of the Tranche 2 Purchase Price to the Seller
by electronic funds transfer or wire transfer of immediately available funds to one or more accounts specified by the Seller and (ii)&nbsp;upon
confirmation of the receipt of the Tranche 2 Purchase Price, the Seller shall deliver to the Buyer a duly executed bill of sale evidencing
the sale, transfer, assignment and conveyance of the Tranche 2 Revenue Participation Right in the form attached hereto as Exhibit&nbsp;B;
provided, that the Buyer shall have the right to, at its option, fund the Tranche 2 Purchase Price on a net basis less the reimbursement
owed by the Seller pursuant to &lrm;Section&nbsp;11.3.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">ARTICLE&nbsp;4</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase; color: #010000"></font>REPRESENTATIONS
AND WARRANTIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">Section&nbsp;4.1</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</font><font style="font-size: 10pt"><u>Parent&rsquo;s
and Seller&rsquo;s Representations and Warranties</u>. Except as set forth on the Disclosure Schedule attached hereto (which may be updated
and delivered by the Seller as of each Closing Date solely with respect to the representations and warranties set forth in Section&nbsp;4.1(h),
4.1(k)&nbsp;and 4.1(l); provided that such Disclosure Schedule may not be updated to the extent any updates would qualify any such representation
and warranty in a manner that would be materially adverse to the Buyer&rsquo;s interests under this Agreement), each of the Parent and
the Seller represents and warrants to the Buyer that as of the Effective Date and as of each Closing Date:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(a)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt"><u>Existence</u>.
The Parent is a public limited company duly incorporated and  validly existing under the laws of Ireland. The Seller is a limited
liability company duly organized, validly existing and in good standing under the laws of the State of Delaware. Avadel Ireland is a
private company limited by shares incorporated under the laws of Ireland, duly incorporated and validly existing under the laws of
Ireland. The Parent and each member of the Seller Group is duly licensed or qualified to do business and is in corporate good
standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and
assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed
or qualified and in corporate good standing has not and would not reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(b)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt"><u>Authorization</u>.
The Parent and each member of the Seller Group has all requisite corporate power and authority to execute, deliver and perform its obligations
under this Agreement. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated
hereby, have been duly authorized by all necessary corporate action on the part of the Parent and each member of the Seller Group.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt; color: #010000">(c)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt"><u>Enforceability</u>.
This Agreement has been duly executed and delivered by an authorized officer of the Parent and each member of the Seller Group and constitutes
the valid and binding obligation of the Parent and each member of the Seller Group, enforceable against the Parent and each member of
the Seller Group in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity
(whether considered in a proceeding in equity or at law).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt; color: #010000">(d)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt"><u>No
Conflicts</u>. The execution, delivery and performance by the Parent and each member of the Seller Group of this Agreement and the consummation
of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;contravene or conflict with the Constitution or organizational
documents, as applicable, of the Parent or any member of the Seller Group, (ii)&nbsp;contravene or conflict with or constitute a material
default under any law binding upon or applicable to the Parent or any member of the Seller Group or the Revenue Participation Right or
(iii)&nbsp;contravene or conflict with or constitute a material default under any material agreement or Judgment binding upon or applicable
to the Parent or any member of the Seller Group or the Revenue Participation Right.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(e)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt"><u>Consents</u>.
Except for the consents that have been obtained on or prior to the Effective Date, the UCC financing statements contemplated by &lrm;Section&nbsp;2.1(c)&nbsp;or
any filings required to be made at the Companies Registration Office of Ireland against the Grantors in respect of the security granted
pursuant to the terms of this Agreement or any Back-Up Security Interest, or any filings required by U.S. federal securities laws or
stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental
Entity or other Person is required to be done or obtained by the Parent or any member of the Seller Group in connection with (i)&nbsp;the
execution and delivery by the Parent or any member of the Seller Group of this Agreement, (ii)&nbsp;the performance by the Seller or
the Parent of its obligations under this Agreement or (iii)&nbsp;the consummation by the Parent or any member of the Seller Group of
any of the transactions contemplated by this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(f)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt"><u>No
Litigation</u>. Neither the Parent nor any of its Subsidiaries is a party to, and has not received any written notice of, any action,
suit, investigation or proceeding pending before any Governmental Entity and, to the Knowledge of the Parent, no such action, suit, investigation
or proceeding has been threatened against the Parent or any member of the Seller Group, that, individually or in the aggregate, has had
or would, if determined adversely, reasonably be expected to have a Material Adverse Effect.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(g)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt"><u>Compliance</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(i)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">All
applications, submissions, information and data related to a Product submitted or utilized as the basis for any request to any Regulatory
Authority by or on behalf of the Parent or any member of the Seller Group were true and correct in all material respects as of the date
of such submission or request, and, to the Knowledge of the Parent any material updates, changes, corrections or modification to such
applications, submissions, information or data required under applicable laws or regulations have been submitted to the necessary Regulatory
Authorities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(ii)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">Neither
the Parent nor any of its Subsidiaries has committed any act, made any statement or failed to make any statement that would reasonably
be expected to provide a basis for the FDA or EMA to invoke its policy with respect to &ldquo;Fraud, Untrue Statements of Material Facts,
Bribery, and Illegal Gratuities&rdquo;, or similar policies, set forth in any applicable laws or regulations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt; color: #010000">(iii)</font><font style="color: #010000">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><font style="font-size: 10pt">None
of the Parent, any of its Subsidiaries and, to the Knowledge of the Parent, any Third Party manufacturer of any Product, has received
from the FDA a &ldquo;Warning Letter&rdquo;, Form&nbsp;FDA-483, &ldquo;Untitled Letter,&rdquo; or similar material written correspondence
or notice alleging violations of applicable laws and regulations enforced by the FDA, or any comparable material written correspondence
from any other Regulatory Authority with regard to either Product or the manufacture, processing, packaging or holding thereof, the subject
of which communication is unresolved and if determined adversely to the Parent or such Subsidiary would, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(iv)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Since
[***], (A)&nbsp;there have been no Safety Notices, (B)&nbsp;to the Knowledge of the Parent, there are no unresolved material product
complaints with respect to any Product, which would result in a Material Adverse Effect, and (C)&nbsp;to the Knowledge of the Parent,
there are no facts currently in existence that would, individually or in the aggregate, reasonably be expected to result in (1)&nbsp;a
material Safety Notice with respect to any Product, or (2)&nbsp;a material change in the labeling of any Product. Since [***], neither
the Parent nor any of its Subsidiaries has experienced any significant failures in the manufacturing of any Product for clinical use
or commercial sale that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred
again, a Material Adverse Effect.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(h)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Licenses</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>In-Licenses</u>.
There are no In-Licenses.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Out-Licenses</u>.
Except as set forth on <u>Schedule&nbsp;4.1(h)(ii)</u>&nbsp;of the Disclosure Schedule, there are no Out-Licenses (any Out-License set
forth on <u>Schedule&nbsp;4.1(h)(ii)</u>&nbsp;of the Disclosure Schedule, an &ldquo;<u>Existing Out-License</u>&rdquo;). Neither the
Parent nor any member of the Seller Group nor the respective counterparty thereto has made or entered into any amendment, supplement
or modification to, or granted any waiver under any provision of any Existing Out-License.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(iii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Validity
and Enforceability of Out-Licenses</u>. Each Existing Out-License is a valid and binding obligation of the Seller Group and, to the Knowledge
of the Parent, the counterparty thereto. To the Knowledge of the Parent, each Existing Out-License is enforceable against each counterparty
thereto in accordance with its terms except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether
considered in a proceeding in equity or at law). Neither the Parent nor any member of the Seller Group has received any written notice
in connection with any Existing Out-License challenging the validity, enforceability or interpretation of any provision of such agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(iv)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Termination</u>. Neither the Parent nor any member of the Seller Group has (A)&nbsp;given notice to a counterparty of the termination
of any Existing Out-License (whether in whole or in part) or any notice to a counterparty expressing any intention or desire to terminate
any Existing Out-License or (B)&nbsp;received from a counterparty thereto any written notice of termination of any Existing Out-License
(whether in whole or in part) or any written notice from a counterparty expressing any intention or desire to terminate any Existing
Out-License.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(v)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Breaches or Defaults</u>. There is and has been no material breach or default under any provision of any Existing Out-License either
by the Parent or a member of the Seller Group or, to the Knowledge of the Parent, by the respective counterparty (or any predecessor
thereof) thereto, and there is no event that upon notice or the passage of time, or both, would reasonably be expected to give rise to
any breach or default either by a member of the Seller Group or, to the Knowledge of the Parent, by the respective counterparty to such
agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(vi)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Payments
Made</u>. The respective counterparty of each Existing Out-License has made all payments (other than payments not yet due) to the Parent
or a member of the Seller Group required under each Existing Out-License.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(vii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Assignments</u>. Neither the Parent nor any member of the Seller Group has consented to any assignment by the counterparty to any Existing
Out-License of any of its rights or obligations under any such Existing Out-License and, to the Knowledge of the Parent, the counterparty
has not assigned any of its rights or obligations under any such Existing Out-License to any Person.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(viii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Indemnification Claims</u>. Neither the Parent nor any member of the Seller Group has notified any Person of any claims for indemnification
under any Existing Out-License nor has the Parent or any member of the Seller Group received any claims for indemnification under any
Existing Out-License.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"><font style="font-size: 10pt">(ix)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Infringement</u>. Neither the Parent nor any of its Subsidiaries has received any written notice from, or given any written notice to,
any counterparty to any Existing Out-License regarding any infringement of any of the Existing Patent Rights licensed thereunder.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Liens; Title to Product Collateral and Revenue Participation Right</u>. The Seller Group is the sole and exclusive owner of all of the
Product Collateral. None of the property or assets, in each case, that specifically relate to the Products, including Intellectual Property
Rights, of the Seller Group is subject to any Lien, except for a Permitted Lien. Upon the applicable Closing Date, the Buyer will have
acquired, subject to the terms and conditions set forth in this Agreement, good and marketable title to the Tranche 1 Revenue Participation
Right or the Tranche 2 Revenue Participation Right, as applicable, free and clear of all Liens, except for a Lien contemplated by subparts
(a), (b), (f), (g), and (k)&nbsp;of the definition of &ldquo;Permitted Liens&rdquo;.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(j)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Manufacturing;
Supply</u>. All Products have, since [***], been manufactured, transported, stored and handled in all material respects in accordance
with applicable law and with good manufacturing practices. Since [***], neither the Parent nor any Affiliate of the Parent has experienced
any significant failures in the manufacturing or supply of any Product that, individually or in the aggregate, have had or would reasonably
be expected to result in, if such failure occurred again, a Material Adverse Effect. The Seller has on hand or has made adequate provisions
to secure sufficient clinical quantities of Products to complete all clinical trials and all activities required for Marketing Approvals,
in each case, that are ongoing or planned as of the Effective Date. The Seller has on hand or has made adequate provisions to secure
sufficient quantities of LUMRYZ to support the commercial launch of LUMRYZ in the Territory.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(k)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Intellectual
Property</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Schedule
4.1(k)(i)(A)</u>&nbsp;of the Disclosure Schedule lists all of the currently existing Patents included within the Patent Rights (the &ldquo;<u>Existing
Patent Rights</u>&rdquo;). The Seller Group is the sole and exclusive owner of all of the Existing Patent Rights. <u>Schedule 4.1(k)(i)(A)</u>&nbsp;of
the Disclosure Schedule specifies as to each listed patent or patent application the jurisdictions by or in which each such patent has
issued as a patent or such patent application has been filed, including the respective patent or application numbers.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Neither
the Parent nor any of its Subsidiaries is a party to any pending and, to the Knowledge of the Parent, there is no threatened, litigation,
interference, reexamination, opposition or like procedure involving any of the Existing Patent Rights.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(iii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">All
of the issued patents within the Existing Patent Rights are (A)&nbsp;to the Knowledge of the Parent, valid and enforceable, and (B)&nbsp;in
full force and effect. None of the issued patents within the Existing Patent Rights have lapsed, expired or otherwise terminated. Neither
the Parent nor any of its Subsidiaries has received any written notice relating to the lapse, expiration or other termination of any
of the issued patents within the Existing Patent Rights, and neither the Parent nor any of its Subsidiaries has received any written
legal opinion that alleges that, an issued patent within any of the Existing Patent Rights is invalid or unenforceable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(iv)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Neither
the Parent nor any member of the Seller Group has received any written notice that there is any, and, to the Knowledge of the Parent,
there is no, Person who is or claims to be an inventor under any of the Existing Patent Rights who is not a named inventor thereof.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(v)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Neither
the Parent nor any of its Affiliates has received any written notice of any claim by any Person challenging the inventorship or ownership
of, the rights of the Seller Group in and to, or the patentability, validity or enforceability of, any of the Existing Patent Rights,
or asserting that the development, manufacture, importation, sale, offer for sale or use of the Product infringes, misappropriates or
otherwise violates or will infringe, misappropriate or otherwise violate such Person&rsquo;s Patents or other intellectual property rights.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(vi)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">To
the Knowledge of the Parent, the discovery, development manufacture, importation, sale, offer for sale or use of each Product, in each
case in the form such Product exists as of the Effective Date and as and to the extent such activity is currently contemplated by the
Parent or any member of the Seller Group, has not and will not, infringe, misappropriate or otherwise violate any Patents or other intellectual
property rights owned by any Third Party.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(vii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">To
the Knowledge of the Parent, no Person has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise
violating, any of the Intellectual Property Rights.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><font style="font-size: 10pt">(viii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller Group has paid all maintenance fees, annuities and like payments (other than any such payments not yet due) required with respect
to each of the Existing Patent Rights.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(l)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Indebtedness</u>.
<u>Schedule 4.1(l)</u>&nbsp;sets forth a complete list of the outstanding Indebtedness of the Parent or any member of the Seller Group
in excess of $[***] in the aggregate.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(m)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Lien
Related Representation and Warranties</u>. The Seller&rsquo;s exact legal name is, and since December&nbsp;4, 2019 has been, &ldquo;Avadel
CNS Pharmaceuticals, LLC&rdquo;. The Seller is, and since December&nbsp;4, 2019 has been, a limited liability company organized in the
State of Delaware. Avadel Ireland&rsquo;s exact legal name is, and for the immediately preceding five (5)&nbsp;years has been, &ldquo;Flamel
Ireland Limited&rdquo;. Avadel Ireland is, and for the prior five (5)&nbsp;years has been, a private company limited by shares incorporated
under the laws of Ireland. The Parent&rsquo;s exact legal name is, and for the immediately preceding five (5)&nbsp;years has been, &ldquo;Avadel
Pharmaceuticals Public Limited Company&rdquo;. The Parent is, and for the prior five (5)&nbsp;years has been, incorporated in Ireland.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(n)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Brokers&rsquo;
Fees</u>. There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized
to act on behalf of the Parent or the Seller who might be entitled to any fee or commission in connection with the transactions contemplated
by this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;4.2</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Buyer&rsquo;s
Representations and Warranties</u>. The Buyer hereby represents and warrants to the Seller that:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Existence;
Good Standing</u>. The Buyer is a designated activity company duly incorporated, duly organized and validly existing under the laws of
Ireland.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Authorization</u>.
The Buyer has the requisite power and authority to execute, deliver and perform its obligations under this Agreement. The execution,
delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by
all necessary action on the part of the Buyer.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Enforceability</u>.
This Agreement has been duly executed and delivered by an authorized person of the Buyer and constitutes the valid and binding obligation
of the Buyer, enforceable against the Buyer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by
general principles of equity (whether considered in a proceeding in equity or at law).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Conflicts</u>. The execution, delivery and performance by the Buyer of this Agreement do not and will not (i)&nbsp;contravene or conflict
with the organizational documents of the Buyer, (ii)&nbsp;contravene or conflict with or constitute a default under any material provision
of any law binding upon or applicable to the Buyer or (iii)&nbsp;contravene or conflict with or constitute a default under any material
contract or other material agreement or Judgment binding upon or applicable to the Buyer.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(e)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Consents</u>.
Except for any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization,
registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Buyer
in connection with (i)&nbsp;the execution and delivery by the Buyer of this Agreement, (ii)&nbsp;the performance by the Buyer of its
obligations under this Agreement or (iii)&nbsp;the consummation by the Buyer of any of the transactions contemplated by this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(f)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Litigation</u>. There is no action, suit, investigation or proceeding pending or, to the knowledge of the Buyer, threatened before any
Governmental Entity to which the Buyer is a party that would, if determined adversely, reasonably be expected to prevent or materially
and adversely affect the ability of the Buyer to perform its obligations under this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(g)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Financing</u>.
The Buyer will have sufficient cash to pay the Purchase Price at the Closing. The Buyer acknowledges that its obligations under this
Agreement are not contingent on obtaining financing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(h)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Brokers&rsquo;
Fees</u>. There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized
to act on behalf of the Buyer who might be entitled to any fee or commission in connection with the transactions contemplated by this
Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">Section&nbsp;4.3</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Implied Representations and Warranties</u>. The Buyer acknowledges and agrees that, other than the express representations and warranties
of the Parent and the Seller specifically contained in &lrm;ARTICLE&nbsp;4, (a)&nbsp;there are no representations or warranties of the
Parent or the Seller either expressed or implied with respect to the Patent Rights or Royalty Payment and that the Buyer does not rely
on, and shall have no remedies in respect of, any representation or warranty not specifically set forth in &lrm;ARTICLE&nbsp;4, and all
other representations and warranties are hereby expressly disclaimed, and (b)&nbsp;nothing contained herein guarantees that sales of
the Products or the aggregate Royalty Payments due to the Buyer will achieve any specific amounts (it being understood and agreed that
nothing in this &lrm;Section&nbsp;4.3 shall limit in any way the Seller&rsquo;s obligations under &lrm;ARTICLE&nbsp;8). Notwithstanding
the foregoing, claims for fraud, gross negligence, or willful misconduct shall not be waived or limited in any way by this &lrm;Section&nbsp;4.3.
Except for the Revenue Participation Right, Back-up Security Interest and the Buyer&rsquo;s rights under &lrm;Section&nbsp;6.5(e), the
Buyer further acknowledges and agrees that no licenses or assignments under any assets (including the Patent Rights or any other intellectual
property) of the Seller and its Affiliates are granted pursuant to this Agreement, including by implication, estoppel, exhaustion or
otherwise.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">ARTICLE&nbsp;5</font><br>
CONDITIONS TO CLOSING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;5.1</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Effective
Date Actions</u>. Prior to or contemporaneously with the execution of this Agreement:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Buyer shall have received a certificate of an authorized officer of the Parent, the Seller, and Avadel Ireland, dated as of the date
of this Agreement, certifying as to (i)&nbsp;the incumbency of each officer of the Parent, the Seller, and Avadel Ireland executing this
Agreement and (ii)&nbsp;the attached thereto copies of the Parent&rsquo;s, the Seller&rsquo;s, and Avadel Ireland&rsquo;s (A)&nbsp;organizational
documents and (B)&nbsp;resolutions adopted by such party&rsquo;s Board of Directors and/or duly appointed committee authorizing the execution
and delivery by the Parent, the Seller, and Avadel Ireland, respectively, of this Agreement and the consummation by the Parent, the Seller,
and Avadel Ireland of the transactions contemplated hereby (the &ldquo;<u>Seller Certificate</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall have received a certificate of an authorized person of the Buyer, dated the date of this Agreement, certifying as to the
incumbency of the officers executing this Agreement on behalf of the Buyer.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Buyer shall have received a valid, properly executed Internal Revenue Service Form&nbsp;W-9 certifying that the Seller is exempt from
U.S. federal &ldquo;backup&rdquo; withholding Tax.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;5.2</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Conditions
to the Tranche 1 Closing Date</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
obligations of the Buyer to consummate the transactions contemplated hereunder to occur at the Tranche 1 Closing are subject to the satisfaction
or waiver, at or prior to the Tranche 1 Closing Date, of each of the following conditions precedent:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Seller
shall have received Marketing Approval from the FDA for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in
adults with narcolepsy, and such Marketing Approval shall not have been withdrawn by the FDA (&ldquo;<u>U.S. Marketing Approval</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller and the Parent shall have performed and complied in all material respects with all agreements, covenants, obligations and conditions
required to be performed and complied with by it under this Agreement at or prior to the Tranche 1 Closing Date, and the Buyer shall
have received a certificate executed by a duly authorized officer of the Seller and the Parent on the Tranche 1 Closing Date certifying
on behalf of the Seller and the Parent to the effect of the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
representations and warranties of the Seller and the Parent contained in &lrm;Section&nbsp;4.1 shall have been true and correct in all
material respects as of the date hereof and shall be true and correct in all material respects as of the Tranche 1 Closing Date as though
made at and as of the date hereof and as of the Tranche 1 Closing Date, respectively, except to the extent any such representation or
warranty expressly speaks as of a particular date, in which case it shall be true and correct in all material respects as of such date;
provided, that to the extent that any such representation or warranty is qualified by the term &ldquo;material&rdquo; or &ldquo;Material
Adverse Effect&rdquo; such representation or warranty (as so written, including the term &ldquo;material&rdquo; or &ldquo;Material Adverse
Effect&rdquo;) shall have been true and correct in all respects as of the date hereof and shall be true and correct in all respects as
of the Tranche 1 Closing Date or such other date, as applicable. The Buyer shall have received a certificate executed by an authorized
officer of the Seller and the Parent on the Tranche 1 Closing Date certifying on behalf of the Seller and the Parent to the effect of
the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iv)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">No
event or events shall have occurred, or be reasonably likely to occur, that, individually or in the aggregate, have had or would reasonably
be expected to result in (or, with the giving of notice, the passage of time or otherwise, would result in) a Material Adverse Effect.
The Buyer shall have received a certificate executed by a duly authorized officer of the Seller and the Parent on the Tranche 1 Closing
Date certifying on behalf of the Seller and the Parent to the effect of the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(v)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
First Shipment of LUMRYZ shall have occurred.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(vi)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
2023 Notes Indenture shall have been amended in accordance with terms mutually agreed upon by the Buyer and the Parent, including the
extension of the Maturity Date therein.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(vii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Buyer shall have received financing statements naming each Grantor as a debtor and the Buyer as the secured party, or other similar instruments,
registrations, or documents, in each case suitable for filing under the UCC (or equivalent law) of all jurisdictions as may be necessary
or, in the reasonable opinion of the Buyer, desirable to perfect the Back-Up Security Interest in the Product Collateral; provided that
the delivery of any such financing statements, instruments, registrations or documents to be filed under or governed under the laws of
any non-U.S. jurisdiction shall be subject to Section&nbsp;6.14(c).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(viii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller and the Parent, respectively, shall have delivered to the Buyer the legal opinions of Goodwin Procter LLP and Arthur Cox LLP covering
the items described on Exhibit&nbsp;C.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
obligations of the Seller to consummate the transactions contemplated hereunder on the Tranche 1 Closing Date are subject to the satisfaction
or waiver, at or prior to the Tranche 1 Closing Date, of each of the following conditions precedent:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Buyer shall have performed and complied in all material respects with all agreements, covenants, obligations and conditions required
to be performed and complied with by it under this Agreement at or prior to the Tranche 1 Closing Date, and the Seller shall have received
a certificate executed by a duly authorized person of the Buyer, on the Tranche 1 Closing Date, certifying on behalf of the Buyer to
the effect of the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated with [***] in this document has been
omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that the registrant treats as private or
confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
representations and warranties of the Buyer contained in &lrm;Section&nbsp;4.2 shall have been true and correct in all material respects
as of the date hereof and shall be true and correct in all material respects as of the Tranche 1 Closing Date as though made at and as
of the date hereof and Tranche 1 Closing Date, respectively, except to the extent any such representation or warranty expressly speaks
as of a particular date, in which case it shall be true and correct in all material respects as of such date; provided, that to the extent
that any such representation or warranty is qualified by the term &ldquo;material,&rdquo; or &ldquo;Material Adverse Effect&rdquo; such
representation or warranty (as so written, including the term &ldquo;material&rdquo; or &ldquo;Material Adverse Effect&rdquo;) shall
have been true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the Tranche 1 Closing
Date or such other date, as applicable. The Seller shall have received a certificate executed by a duly authorized person of the Buyer
on the Tranche 1 Closing Date certifying on behalf of the Buyer to the effect of the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
obligations of each Party to consummate the transactions contemplated hereunder on the Tranche 1 Closing Date are subject to the satisfaction
or waiver, at or prior to the Tranche 1 Closing Date, of each of the following conditions precedent:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">There
shall not have been issued and be in effect any Judgment of any Governmental Entity enjoining, preventing or restricting Buyer&rsquo;s
purchase of the Tranche 1 Revenue Participation Right.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">There
shall not have been instituted or be pending any action or proceeding by any Governmental Entity or any other Person (i)&nbsp;challenging
or seeking to make illegal, to delay materially or otherwise directly or indirectly to restrain or prohibit the Buyer&rsquo;s purchase
of the Tranche 1 Revenue Participation Right, (ii)&nbsp;seeking to obtain material damages in connection with the transactions contemplated
hereby or (iii)&nbsp;seeking to restrain or prohibit the Buyer&rsquo;s purchase of the Tranche 1 Revenue Participation Right.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;5.3</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Conditions
to the Tranche 2 Closing Date</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
obligations of the Buyer to consummate the transactions contemplated hereunder on the Tranche 2 Closing Date are subject to the satisfaction
or waiver, at or prior to the Tranche 2 Closing Date, of each of the following conditions precedent:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller and the Parent shall have performed and complied in all material respects with all agreements, covenants, obligations and conditions
required to be performed and complied with by it under this Agreement at or prior to the Tranche 2 Closing Date, and the Buyer shall
have received a certificate executed by a duly authorized officer of the Seller and the Parent on the Tranche 2 Closing Date certifying
on behalf of the Seller and the Parent to the effect of the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
representations and warranties of the Seller and the Parent contained in &lrm;Section&nbsp;4.1 shall have been true and correct in all
material respects as of the date hereof and shall be true and correct in all material respects as of the Tranche 2 Closing Date as though
made at and as of the date hereof and as of the Tranche 2 Closing Date, respectively, except to the extent any such representation or
warranty expressly speaks as of a particular date, in which case it shall be true and correct in all material respects as of such date;
provided, that to the extent that any such representation or warranty is qualified by the term &ldquo;material&rdquo; or &ldquo;Material
Adverse Effect&rdquo; such representation or warranty (as so written, including the term &ldquo;material&rdquo; or &ldquo;Material Adverse
Effect&rdquo;) shall have been true and correct in all respects as of the date hereof and shall be true and correct in all respects as
of the Tranche 2 Closing Date or such other date, as applicable. The Buyer shall have received a certificate executed by an authorized
officer of the Seller and the Parent on the Tranche 2 Closing Date certifying on behalf of the Seller and the Parent to the effect of
the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">No
event or events shall have occurred, or be reasonably likely to occur, that, individually or in the aggregate, have had or would reasonably
be expected to result in (or, with the giving of notice, the passage of time or otherwise, would result in) a Material Adverse Effect.
The Buyer shall have received a certificate executed by a duly authorized officer of the Seller and the Parent on the Tranche 2 Closing
Date certifying on behalf of the Seller and the Parent to the effect of the foregoing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Buyer shall have received financing statements naming each Grantor as a debtor and the Buyer as the secured party, or other similar
instruments, registrations, or documents, in each case suitable for filing under the UCC (or equivalent law) of all jurisdictions as may
be necessary or, in the reasonable opinion of the Buyer, desirable to perfect the Back-Up Security Interest in the Product Collateral;
provided that the delivery of any such financing statements, instruments, registrations or documents to be filed under or governed under
the laws of any non-U.S. jurisdiction shall be subject to Section 6.14(c).&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
obligations of each Party to consummate the transactions contemplated hereunder on the Tranche 2 Closing Date are subject to the satisfaction
or waiver, at or prior to the Tranche 2 Closing Date, of each of the following conditions precedent:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">There
shall not have been issued and be in effect any Judgment of any Governmental Entity enjoining, preventing or restricting the consummation
of the transactions contemplated by this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">There
shall not have been instituted or be pending any action or proceeding by any Governmental Entity or any other Person (i)&nbsp;challenging
or seeking to make illegal, to delay materially or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions
contemplated hereby, (ii)&nbsp;seeking to obtain material damages in connection with the transactions contemplated hereby or (iii)&nbsp;seeking
to restrain or prohibit the Buyer&rsquo;s purchase of the Tranche 2 Revenue Participation Right.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">ARTICLE&nbsp;6</font><br>
COVENANTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.1</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Reporting</u>.
From and after the Effective Date:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Following
the end of each Calendar Quarter, promptly, but in any event, no later than the Specified Delivery Date, the Seller shall provide the
Buyer a reasonably detailed quarterly report setting forth, with respect to such Calendar Quarter, (i)&nbsp;the Clinical Updates, (ii)&nbsp;the
Commercial Updates, (iii)&nbsp;the Regulatory Updates, and (iv)&nbsp;the Intellectual Property Updates (the &ldquo;<u>Reports</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall include in each Report (i)&nbsp;any material CMC updates with respect to the Commercialization of the Product and (ii)&nbsp;to
the extent disclosure is permitted under each applicable Out-License, whether any development, sales, regulatory or other milestone event
set forth in such Out-License was achieved and a short description of the applicable milestone.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall also provide the Buyer with such additional information regarding the updates included in each Report as the Buyer may reasonably
request from time to time. At the Buyer&rsquo;s election, the Buyer shall be entitled to a quarterly update meeting, or as the Buyer
may otherwise reasonably request, to discuss the Reports and Royalty Reports delivered by the Seller pursuant to &lrm;Section&nbsp;6.1
and &lrm;&lrm;Section&nbsp;6.2(b), respectively. The Seller and the Parent shall prepare and maintain and shall cause their Affiliates
and Licensees to prepare and maintain reasonably complete and accurate records of the information to be disclosed in each Report. All
Reports, and the Confidential Information contained therein, shall be the Confidential Information of Seller and subject to the obligations
of confidentiality set forth in &lrm;ARTICLE&nbsp;8.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">To
the extent any reporting, notice or information sharing provisions under this <u>Section&nbsp;6.1</u> or as provided elsewhere in this
Agreement would reasonably be expected by either the Buyer or the Seller to violate any valid order of a court of competent jurisdiction,
confidentiality obligation or applicable Law, or constitute a waiver or any attorney/client or similar privilege, or provide the Buyer
with material, non-public information of the Seller or Parent, then the Buyer and Seller shall cooperate to determine appropriate scaled,
redacted or alternative delivery method for such reporting, notice or information sharing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.2</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Royalty
Payments; Royalty Reports; Put/Call Option</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Royalty
Payments</u>. From and after the First Shipment of a Product in any country, the Seller shall pay to the Buyer, without any setoff or
offset (subject, in each case, to &lrm;Section&nbsp;6.13), the Royalty Payment for each Calendar Quarter promptly, but in any event no
later than the Specified Delivery Date. The Royalty Payment payable for the Calendar Quarter during which each Closing occurs shall be
calculated from the start of such Calendar Quarter, and not from the date of such Closing. A late fee of [***]% over the Prime Rate (calculated
on a per annum basis) will accrue on all unpaid amounts with respect to any Royalty Payment from the date such obligation was due. The
imposition and payment of a late fee shall not constitute a waiver of the Buyer&rsquo;s rights with respect to such payment default.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Royalty
Reports</u>. From and after the First Shipment of a Product in any country, for each Calendar Quarter promptly, but in any event no later
the Specified Delivery Date, the Seller shall provide to Buyer a report (a &ldquo;<u>Royalty Report</u>&rdquo;), in substantially the
form to be reasonably agreed between Buyer and Seller within [***] days of the Effective Date, setting forth in reasonable detail with
respect each Product, (A)&nbsp;Gross Sales and Net Sales for the applicable Calendar Quarter and calendar year to date, on a country-by-country
basis (including a detailed break-down of all permitted deductions from Gross Sales used to determine Net Sales and any Net Sales described
in &lrm;Section&nbsp;6.5(e)), (B)&nbsp;the calculation of the Tranche 1 Royalty Payment and, if applicable, the Tranche 2 Royalty Payment
payable to the Buyer for the applicable Calendar Quarter, identifying, on a country-by-country basis, the number of units of each Product
sold by the Seller, its Affiliates and each Licensee; and (C)&nbsp;foreign currency exchange rates used (which shall be rates of exchange
determined in a manner consistent with the Seller&rsquo;s method for calculating rates of exchange in the preparation of the Seller&rsquo;s
annual financial statements in accordance with accounting principles generally accepted in the United States).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Put/Call
Option</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">If
the Parent enters into a definitive agreement with a Person that is not an Affiliate of the Parent to consummate a Change of Control
(such party, the Acquiror, and such agreement, a &ldquo;<u>CoC Agreement</u>&rdquo;), the Seller or such Acquiror shall have the option
to prepay (the &ldquo;<u>Tranche 1 Call Option</u>&rdquo;), or the Buyer may require the Seller to prepay or cause a prepayment (the
 &ldquo;<u>Tranche 1 Put Option</u>&rdquo;) of, a prespecified amount (the &ldquo;<u>Tranche 1 Put/Call Payment</u>&rdquo;) on the date
of consummation of such Change of Control (the &ldquo;<u>Tranche 1 Put/Call Date</u>&rdquo;) to the Buyer and terminate the Tranche 1
Royalty Payments and all obligations thereto, with such pre-specified payment amount to be based on the Tranche 1 Put/Call Date, as follows:
(a)&nbsp;[***] if the Tranche 1 Put/Call Date is after the Tranche 1 Closing Date but prior to or on the first anniversary of the Tranche
1 Closing Date, (b)&nbsp;[***] if the Tranche 1 Put/Call Date is after the first anniversary of the Tranche 1 Closing Date but prior
to or on the second anniversary of the Tranche 1 Closing Date, and (c)&nbsp;an amount equal to [***]; <i>minus</i> the aggregate amount
of all Tranche 1 Royalty Payments received by the Buyer from the Seller as of the Tranche 1 Put/Call Date if the Tranche 1 Put/Call Date
is after the second anniversary of the Tranche 1 Closing Date.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">If
the Parent enters into a COC Agreement, the Seller or the Acquiror shall have the option to prepay (the &ldquo;<u>Tranche 2 Call Option</u>&rdquo;),
or the Buyer may require the Seller to prepay or cause a prepayment (the &ldquo;<u>Tranche 2 Put Option</u>&rdquo;) of, a prespecified
amount (the &ldquo;<u>Tranche 2 Put/Call Payment</u>&rdquo;) on the date of consummation of such Change of Control (the &ldquo;<u>Tranche
2 Put/Call Date</u>&rdquo;) to the Buyer and terminate the Tranche 2 Royalty Payments and all obligations thereto, with such pre-specified
payment amount to be based on the Tranche 2 Put/Call Date, as follows: (a)&nbsp;[***] if the Tranche 2 Put/Call Date is after the Tranche
1 Closing Date but prior to or on the Tranche 2 Closing Date, (b)&nbsp;[***] if the Tranche 2 Put/Call Date is after the Tranche 2 Closing
Date but prior to or on the first anniversary of the Tranche 2 Closing Date, (c)&nbsp;[***] if the Tranche 2 Put/Call Date is after the
first anniversary of the Tranche 2 Closing Date but prior to or on the second anniversary of the Tranche 2 Closing Date, and (d)&nbsp;an
amount equal to [***]; <i>minus</i> the aggregate amount of all Tranche 2 Royalty Payments received by the Buyer from the Seller as of
the Tranche 2 Put/Call Date if the Tranche 2 Put/Call Date is after the second anniversary of the Tranche 2 Closing Date.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">If
the Parent enters into a COC Agreement and the date of consummation of such Change of Control is prior to the Tranche 1 Closing Date,
the Seller or the Acquiror shall have the option to prepay (the &ldquo;<u>Pre-Funding Call Option</u>&rdquo;), or the Buyer may require
the Seller to prepay or cause a prepayment of (the &ldquo;<u>Pre-Funding Put Option</u>&rdquo;), [***] (the &ldquo;<u>Pre-Funding Put/Call
Payment</u>&rdquo;) on the date of consummation of such Change of Control to the Buyer. Upon payment of the Pre-Funding Put/Call Payment,
the Tranche 1 Royalty Payments and the Tranche 2 Royalty Payments and all obligations thereto shall terminate.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iv)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Upon
the Parent entering into a CoC Agreement, the Seller shall, no later than [***] Business Days thereafter, deliver notice of the Parent
entering into such CoC Agreement to the Buyer, including whether the Seller is exercising a Call Option. If the Seller elects to exercise
a Call Option, or if the Buyer exercises a Put Option by delivering notice to the Seller within [***] Business Days after receiving such
notice from the Seller, the Seller shall, no later than [***] Business Days following the consummation of such Change of Control, pay
the applicable Put/Call Payment to the Buyer. The Seller&rsquo;s obligation to pay such Put/Call Payment following the Seller&rsquo;s
exercise of such Call Option or the Buyer&rsquo;s exercise of such Put Option shall be contingent upon the consummation of such Change
of Control; if such Change of Control is not consummated, the exercise of such Call Option or such Put Option shall be void. Upon the
Buyer&rsquo;s receipt of the applicable Put/Call Payment, the Seller&rsquo;s obligations to make the Tranche 1 Royalty Payments or the
Tranche 2 Royalty Payments, as applicable, shall terminate and all rights and/or obligations of the Buyer in respect of the Tranche 1
Revenue Participation Right and/or the Tranche 2 Revenue Participation Right, as applicable, shall automatically without any further
action of the parties be deemed to be released and irrevocably terminated. If both the Tranche 1 Put/Call Payment and the Tranche 2 Put/Call
Payment are made to the Buyer, or if the Pre-Funding Put/Call Payment is made to the Buyer, this Agreement shall automatically terminate.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(v)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
payment of the applicable Put/Call Payment shall be made by wire transfer of immediately available funds to one or more accounts specified
by the Buyer or, if not timely designated by the Buyer, to the account to which payments under the Royalty Payments were transmitted
or are to be transmitted pursuant to &lrm;Section&nbsp;6.2(a). Upon the Buyer&rsquo;s receipt of (a)&nbsp;the Tranche 1 Put/Call Payment
and (b)&nbsp;if the Tranche 2 Closing occurs, the Tranche 2 Put/Call Payment, then except as set forth in &lrm;Section&nbsp;9.3, this
Agreement shall terminate and all rights and obligations of the parties hereunder shall automatically without any further action of the
parties be deemed to be released and irrevocably terminated. Notwithstanding any of the foregoing to the contrary, in the event that
a Call Option or a Put Option is exercised during any Calendar Quarter during which the Seller has earned Net Sales and would otherwise
be obligated to make a Royalty Payment to the Buyer, the Seller shall be obligated to make all Royalty Payments otherwise due in accordance
with &lrm;Section&nbsp;6.2(a)&nbsp;for all such earned Net Sales up to the date the Seller remits the applicable Put/Call Payment to
the Buyer, and such Put/Call Payment shall include the foregoing amount of such Royalty Payment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Any
payments required to be made by either party under this Agreement shall be made in United States Dollars via electronic funds transfer
or wire transfer of immediately available funds to such bank account as the other party shall designate in writing prior to the date
of such payment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.3</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Disclosures</u>.
Except (a)&nbsp;for a press release previously approved in form and substance by the Seller and the Buyer or any other public announcement
using substantially the same text as such press release and (b)&nbsp;any disclosure required by applicable law, by the rules&nbsp;and
regulations of any securities exchange or market on which any security of such party hereto may be listed or traded or by any Governmental
Authority of competent jurisdiction, neither the Buyer nor the Parent or the Seller shall, and each party hereto shall cause its Affiliates
not to, without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld, delayed or conditioned),
issue any press release or make any other public disclosure with respect to this Agreement or any of the other Transaction Documents
or any of the transactions contemplated hereby or thereby. The Buyer acknowledges that it will be necessary for the Parent to file this
Agreement with the SEC and to make other public disclosures regarding the terms of this Agreement and payments made under this Agreement
in its reports filed with the SEC, and the Seller agrees that it will provide the Buyer a reasonable opportunity to review and comment
on any proposed redactions to the copy of this Agreement to be filed with the SEC, as well as on such other public disclosures made by
the Parent or the Seller relating to the Buyer or this Agreement or the transactions contemplated thereby (e.g., press releases or Current
Report on Form&nbsp;8-K), provided that the Seller shall not be required to provide the Buyer the opportunity to review and comment on
any disclosure substantively identical to any disclosure previously reviewed and commented upon by the Buyer.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.4</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Inspections
and Audits of the Seller</u>. Following the Tranche 1 Closing, upon at least fourteen (14) Business Days written notice and during normal
business hours, no more frequently than once per calendar year, the Buyer may cause an inspection and/or audit by an independent public
accounting firm reasonably acceptable to the Seller to be made of the Seller&rsquo;s books of account for the three (3)&nbsp;calendar
years prior to the audit for the purpose of determining the correctness of Royalty Payments made under this Agreement. Upon the Buyer&rsquo;s
reasonable request, no more frequently than once per calendar year while any Out-License remains in effect, the Seller shall use Commercially
Reasonable Efforts to exercise any rights it may have under any Out-License relating to a Product to cause an inspection and/or audit
by an independent public accounting firm to be made of the books of account of any counterparty thereto for the purpose of determining
the correctness of Royalty Payments made under this Agreement. All of the reasonable and documented out-of-pocket expenses of any inspection
or audit requested by the Buyer hereunder (including the reasonable fees and expenses of such independent public accounting firm designated
for such purpose) shall be borne solely by the Buyer, unless the independent public accounting firm determines that Royalty Payments
previously paid during the period of the audit were underpaid by an amount greater than [***]% of the Royalty Payments actually paid
during such period, in which case such expenses shall be borne by the Seller. Any such accounting firm shall not disclose the confidential
information of the Seller or any such Licensee relating to a Product to the Buyer, except to the extent such disclosure is necessary
to determine the correctness of Royalty Payments or otherwise would be included in a Report. All information obtained by the Buyer as
a result of any such inspection or audit shall be Confidential Information subject to &lrm;ARTICLE&nbsp;8. If any audit discloses any
underpayments by the Seller to the Buyer, then such underpayment, shall be paid by the Seller to the Buyer within [***] calendar days
of it being so disclosed. If any audit discloses any overpayments by the Seller to the Buyer, then the Seller shall have the right to
credit the amount of the overpayment against each subsequent quarterly Royalty Payment due to the Buyer until the overpayment has been
fully applied. If the overpayment is not fully applied prior to the final quarterly Royalty Payment due hereunder, the Buyer shall promptly
refund an amount equal to any such remaining overpayment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.5</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Intellectual
Property Matters</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Each
of the Seller and the Parent shall, and the Parent shall cause each applicable Guarantor to, at its sole expense, either directly or
by causing any Licensee to do so, use Commercially Reasonable Efforts to (x)&nbsp;take such actions (including taking legal action to
specifically enforce the applicable terms of any In-License or Out-License) and (y)&nbsp;prepare, execute, deliver and file any and all
agreements, documents or instruments, in each case ((x)&nbsp;and (y)) that are necessary to diligently prosecute and maintain, and to
avoid disclaimer or abandonment of, the Patent Rights in the Territory. Each of the Seller and the Parent shall, and the Parent shall
cause each applicable Guarantor to, use Commercially Reasonable Efforts to ensure that all patent applications in the Patent Rights are
diligently prosecuted with the intent to protect all Products in the Territory. In the exercise of its reasonable business discretion,
each of the Seller and the Parent shall, and the Parent shall cause each applicable Guarantor to, use Commercially Reasonable Efforts
to diligently defend or assert the Patent Rights against material infringement or interference by any other Persons in the Territory,
and against any material claims of invalidity or unenforceability asserted by a Third Party in a court or administrative proceeding (including
any reexamination, <i>inter partes</i> review, opposition, or like proceeding), in each case where such infringement, interference, or
claim of invalidity or enforceability outside of the United States would reasonably be expected to have a Material Adverse Effect, including,
without limitation, by bringing any legal action for infringement or defending any counterclaim of invalidity or action of a Third Party
for declaratory judgment of non-infringement or non-interference, or by otherwise abating such infringement or claims of invalidity or
unenforceability. Notwithstanding any other obligation of the Parent or the Seller under this &lrm;Section&nbsp;6.5(a), each of the Seller
and the Parent shall, and the Parent shall cause each applicable Guarantor to, (i)&nbsp;reasonably and in good faith evaluate and respond
to (A)&nbsp;certifications made by a Third Party under paragraph IV of 21 U.S.C. &sect;355(j)(2)(A)(vii)&nbsp;or &sect;355(b)(2)(A)&nbsp;with
respect to any Orange Book Patent and (B)&nbsp;any claim of invalidity or unenforceability by a Third Party against an Orange Book Patent,
including in each case by initiating an appropriate legal action and (ii)&nbsp;not disclaim or abandon any Orange Book Patents.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall provide to the Buyer a copy of any written notice received by the Parent or any member of the Seller Group from a Third
Party alleging or claiming that the making, having made, using, importing, offering for sale or selling of a Product infringes or misappropriates
any Patents or other intellectual property rights of such Third Party, together with copies of material correspondence sent or received
by the Parent or any member of the Seller Group related thereto, as soon as practicable and in any event not more than [***] following
such delivery or receipt.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall promptly inform the Buyer of any infringement by a Third Party of any Patent Right of which any of the individuals named
in the definition of &ldquo;Knowledge of the Parent&rdquo; (or the successors of such Person at the Parent) becomes aware. Without limiting
the foregoing, the Seller shall provide to the Buyer a copy of any written notice alleging infringement of any Patent Rights that is
delivered or received by the Parent or any member of the Seller Group, as well as copies of material correspondence related thereto,
as soon as practicable and in any event not more than [***] following such delivery or receipt.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Within
[***] of initiating, or permitting a Licensee to initiate, an enforcement action regarding any suspected infringement by a Third Party
of any Patent Right, the Seller shall provide the Buyer with written notice of such enforcement action.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(e)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">If
the Parent or any member of the Seller Group recovers monetary damages from a Third Party in an action brought for such Third Party&rsquo;s
infringement of any Patent Rights relating to a Product, where such damages, whether in the form of judgment or settlement, are awarded
for such infringement of such Patent Rights, (i)&nbsp;such recovery will be allocated first to the reimbursement of any expenses incurred
by the Seller (or any party to an In-License or Permitted Licensees of such Patent Rights entitled to such reimbursement under any such
In-License or Out-License ) in bringing such action (including all reasonable attorney&rsquo;s fees), (ii)&nbsp;any remaining amounts
will be reduced, if applicable, to comply with allocation of recovered damages with licensors of such Patent Rights required under any
In-Licenses or Permitted Licensees of such Patent Rights under any Out-Licenses, if any, and (iii)&nbsp;any residual amount of such damages
after application of (i)&nbsp;and (ii)&nbsp;will be treated as Net Sales.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.6</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>In-Licenses</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall promptly (and in any event within [***] Business Days) provide the Buyer with (i)&nbsp;executed copies of any In-License
entered into by the Seller or its Affiliates, and (ii)&nbsp;executed copies of each amendment, supplement, modification or written waiver
of any provision of any In-License.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Each
of the Seller and the Parent shall, and the Parent shall cause each applicable Guarantor to, use Commercially Reasonable Efforts to comply
in all material respects with its obligations under any In-Licenses it enters into and shall not take any action or forego any action
that would reasonably be expected to result in a material breach thereof. Promptly, and in any event within [***] Business Days, after
receipt of any (written or oral) notice from a counterparty to any In-License or its Affiliates of an alleged material breach under any
In-License, the Seller shall provide the Buyer a copy thereof. Each of the Seller and the Parent shall, and the Parent shall cause each
applicable Guarantor to, use its Commercially Reasonable Efforts to cure any material breaches by it under any In-License and shall give
written notice to the Buyer upon curing any such breach. Each of the Seller and the Parent shall, and the Parent shall cause each applicable
Guarantor to, provide the Buyer with written notice following becoming aware of any party&rsquo;s material breach of its obligations
under any In-License. Each of the Seller and the Parent shall, and the Parent shall cause each applicable Guarantor to, not terminate
any In-License without providing the Buyer prior written notice. Promptly, and in any event within [***] Business Days following the
Parent&rsquo;s, Seller&rsquo;s, or a Guarantor&rsquo;s notice to a counterparty to any In-License of an alleged breach by such counterparty
under any such In-License, the Seller shall provide the Buyer a copy thereof.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.7</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Out-Licenses</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Parent shall not, and shall cause each Guarantor to not enter into an Out-License granting a license or sublicense of any Intellectual
Property Right to market, detail, promote, sell or secure reimbursement of a Product within the Territory unless it has received
the Buyer&rsquo;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed). The Seller may not enter
into an Out-License with an Affiliate granting a license or sublicense of any Intellectual Property Right to market, detail, promote,
sell or secure reimbursement of a Product within the Territory unless it has received the Buyer&rsquo;s prior written consent (such
consent not to be unreasonably withheld, conditioned or delayed). Subject to compliance with this &lrm;Section&nbsp;6.7, the Seller may
enter into an Out-License with a Third Party or enter into an agreement to research, develop or manufacture any Product in all or any
portion of the world without the Buyer&rsquo;s prior written consent; provided, that such license shall not assign or otherwise convey
title to or impose any Lien (other than Permitted Liens) on any of the Product Collateral, other than the grant of the license or sublicense
thereunder, in favor of any Third Party (any such license, a &ldquo;<u>Permitted License</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall promptly (and in any event within [***] Business Days) provide the Buyer with (i)&nbsp;executed copies of each Out-License,
and (ii)&nbsp;executed copies of each amendment, supplement, modification or written waiver of any material provision of an Out-License.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall include in all Out-Licenses (other than Existing Out-Licenses) provisions permitting the Seller to audit such Licensee and
shall use commercially reasonable efforts to include terms and conditions consistent in all material respects with the Buyer&rsquo;s
rights to audit the Seller set forth in &lrm;Section&nbsp;6.4.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall provide the Buyer prompt (and in any event within [***] Business Days) written notice of a Licensee&rsquo;s material breach
of its obligations under any Out-License of which any of the individuals named in the definition of &ldquo;Knowledge of the Parent&rdquo;
(or the successors of such Person at the Seller) becomes aware.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(e)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall provide the Buyer with written notice promptly (and in any event within [***] Business Days) following the termination of
any Out-License.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(f)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">On
or prior to the Tranche 1 Closing Date, the Parent shall cause Avadel Ireland to enter into an exclusive license with the Seller with
respect to the Commercialization of Intellectual Property Product Rights in the United States. For as long as such license is in effect,
the Parent shall own the Seller and Avadel Ireland as wholly-owned subsidiaries.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.8</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Restricted
Indebtedness</u>. Prior to the Minimum Return Date, the Parent shall not, and shall not permit any of its Subsidiaries to, create, incur,
assume or suffer to exist any Restricted Indebtedness. As a condition to the incurrence of any secured Permitted Indebtedness for borrowed
money with one or more lenders that is secured by the Product Collateral, the Buyer shall enter, and the Parent and the applicable Subsidiaries
shall enter and cause such lender or lenders or any agent, representative or trustee acting on behalf of such lender or lenders to enter
into an Acceptable Intercreditor Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.9</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Diligence</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller shall use Commercially Reasonable Efforts to Commercialize (either directly or through Licensees) the Products in the Territory.
In furtherance of the foregoing, the Seller shall use Commercially Reasonable Efforts to prepare, execute, deliver and file any and all
agreements, documents or instruments that are necessary or desirable to secure and maintain all Marketing Approvals required to Commercialize
Products in the Territory and the Seller shall use Commercially Reasonable Efforts to not withdraw or abandon, or fail to take any action
necessary to prevent the withdrawal or abandonment of, any such Marketing Approvals.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">On
a country-by-country and Product-by-Product basis, if a Loss of Market Exclusivity has occurred in such country for such Product, the
Seller&rsquo;s obligations under &lrm;Section&nbsp;6.9(a)&nbsp;shall no longer apply in such country for such Product.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.10</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Efforts
to Consummate Transactions</u>. Subject to the terms and conditions of this Agreement, each of the Buyer and the Seller and the Parent
will, and the Parent shall cause each applicable Guarantor to, use its commercially reasonable efforts prior to the Closing to take,
or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable law to consummate
the transactions contemplated by this Agreement. The Buyer and the Seller and the Parent, and the Parent shall cause each applicable
Guarantor to, agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions
as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.11</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Further
Assurances</u>. After the Closing, the Buyer and the Seller and the Parent, and the Parent shall cause each applicable Guarantor to,
agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may
be reasonably necessary in order to give effect to the transactions contemplated by this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">Section&nbsp;6.12</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Back-Up
Security Interest</u>. Notwithstanding anything herein to the contrary, the Seller and the Parent shall not (and the Parent shall procure
that no Grantor shall) enter into any contracts or arrangement or otherwise knowingly take any action or knowingly fail to act in a
manner that would, individually or in the aggregate, reasonably be expected to materially and adversely affect the Buyer&rsquo;s interest
in the Revenue Participation Right or the Back-Up Security Interest. The Buyer and Seller agree that the amendment of the 2023 Notes
Indenture, and the entry into any agreement evidencing any secured Indebtedness permitted by clause (b)&nbsp;of the definition of Restricted
Indebtedness, which shall be subject to and in compliance with an Acceptable Intercreditor Agreement, shall be deemed to not materially
and adversely affect the Buyer&rsquo;s interest in the Revenue Participation Right or the Back-Up Security Interest.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;6.13</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Certain
Tax Matters</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Seller and the Buyer agree that for Tax purposes, (a)&nbsp;the Seller and the Buyer shall treat the transactions contemplated by this
Agreement as a sale of the Revenue Participation Right and (b)&nbsp;any and all amounts remitted by the Seller to the Buyer after the
Closing Date pursuant to this Agreement shall be treated as &ldquo;royalties&rdquo; within the meaning of Article&nbsp;12 or &ldquo;Other
Income&rdquo; within the meaning of Article&nbsp;22, in each case, of the Convention Between the Government of the United States of America
and the Government of Ireland for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion With Respect to Taxes on Income
and Capital Gains (the &ldquo;<u>U.S.-Ireland Treaty</u>&rdquo;). The Buyer and Seller hereto agree not to take any position that is
inconsistent with the provisions of this &lrm;Section&nbsp;6.13(a)&nbsp;on any tax return or in any audit or other tax-related administrative
or judicial proceeding unless the other party hereto has consented in writing (such consent not to be unreasonably withheld, conditioned
or delayed) to such actions. If there is an inquiry by any Governmental Entity of the Buyer or the Seller related to the treatment described
in this &lrm;Section&nbsp;6.13(a), the Buyer and Seller hereto shall cooperate with each other in responding to such inquiry in a reasonable
manner which is consistent with this &lrm;Section&nbsp;6.13(a).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Notwithstanding
anything to the contrary in this Agreement, each of the Buyer and the Seller shall be entitled to withhold and deduct (or cause to be
withheld and deducted) from any amount payable under this Agreement to the other party any Tax that the Buyer or the Seller, as applicable,
determines that it is required to withhold and deduct under applicable law, and any such amount withheld and deducted shall be treated
for all purposes of this Agreement as being paid to the other party, with the party withholding such amount not required to pay any additional
amount to the other party in respect of such amount withheld and deducted; provided that each of the Buyer and the Seller shall give
the other party prior notice and the opportunity, in good faith, to contest and prevent such withholding and deduction. The Buyer and
Seller hereto shall use commercially reasonable efforts to give or cause to be given to the other party hereto such assistance and such
information concerning the reasons for withholding or deduction (including, in reasonable detail, the method of calculation for the deduction
or withholding thereof) as may be reasonably necessary to enable the Buyer or the Seller, as applicable, to claim exemption therefrom,
or credit therefor, or relief (whether at source or by reclaim) therefrom, and, in each case, shall furnish the Buyer or the Seller,
as applicable, with proper evidence of the taxes withheld and deducted and remitted to the relevant taxing authority. Promptly after
any assignment by the Buyer pursuant to Section&nbsp;11.4, the Buyer shall cause the assignee(s)&nbsp;to provide to the Seller (i)&nbsp;an
IRS Form&nbsp;W-8BEN-E certifying that it is exempt from U.S. federal withholding Tax in respect of payments with respect to the Revenue
Participation Right under the U.S.-Ireland Treaty and/or (ii)&nbsp;an IRS Form&nbsp;W-8IMY, accompanied by IRS Form(s)&nbsp;W-8W-8BEN-E
certifying that the applicable beneficial owner is exempt from U.S. federal withholding Tax in respect of payments with respect to the
Revenue Participation Right under an applicable United States income Tax treaty or IRS Form(s)&nbsp;W-9, from the applicable beneficial
owner, in each case, as applicable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">Section&nbsp;6.14</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Collateral
Covenants</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Parent shall promptly cause any of its Subsidiaries that may acquire, in-license or own any portion of the Product Collateral (and
in any event no later than [***] after the event leading to such acquisition, license or ownership or, if owned as of the date hereof) to enter into a joinder
agreement, in form and substance reasonably acceptable to the Buyer, to become a Grantor party and a Guarantor party to this
Agreement solely for the limited purposes provided for herein.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">The
Parent and the Seller shall use commercially reasonable efforts and cooperate with the Buyer to facilitate the delivery within [***]
days of the date of this Agreement (or within [***] days after the formation or acquisition of a Subsidiary that meets the
criteria of Section 6.14(a)) of (i)&nbsp;Irish-law governed guarantees and Irish-law governed security agreements to be executed by
Avadel Ireland and the Parent and any Joining Subsidiary incorporated in Ireland (collectively, the &ldquo;<u>Irish
Obligors</u>&rdquo;), in respect of the amounts and granting the Back-Up Security Interest in the Product Collateral owned by such
Irish Obligors, in each case consistent with the requirements of &lrm;Section&nbsp;2.1(c), (ii)&nbsp;a UCC financing statement for
each Irish Obligor in respect of the Product Collateral owned by such Irish Obligors in proper form of filing in Washington, D.C.
and (iii)&nbsp;any documents necessary to perfect under Irish law any such Back-Up Security Interest in respect of the Product
Collateral owned by such Irish Obligors. Additionally, the Parent and the Seller agree further to cause the Irish Obligors or any
Joining Subsidiary to deliver such other agreements, documents and instruments, and take any action, including to effect any
registrations, filings and notifications and obtain any consents, waivers or acknowledges, reasonably requested by the Buyer in its
good faith business judgment in order to perfect such Back-Up Security Interest in the Product Collateral owned by such Irish
Obligors under Irish law or such Joining Subsidiary under applicable law.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Notwithstanding
anything to the contrary in &lrm;this Section&nbsp;6.14 or otherwise in this Agreement, (A)&nbsp;none of the Irish Obligors or
Joining Subsidiaries (other than organized in the United Sates, any State thereof, or the District of Columbia) shall be required
(and the Parent and the Seller shall not be obligated to cause the Irish Obligors or such Joining Subsidiaries) to grant the Back-Up
Security Interest in, or perfect such Back-Up Security Interest in, under Irish law or such applicable law, respectively,
(x)&nbsp;any Product Collateral where Irish law or such applicable law does not contemplate, provide for or permit a security
interest to be granted in any such Product Collateral, including if such Back-Up Security Interest is not permitted by the terms of
any constitutional documents of the Irish Obligors, or (y)&nbsp;any Product Collateral where the burden or cost of obtaining a grant
of a Back-Up Security Interest therein or perfection thereof exceeds the practical benefit to the Buyer afforded thereby as
reasonably mutually determined by the Seller and the Buyer, unless not obtaining such grant would reasonably be expected to result
in a Material Adverse Effect, (B)&nbsp;any documents executed by the Irish Obligors or Joining Subsidiaries granting of any such
Back-Up Security Interest, or otherwise contemplated by Section&nbsp;6.14(a), Section&nbsp;6.14(b)&nbsp;or
Section&nbsp;6.14(d)&nbsp;shall (x)&nbsp;prior to the entry thereof require the completion of any necessary steps or approvals of
the Irish Obligors or Joining Subsidiaries required under Irish law or such applicable law, respectively, (y)&nbsp;include any
customary limitation language under Irish law or such applicable law, respectively as may be agreed by the Buyer and Seller, acting
reasonably and in good faith, and (z)&nbsp;shall in any case be in form and substance customary for royalty transactions in the
nature of this Agreement as may be determined by the Seller and the Buyer, each acting reasonably and in good faith.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">In
furtherance of the foregoing, the Parent agrees to cause each of the Joining Subsidiaries and the Irish Obligors which own Product Collateral
to take such other action consistent with the requirements of &lrm;Section&nbsp;6.14(b)&nbsp;as shall be necessary or appropriate to
establish, create, preserve, protect and perfect the Back-Up Security Interest in favor of the Buyer in the Product Collateral under
U.S. law,&nbsp;Irish law (in the case of the Irish Obligors), and other applicable law, and to execute such other collateral documents
in form and substance reasonably acceptable to the Buyer, as may be reasonably required or requested by the Buyer in connection with
the actions contemplated hereby.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">ARTICLE&nbsp;7</font><br>
INDEMNIFICATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;7.1</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>General
Indemnity</u>. From and after the Closing:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">the
Seller hereby agrees to indemnify, defend and hold harmless the Buyer and its Affiliates and its and their directors, managers, trustees,
officers, agents and employees (the &ldquo;<u>Buyer Indemnified Parties</u>&rdquo;) from, against and in respect of all Losses suffered
or incurred by the Buyer Indemnified Parties to the extent arising out of or resulting from (i)&nbsp;any breach of any of the representations
or warranties of the Seller in this Agreement, and (ii)&nbsp;any breach of any of the covenants or agreements of the Seller in this Agreement;
and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">the
Buyer hereby agrees to indemnify, defend and hold harmless the Seller and its Affiliates and its and their directors, officers, agents
and employees (the &ldquo;<u>Seller Indemnified Parties</u>&rdquo;) from, against and in respect of all Losses suffered or incurred by
the Seller Indemnified Parties to the extent arising out of or resulting from (i)&nbsp;any breach of any of the representations or warranties
of the Buyer in this Agreement, and (ii)&nbsp;any breach of any of the covenants or agreements of the Buyer in this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">Section&nbsp;7.2</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Notice
of Claims</u>. If either a Buyer Indemnified Party, on the one hand, or a Seller Indemnified Party, on the other hand (such Buyer Indemnified
Party on the one hand and such Seller Indemnified Party on the other hand being hereinafter referred to as an &ldquo;<u>Indemnified Party</u>&rdquo;),
has suffered or incurred any Losses for which indemnification may be sought under this &lrm;ARTICLE&nbsp;7, the Indemnified Party shall
so notify the other party from whom indemnification is sought under this &lrm;ARTICLE&nbsp;7 (the &ldquo;<u>Indemnifying Party</u>&rdquo;)
promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the
method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement
in respect of which such Loss shall have occurred. If any claim, action, suit or proceeding is asserted or instituted by or against a
Third Party with respect to which an Indemnified Party intends to claim any Loss under this &lrm;ARTICLE&nbsp;7, such Indemnified Party
shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense
of such claim, action, suit or proceeding. A failure by an Indemnified Party to give notice and to tender the defense of such claim,
action, suit or proceeding in a timely manner pursuant to this &lrm;Section&nbsp;7.2 shall not limit the obligation of the Indemnifying
Party under this &lrm;ARTICLE&nbsp;7, except to the extent such Indemnifying Party is actually prejudiced thereby.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;7.3</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Limitations
on Liability</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Other
than with respect to fraud, gross negligence, or willful misconduct, in no event shall the Seller&rsquo;s aggregate liability for Losses
under Section&nbsp;7.1(a)&nbsp;exceed the Losses Cap less the payments actually received by the Buyer in respect of the Revenue Participation
Right as of the date any claim for Losses is made.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Except
for claims arising from a breach of confidentiality obligations under &lrm;ARTICLE&nbsp;8 or in cases of fraud, gross negligence, or
willful misconduct, no party hereto shall be liable for any consequential, punitive, special or incidental damages under this &lrm;ARTICLE&nbsp;7
(and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of
such party (including under this &lrm;ARTICLE&nbsp;7) in or pursuant to this Agreement. In connection with the foregoing, the Buyer and
the Seller acknowledge and agree that (i)&nbsp;the Buyer&rsquo;s damages, if any, for any such action or claim will typically include
Losses for Royalty Payments that the Buyer was entitled to receive in respect of its ownership of the Royalty Payments but did not receive
timely or at all due to such indemnifiable event and (ii)&nbsp;the Buyer shall be entitled to make claims for all such missing or delayed
Royalty Payments as Losses hereunder, and such missing or Royalty Payments shall not be deemed consequential, punitive, special, indirect
or incidental damages.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">Section&nbsp;7.4</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Exclusive
Remedy</u>. Except as set forth in &lrm;Section&nbsp;11.11, from and after the Effective Date, the rights of the Buyer and Seller pursuant
to (and subject to the conditions of) this &lrm;ARTICLE&nbsp;7 shall be the sole and exclusive remedy of the Buyer and Seller and their
respective Affiliates with respect to any Losses (whether based in contract, tort or otherwise) resulting from or relating to any breach
of the representations, warranties covenants and agreements made under this Agreement or any certificate, document or instrument delivered
hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after
the Effective Date, any other claim or action in respect of any such breach. Notwithstanding the foregoing, claims for fraud, gross negligence,
or willful misconduct shall not be waived or limited in any way by this &lrm;ARTICLE&nbsp;7.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">Section&nbsp;7.5</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Tax
Treatment of Indemnification Payments</u>. For all purposes hereunder, any indemnification payments made pursuant to this &lrm;ARTICLE&nbsp;7
will be treated as an adjustment to the Purchase Price for Tax purposes to the fullest extent permitted by applicable law.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">ARTICLE&nbsp;8</font><br>
CONFIDENTIALITY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;8.1</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Confidentiality</u>.
Except as provided in this &lrm;ARTICLE&nbsp;8, &lrm;Section&nbsp;11.4 or otherwise agreed in writing by the parties, the parties hereto
agree that, during the term of this Agreement and for [***] thereafter, each party (the &ldquo;<u>Receiving Party</u>&rdquo;) shall keep
confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement
(which includes the exercise of any rights or the performance of any obligations hereunder) any information furnished to it by or on
behalf of the other party (the &ldquo;<u>Disclosing Party</u>&rdquo;) pursuant to this Agreement (such information, &ldquo;<u>Confidential
Information</u>&rdquo; of the Disclosing Party), except for that portion of such information that:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">was
already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing
Party;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">became
generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission
of the Receiving Party in breach of this Agreement or any other agreement;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(d)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">is
independently developed by the Receiving Party or any of its Affiliates, as evidenced by written records, without the use of or reference
of the Confidential Information; or</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(e)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">is
subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party without obligations of confidentiality with
respect thereto.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;8.2</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Authorized
Disclosure</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Either
party may disclose Confidential Information to the extent such disclosure is reasonably necessary in the following situations:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(i)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">prosecuting
or defending litigation;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">complying
with applicable laws and regulations, including regulations promulgated by securities exchanges;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">complying
with a valid order of a court of competent jurisdiction or other Governmental Entity;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(iv)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">for
regulatory, Tax or customs purposes;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(v)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">for
audit purposes, provided that each recipient of Confidential Information must be bound by customary and reasonable obligations of confidentiality
and non-use prior to any such disclosure;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(vi)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">disclosure
to its Affiliates and Representatives on a need-to-know basis, provided that each such recipient of Confidential Information must be
bound by contractual or professional obligations of confidentiality and non-use at least as stringent as those imposed upon the parties
hereunder prior to any such disclosure;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(vii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">upon
the prior written consent of the Disclosing Party;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(viii)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">disclosure
to its potential or actual investors, financing sources (including debt financing sources), partners, collaborators or acquirers, and
their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made
only to the extent customarily required to consummate or required to perform such investment, financing transaction partnership, collaboration
or acquisition and that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use
prior to any such disclosure;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(ix)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">as
is necessary in connection with a permitted assignment pursuant to &lrm;Section&nbsp;11.4.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Notwithstanding
the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&rsquo;s Confidential Information
pursuant to &lrm;Section&nbsp;8.2(a)(i), &lrm;(ii), &lrm;(iii)&nbsp;or &lrm;(iv), it will, except where impracticable, give reasonable
advance notice to the Disclosing Party of such disclosure and use reasonable efforts to secure confidential treatment of such information.
In any event, the Buyer shall not file any patent application based upon or using the Confidential Information of Seller provided hereunder.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Notwithstanding
anything set forth in this Agreement, materials and documentation relating to the Seller&rsquo;s Intellectual Property Rights may be
only disclosed to or accessed by the Buyer and its attorneys and auditors, without further disclosure to any other Representative of
the Buyer.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">ARTICLE&nbsp;9</font><br>
TERMINATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;9.1</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Mutual
Termination</u>. This Agreement may be terminated by mutual written agreement of the Buyer and the Seller.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;9.2</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Automatic
Termination</u>. Unless earlier terminated as provided in &lrm;Section&nbsp;9.1, following the Effective Date, this Agreement shall continue
in full force and effect until the earlier of (a)&nbsp;[***] days after such time as the Seller is no longer obligated to make any Royalty
Payments under this Agreement or (b)&nbsp;the Royalty Termination Date, at which point, in each case, this Agreement shall automatically
terminate, except with respect to any rights that shall have accrued prior to such termination.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; background-color: white"><font style="font-size: 10pt">Section&nbsp;9.3</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Survival</u>.
Notwithstanding anything to the contrary in this &lrm;ARTICLE&nbsp;9, the following provisions shall survive termination of this Agreement:
 &lrm;Section&nbsp;6.3 (Disclosures), &lrm;ARTICLE&nbsp;7 (Indemnification), &lrm;ARTICLE&nbsp;8 (Confidentiality), this &lrm;Section&nbsp;9.3
(Survival) and &lrm;ARTICLE&nbsp;11 (Miscellaneous). Termination of the Agreement shall not relieve any party of liability in respect
of breaches under this Agreement by any party on or prior to termination.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">ARTICLE&nbsp;10</font><br>
EVENTS OF DEFAULT REMEDIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;10.1</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Remedies
Upon Event of Default</u>. If any Event of Default under clause (d)&nbsp;of the definition thereof has occurred and is continuing, the
Seller shall immediately pay the Royalty Cap (less the aggregate of all of the payments of the Seller in respect of the Royalty Payments
made to the Buyer prior to such date) to the Buyer or the Buyer&rsquo;s designee without demand, presentment, notice of demand or of
dishonor and nonpayment, protest, notice of protest, notice of intention to accelerate, declaration or notice of acceleration or any
other notice or declaration of any kind, all of which are hereby expressly waived by the Seller. In addition, if any other Event of Default
has occurred and is continuing, the Buyer may declare any or all of the Royalty Cap (less the aggregate of all of the payments of the
Seller in respect of the Royalty Payments made to the Buyer prior to such date) immediately due and payable (and all of such amounts
shall thereupon be immediately due and payable, without demand, presentment, notice of demand or of dishonor and nonpayment, protest,
notice of protest, notice of intention to accelerate, declaration or notice of acceleration or any other notice or declaration of any
kind, all of which are hereby expressly waived by the Seller) or otherwise exercise all rights and remedies available to it under this
Agreement and applicable law. Notwithstanding anything to the contrary in this Agreement, after the occurrence and during the continuation
of an Event of Default but prior to the occurrence of a Recharacterization Event, the Buyer shall not be entitled to, and the Buyer agrees
that it shall not, exercise any rights as a secured creditor under the UCC other than rights provided to a purchaser of accounts or payment
intangibles in respect of such purchased accounts or payment intangibles.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase">ARTICLE&nbsp;11</font><br>
MISCELLANEOUS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.1</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Headings</u>.
The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits and Schedules
are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation
of this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.2</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Notices</u>.
All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, facsimile, courier
service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party
hereto in accordance with this &lrm;Section&nbsp;11.2:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Seller, the Parent, or Avadel Ireland, to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Avadel CNS Pharmaceuticals, LLC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">c/o Avadel Pharmaceuticals PLC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; background-color: white">16640 Chesterfield Grove Road,
Suite&nbsp;200</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; background-color: white">Chesterfield, MO 63005<br>
Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal Department<br>
Email: [***]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Goodwin Procter LLP<br>
100 Northern Avenue<br>
Boston, MA 02210<br>
Attention: Robert E. Puopolo<br>
Email: RPuopolo@goodwinlaw.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Buyer, to it at:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">RTW Royalty II DAC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">2nd Floor</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Palmerston House</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Denzille Lane</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Dublin 2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">D02 WD37</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Ireland</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">RTW Investments, LP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">40 10th Avenue, Floor 7</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">New York, NY 10014</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Attn: Roderick Wong and Tony Nguyen</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Email: [***]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Gibson, Dunn&nbsp;&amp; Crutcher LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">555 Mission Street</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">San Francisco, CA 94105</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Attention: Ryan Murr; Todd Trattner</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">E-mail: rmurr@gibsondunn.com; ttrattner@gibsondunn.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All notices and communications under this Agreement shall be deemed
to have been duly given (i)&nbsp;when delivered by hand, if personally delivered, (ii)&nbsp;when sent, if sent by facsimile, with an
acknowledgement of sending being produced by the sending facsimile machine, (iii)&nbsp;when sent, if by email with PDF attachment, with
an acknowledgement of receipt being produced by the recipient&rsquo;s email account, or (iv)&nbsp;one Business Day following sending
within the United States by overnight delivery via commercial one-day overnight courier service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.3</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Expenses</u>.
Within [***] Business Days following the Effective Date, the Seller shall reimburse the Buyer for the Transaction Expenses incurred prior
to or on the Effective Date. Upon each of the Tranche 1 Closing and, if applicable, the Tranche 2 Closing, the Seller shall reimburse
the Buyer for any and all other Transaction Expenses incurred prior to or on such Closing Date. Except as otherwise provided herein,
all fees, costs and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation,
execution and delivery of this Agreement and to consummate the transactions contemplated hereby shall be paid by the party hereto incurring
such fees, costs and expenses.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.4</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Assignment</u>.
No Grantor may assign, in whole or in part, this Agreement, any of its rights or obligations hereunder, or any of its rights in a
Product, including any Product Rights, without the Buyer&rsquo;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, the Parent may assign this agreement in its entirety without
the Buyer&rsquo;s prior written consent, to a Third Party in connection with a Change of Control, provided that upon closing such
Change of Control, the Parent causes such Third Party to deliver a writing to the Buyer, in form and substance reasonably acceptable
to the Buyer, in which it assumes all of the obligations of Parent to the Buyer under this Agreement, and such Third Party shall be
deemed an assignee of the Parent under this Agreement. For the avoidance of doubt and subject to
Section&nbsp;6.7, nothing in this Section&nbsp;11.4 shall restrict the Seller from licensing any Product Rights pursuant to a
Permitted License, from transferring the Marketing Approvals for any jurisdiction to a Licensee in connection with a Permitted
License covering such jurisdiction, or incurring any Permitted Indebtedness. Prior to the Tranche 1 Closing, the Buyer may assign
this Agreement in whole or in part to one or more of its Affiliates. Following the Tranche 2 Closing, or if after August&nbsp;31,
2024, the Tranche 2 Closing has not occurred, then following the Tranche 1 Closing, the Buyer may assign this Agreement in whole or
in part to any Person, including to any Third Party or to one or more of its Affiliates. This Agreement shall be binding upon, inure
to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns.&nbsp; Any
purported assignment in violation of this &lrm;Section&nbsp;11.4 shall be null and void.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.5</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Amendment
and Waiver</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">This
Agreement may be amended, modified or supplemented only in a writing signed by each of the Buyer and the Seller; <u>provided</u> that
any amendment, modification or supplement to &lrm;Section&nbsp;11.4, this &lrm;Section&nbsp;11.5, or &lrm;Section&nbsp;11.14 shall also
require the written consent of the Parent, Avadel Ireland, or any other Grantor. Any provision of this Agreement may be waived only in
a writing signed by the party hereto granting such waiver.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">No
failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise
of any other right, power or remedy. No course of dealing between the parties hereto shall be effective to amend, modify, supplement
or waive any provision of this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.6</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Entire
Agreement</u>. This Agreement, the Exhibits annexed hereto and the Disclosure Schedule constitute the entire understanding between the
parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto.
Upon execution of this Agreement, the Confidential Disclosure Agreement between RTW Investments, LP and the Parent, effective as of September&nbsp;15,
2022 is hereby terminated without further force and effect, superseded by &lrm;ARTICLE&nbsp;8 of this Agreement and all obligations among
the parties relating to confidentiality shall be governed by &lrm;ARTICLE&nbsp;8 of this Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.7</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>No
Third Party Beneficiaries</u>. This Agreement is for the sole benefit of the Seller and the Buyer and their permitted successors and
assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such
successors and assigns, any legal or equitable rights hereunder, except that the Indemnified Parties shall be third party beneficiaries
of the benefits provided for in &lrm;Section&nbsp;7.1.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.8</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Governing
Law</u>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect
to any choice or conflict of law provision or rule&nbsp;that would cause the application of the laws of any other jurisdiction.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.9</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Jurisdiction;
Venue</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">EACH
OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE
JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY
APPELLATE COURT THEREOF,&nbsp;IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT
OF ANY JUDGMENT IN RESPECT THEREOF, AND THE BUYER, THE PARENT AND THE SELLER HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS
IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY&nbsp;BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW,&nbsp;IN SUCH FEDERAL COURT. THE BUYER, THE PARENT AND THE SELLER HEREBY AGREE THAT A FINAL JUDGMENT IN ANY
SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY&nbsp;BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER
MANNER PROVIDED BY APPLICABLE LAW. EACH OF THE BUYER, THE PARENT AND THE SELLER HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION
AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS. THE BUYER, THE PARENT AND THE SELLER AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, THAT PROCESS MAY&nbsp;BE SERVED ON THE BUYER, THE PARENT OR THE SELLER IN THE SAME MANNER THAT NOTICES MAY&nbsp;BE GIVEN PURSUANT
TO SECTION&nbsp;&lrm;11.2 HEREOF.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">EACH
OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY&nbsp;LEGALLY AND EFFECTIVELY DO SO,
ANY OBJECTION THAT IT MAY&nbsp;NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO
THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT. EACH OF THE BUYER, THE PARENT AND THE SELLER HEREBY IRREVOCABLY WAIVES, TO THE
FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY
SUCH COURT.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">(c)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt; text-transform: uppercase">Each
Party hereby jointly and severally waives any and all right to trial by jury in any action or proceeding relating to this Agreement or
any other document delivered hereunder or in connection herewith, or any transaction arising from or connected to any of the foregoing.
Each of the Parties represents that this waiver is knowingly, willingly, and voluntarily given</font><font style="font-size: 10pt">.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.10</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Severability</u>.
If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any
jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a
manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain
in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation
or jurisdiction.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.11</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Specific
Performance</u>. Each of the parties acknowledges and agrees that the other party would be damaged irreparably in the event any of the
provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated. Accordingly,
each of the parties agrees that, without posting bond or other undertaking, the other party will be entitled to seek an injunction or
injunctions to prevent breaches or violations of the provisions of this Agreement and to seek to enforce specifically this Agreement
and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state
thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in
equity. Each of the parties further agrees that, in the event of any action for specific performance in respect of such breach of violation,
it will not assert the defense that a remedy at law would be adequate.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.12</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Counterparts</u>.
This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed
counterparts transmitted by telecopy, facsimile or other similar means of electronic transmission, including &ldquo;PDF,&rdquo; shall
be considered original executed counterparts, provided receipt of such counterparts is confirmed.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.13</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Relationship
of the Parties</u>. The relationship between the Buyer and the Seller is solely that of purchaser and seller, and neither the Buyer nor
the Seller has any fiduciary or other special relationship with the other party or any of its Affiliates. This Agreement is not a partnership
or similar agreement, and nothing contained herein shall be deemed to constitute the Buyer and the Seller as a partnership, an association,
a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes. The Buyer and the Seller agree
that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Entity.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.14</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt"><u>Guaranty</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(a)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">Each
Guarantor (i)&nbsp;hereby unconditionally guarantees the due and punctual payment and full and timely performance of all of
Seller&rsquo;s obligations and commitments under this Agreement, (ii) hereby unconditionally guarantees that the Revenue
Participation Right will be sold at each Closing as contemplated by this Agreement and (iii) without limiting the foregoing or being
limited thereby, hereby further covenants to procure and cause Seller to take such actions that may be necessary or useful to
support and duly complete the performance of Seller&rsquo;s obligations and commitments under this Agreement, including in relation
to Buyer&rsquo;s exercise of its rights under this Agreement, (collectively, (i), (ii), and (iii) the
 &ldquo;<u>Guaranty</u>&rdquo;). This Guaranty is an irrevocable guaranty of payment and performance (and not just of collection) and
shall continue in effect notwithstanding any extension or modification of the terms of this Agreement, any assumption of any such
guaranteed obligations by any other party or any other act or event that might otherwise operate as a legal or equitable discharge
of any Guarantor. Each Guarantor hereby waives all its rights to subrogation arising out of any payment or performance by such
Guarantor under this Guaranty. The obligations of each Guarantor hereunder shall be absolute and unconditional, and shall not be
affected by or contingent upon (a)&nbsp;the liquidation or dissolution of, or the merger or consolidation of Seller with or into any
corporation, or any sale or transfer by Seller or all or any part of its property or assets, (b)&nbsp;the bankruptcy, receivership,
insolvency, reorganization or similar proceedings involving or affecting Seller, or (c)&nbsp;any modification, alteration, amendment
or addition of or to the Agreement. Each Guarantor hereby waives all suretyship defenses and protest, notice of protest, demand for
performance, diligence, notice of any other action at any time taken or omitted by Buyer and, generally, all demands and notices of
every kind in connection with this Guaranty, and Seller&rsquo;s obligations hereby guaranteed, and which such Guarantor may
otherwise assert against Buyer. This Guaranty shall continue to be effective or shall be reinstated, as the case may be, if at any
time payment or performance of any of the obligations of Seller under this Agreement is rescinded or must otherwise be restored or
returned by Buyer upon the insolvency, bankruptcy or reorganization of Seller or otherwise. Each Guarantor acknowledges that each of
the waivers set forth in this Guaranty is made with full knowledge of its significance and consequences and under the circumstances
the waivers are reasonable and not contrary to public policy. If any of said waivers is determined to be contrary to any applicable
law or public policy, such waivers shall be effective only to the extent permitted by law. Nothing in this <u>Section&nbsp;11.14 </u>shall
modify any of the limitations set forth in <u>Article&nbsp;</u>7 of this Agreement, or the maximum liability of the Seller as set
forth in this Agreement, all of which also shall apply to, and similarly limit, each Guarantor&rsquo;s obligations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white"><font style="font-size: 10pt">(b)</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<font style="font-size: 10pt">This
guaranty does not apply to any liability to the extent that it would result in the guaranty constituting unlawful financial assistance
within the meaning of section 82 of the Irish Companies Act or any equivalent and applicable provisions under the laws of the United
States or any state or district thereof.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-size: 10pt">Section&nbsp;11.15</font>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u>Section
409 Authorisation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white">(a) Each of the Parent and Avadel Ireland hereby irrevocably and unconditionally
authorizes any and each solicitor of the Buyer (the &ldquo;Buyer&rsquo;s Solicitor&rsquo;s&rdquo;) to sign or complete (whether electronically
or otherwise) on behalf of the Parent and Avadel Ireland all required security related registration forms required to be delivered to
the Companies Registration Office (the &ldquo;CRO&rdquo;) in connection with the Back-Up Security Interest and this Agreement and to file
(whether electronically or otherwise) each such registration form with the CRO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in; background-color: white">(b) In giving this authorization, each of the Parent and Avadel Ireland
agrees and acknowledges that no solicitor/client relationship exists between the Buyer&rsquo;s Solicitors and the Parent or Avadel Ireland
and that the Buyer&rsquo;s Solicitors have no liability or responsibility to the Parent or Avadel Ireland for any failure to comply with
the terms of this authorization where such failure is due to anything outside the reasonable control of the Buyer&rsquo;s Solicitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>[Signature Page&nbsp;Follows]</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above
written.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-indent: -6.55pt">SELLER:</p></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">AVADEL CNS PHARMACEUTICALS, LLC</font></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 47%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid">/s/ Gregory Divis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Name: Gregory Divis</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Title: &#8239;President</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-indent: -6.55pt">PARENT (for the
                    limited purposes provided for herein):</p></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">AVADEL PHARMACEUTICALS PLC</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 47%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid">/s/ Gregory Divis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Name: Gregory Divis</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Title: Chief Executive Officer</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-indent: -6.55pt">AS A GUARANTOR
                    (for the limited purposes provided for herein):</p></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">FLAMEL IRELAND LTD</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 47%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid">/s/ Rosemarie Tully</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Name:  Rosemarie Tully</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Title: President</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to Purchase
and Sale Agreement]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above
written.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-indent: -6.55pt">BUYER:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-indent: -6.55pt">&nbsp;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">RTW ROYALTY II DAC</font></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 47%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid">/s/ Roderick Wong, M.D.</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Name:  Roderick Wong, M.D.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Title: Authorized Attorney</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page&nbsp;to Purchase and Sale Agreement]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Exhibit&nbsp;A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LUMRYZ</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit&nbsp;B</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Bill of Sale</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain information indicated
with [***] in this document has been omitted from this exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type that
the registrant treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit&nbsp;C</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>avdl-20230329.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWauBqbOdzZR+WYkxtmB0bQnqzyIujbwtUy92tqk2YUQH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:avdl="http://avadel.com/20230329" elementFormDefault="qualified" targetNamespace="http://avadel.com/20230329">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://avadel.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avdl-20230329_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avdl-20230329_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>avdl-20230329_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>avdl-20230329_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://avadel.com/role/Cover" xlink:href="avdl-20230329.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://avadel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140226874004384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">March 29, 2023, Avadel Pharmaceuticals plc (the &#8220;Company&#8221;)
filed a Current Report on Form 8-K (the &#8220;Original 8-K&#8221;) to disclose that (i) the Company and Avadel Finance Cayman Limited,
a Cayman Islands exempted company (the &#8220;Issuer&#8221;) had entered into separate, privately negotiated exchange agreements (the &#8220;Exchange
Agreements&#8221;) with certain holders of its outstanding 4.50% exchangeable senior notes due October 2, 2023 and issued on April 4, 2022
(the &#8220;2023 Notes&#8221;) pursuant to which the Issuer will exchange approximately $96.2 million in aggregate principal amount of the
2023 Notes for an aggregate principal amount of new 6.00% exchangeable senior notes due April 1, 2027 (the &#8220;2027 Notes&#8221;) that
will be determined pursuant to the terms of the Exchange Agreements (the &#8220;Exchange Transactions&#8221;) as described in greater detail
in the Original 8-K and (ii) that Avadel CNS Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of the Company (&#8220;Avadel CNS&#8221;),
the Company, and each guarantor party thereto, and RTW Royalty II DAC (&#8220;RTW&#8221;) entered into a Purchase and Sale Agreement (the
&#8220;Royalty Purchase Agreement&#8221;), pursuant to which Avadel CNS sold to RTW the right to receive certain royalty payments from Avadel
CNS for a purchase price of up to $75.0 million in cash.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 29,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVADEL PHARMACEUTICALS PLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001012477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1341933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10
        Earlsfort Terrace<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D02 T380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1
901 5201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American
Depositary Shares*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVDL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tm2310752d2_8ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="avdl-20230329.xsd" xlink:type="simple"/>
    <context id="From2023-03-29to2023-03-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-03-29to2023-03-29">0001012477</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-03-29to2023-03-29">true</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-03-29to2023-03-29">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-03-29to2023-03-29">2023-03-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-03-29to2023-03-29">AVADEL PHARMACEUTICALS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-03-29to2023-03-29">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-03-29to2023-03-29">001-37977</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-03-29to2023-03-29">98-1341933</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-03-29to2023-03-29">10         Earlsfort Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-03-29to2023-03-29">Dublin 2</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2023-03-29to2023-03-29">IE</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2023-03-29to2023-03-29">D02 T380</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-03-29to2023-03-29">353</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-03-29to2023-03-29">1 901 5201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-03-29to2023-03-29">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-03-29to2023-03-29">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-03-29to2023-03-29">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-03-29to2023-03-29">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-03-29to2023-03-29">American Depositary Shares*</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-03-29to2023-03-29">AVDL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-03-29to2023-03-29">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-03-29to2023-03-29">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="From2023-03-29to2023-03-29">March 29, 2023, Avadel Pharmaceuticals plc (the &#x201c;Company&#x201d;)
filed a Current Report on Form 8-K (the &#x201c;Original 8-K&#x201d;) to disclose that (i) the Company and Avadel Finance Cayman Limited,
a Cayman Islands exempted company (the &#x201c;Issuer&#x201d;) had entered into separate, privately negotiated exchange agreements (the &#x201c;Exchange
Agreements&#x201d;) with certain holders of its outstanding 4.50% exchangeable senior notes due October 2, 2023 and issued on April 4, 2022
(the &#x201c;2023 Notes&#x201d;) pursuant to which the Issuer will exchange approximately $96.2 million in aggregate principal amount of the
2023 Notes for an aggregate principal amount of new 6.00% exchangeable senior notes due April 1, 2027 (the &#x201c;2027 Notes&#x201d;) that
will be determined pursuant to the terms of the Exchange Agreements (the &#x201c;Exchange Transactions&#x201d;) as described in greater detail
in the Original 8-K and (ii) that Avadel CNS Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of the Company (&#x201c;Avadel CNS&#x201d;),
the Company, and each guarantor party thereto, and RTW Royalty II DAC (&#x201c;RTW&#x201d;) entered into a Purchase and Sale Agreement (the
&#x201c;Royalty Purchase Agreement&#x201d;), pursuant to which Avadel CNS sold to RTW the right to receive certain royalty payments from Avadel
CNS for a purchase price of up to $75.0 million in cash.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M=U\Z=P]:9/;KXD)H+1+[<TWQBB)-!VQ?"KSS%@_F@V7YO?GZ?U!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !M,'Y6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( &TP?E8/J4@O[0   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &TP?E:97)PC$ 8  )PG   3
M          "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M;3!^5B+463G4!@  >Q8  !@              ("!# @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &TP?E:?H!OPL0(  .(,   -
M          "  18/  !X;"]S='EL97,N>&UL4$L! A0#%     @ ;3!^5I>*
MNQS     $P(   L              ( !\A$  %]R96QS+RYR96QS4$L! A0#
M%     @ ;3!^5JK$(A8S 0  (@(   \              ( !VQ(  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( &TP?E8D'INBK0   /@!   :
M      "  3L4  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( &TP?E9ED'F2&0$  ,\#   3              "  2 5  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  &H6      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2310752d2_8ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://avadel.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" original="tm2310752d2_8ka.htm">tm2310752d2_8ka.htm</File>
    <File>avdl-20230329.xsd</File>
    <File>avdl-20230329_lab.xml</File>
    <File>avdl-20230329_pre.xml</File>
    <File>tm2310752d2_ex10-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2310752d2_8ka.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2310752d2_8ka.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avdl-20230329_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avdl-20230329_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avdl-20230329.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "avdl",
   "nsuri": "http://avadel.com/20230329",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2310752d2_8ka.htm",
      "contextRef": "From2023-03-29to2023-03-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://avadel.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2310752d2_8ka.htm",
      "contextRef": "From2023-03-29to2023-03-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-23-038584-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-038584-xbrl.zip
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M$*!(!J%FE&^8YBSBXIG7'I>8\8UL#'<S'L,CEIXHMV -*D(3K\Z0@" ;XA-
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MT;ODQJ0[1].MY<ZG9IL ?ATC"P58/ZZ_#RR_%RU!CQ2]RW2#G2SHI-^DP4H
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M7*0$E_<.%-)9"N=/%Y>K)>J]]/RO:?J.G+W ;CG9^-1]U[K>>(3=<I^0W S
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M)/?V$,+LV<0*/"T)9(0H)0H8%G#G& DQ@&0Z"=L@#E#<D)J^,3T]40J(*OS
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M#&FXRRR5"ME[@$MY=3P*NIX8<6N@"Z2IH$$U0$D18(41#0>":N2XYC=A_ I
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M8AOGH+U$,\IB#HYT_@@L]1$FVK!&%)K$Z$([\35<?L.!_S"65V"[%AQFW40
M.P]8MZ)[.U!;>S$9<D!MNQ=M66\.=F.7E](WN[Y&B6PQ"SJ@3UZ[,%6YN)LD
MV4P&4[.E<>1?[13I5K@Y+MMBN]E#TGD'#:7])>2[K;60M+B@&JUE"9B,A6S"
M9F*@XR0ZTH =;%1"+>,)U%*A2]I%+NH(?+9$!_?;HH/[JU9&-R"UZ]TKQ'L8
M34&S6./%N.YX+$(!;RD+)W_21:S&H%51-Q6PU3\ 90Z1Z?(/;XTSM/:#Q:K5
MO]!Q^96=HO SH6928(4&U.D5)5EU73,&D6B4I,F(E5X3+NI>).V,7'3$!OJ2
MP3UM>PJUV@E,GDH#<A:]2G'*2D<8N)]@?CN(A M,(F;@I]!B0$6)YH(8*BOC
M$N%GW1=S!;>,2!3LQ8UW^CV;'-LR"WZ8!:I3&)RDA^(?ZDND6_W@QU1=\>CD
M0=3CG')+"XTA9BIWW/HV6@[;AP@CYS.;0NR\?%OS6'*ER5N,Y/!R[B,)S#-[
MIT&,W$@F+!Y6^@3<^)G9*S\PE X-[@H3A W_RB:=-DOM&#QP/_NU_FN,Z4<L
M]8V3L3834Q1%^<I@*B.-5&@K(S$4BUK!=?ZX+NN6P:67N":FY_(]-,M .Z#?
M^S;-,BA58*HQY9S,@Y"B"4$M#LPM11W <R!Q5!PBAVUAGZ^*^M;I13-0O*2@
M.)W7.TT\G(1X#ERFW4!$"PVX/?NNAR@%4T*W%/^^A;DZ3+("?WBCBW0)@MBY
M5*,=GCN]S?#B+B^?R4):U%(WQF(G7^EJM5U.!3N]]JCNFR]VB5J,F&N[O;[8
M?=GM]E^-Z;<!W)FV@"REYM(XL'[K&B_#BD&1%YN@" =%GFZ"(IN@R"8H4N>0
M*FW18,7 $H2H-<8V\HF1NXAX<]^[+K7;!33Z)MG:2]]-ZT^V+-<>HF(,"GEA
M>M.V%F3#]XFZQ P[I/$Y=NRNB$+9/L <.ZYA1.M<:?>WEVC!&:,S[N^(]$U5
MGPKM6E2?P(R8<#(9 DU40XKCQ&@, M_$R[$)8XX@KKZ)SD#^DN47ZV0:T48'
M6?;9>":</ ^&4FLM6/WUX.#CXAJ66^L@LYYT.?@F='E-%7<9E>AM!KN1:!.W
M"X-VP-)'['DR7P^C/(\)3>(*]OLBJ\CEBPF5&#^-AT5HV.]4<4DU.4MBZDMK
MZK[Y>4Z-=!)=!9GMTT$0A"Z(%Q)>9-"*@-Z0(TN*=1F7F#B4QP67\%Y7UU#'
M@0MUXB:.B3W:C/$FB=C4*,"<.';$S8F(,:<:#DCMZY".0I6R4XTA[IQ<*Z!Z
M(^2X% /A%AE,W68QH9'?/-*DOCMG>O%YIIPH80V-\UM+KZWE<^'Y<S*LX,4P
M*TIQ>[2G<GCOTH)PJ24^8WV^I?$=D,=M^&<5%\;D97>=OLDO4:3?$J+X*T'A
MI*>2>DP V"9]WWDJ>QNE?X4+#U*JZ8R3]%@<9.-'2RJC>V#@1K=#!CYL="9#
MNU=WG2, -V*8Y)M+-% J^QI;K.%'NY'J/B0Q>_I)_+%U0IUK1#.4:(!"]0S^
M2?FTPM=ZH.C76?Z"FM?GA] 5>T@KKE<,76JZCQ.>\X3,+@._K\--GI]M@8/M
MT5+1^/XD!S>J++@\2U%56K%*V6=+[LM5EG\F\$2J::$4+J :":95*7+_C#W<
M%K7,0?G),*#;[YD6F D:W8G<[F+[$G0S%J=:S?#H]/CLX-&2S^0>F)"F%>)"
MH@\+Z@"Y<X3I#&*$]V'\7*HZB(82ITX4(A=Y.2TN+]AFB%&R.-Q6/@13IDH)
M?L]F"JS?088@0JCVCM0TC>5'=R1TA4-L;F\@$7&?59!&%&-RU99KCL&C);F+
M>R Y)!C=BY6;-6';U*MH'KI=<=O ZYP>NO SM5>29JR)U7W)#@KUID>32:XF
ME!^@H:,H>!Z1DX\L(C+\)+C.1M0H"US?8B(:U1B59U,%XY!3REB>+"(-:UWD
M!WFTQ!;?GWC4@? 0\SD&YI/F7I(OQQ\<'&4BOY7DJ-<2P1I.3#7BJG#;@%%G
M9W*I&8):T@G,:P36UAPLN$EOL/7'C+D5<OOC_LB-$H>L%3;VK# @%YWO$3H.
M-^W3HAC(I\-#742,!8ZVB'@+F_%9?$%,!TDGA=_"DPNC=2Y807XDR=P)_@!2
M*$;"8K==O!ES&"P,"&6ON'EECY5S?;X',9FBTI/408,'4?K9*41GKPYA,$K;
MPS%VO<O&XP!1Y:TI0.[<@AKAC:/+C!++\%D.\H1<BXH:ME.6]+(.()K[6XR)
M?/%X_A6[G-R_XV],5>Z)[DZ'.V08 WMM/*/^V<[^WA.#>0H\ Z,LP"J,R+*2
MRCYU_3=TQ<R'EYO,!\Y\>+;)?-AD/CRJS(>_S.NGM\OK5^7N!67UDCC&R%ZA
M41\=S @GW?<,+-5X%$<Y8>UX8N  ;81$\>KN>R+  ^[BW'SVCAA#M-_#$.PJ
MP5.3GTLQ4L*)HF$3- 8%?+4OV5Q0I83-/-,=6AD0Q:!<\/V,&IWP05%?9F2.
M=0-G\+8H,+T'G1)50$S>U[:BW;Y$8;D!ZXG4%\4Q YCB=$3@XBLB EW%]/,R
MJHHL;2\%0)Y_&8\JL+W[/2S!P'.3S[+<E-!0$7088")J"@^ZB&>A*8E.8MT<
MW5Q7YD!58?!'!B9D<,G%Y90XA+YU?J8BF]!<^JN;171$;:B<TD4E?:E(H,%Y
M+/RGD0G@-(E:XYS8:[<IQ_#X:5O/ZZ!Y-,81\,GY3\M'\-TOE"PWHR?GE'E1
M28H$&LCG< 9^QSJ0,Q"LJ@S^ 5R4P!D;-=FA]'T+Z%&\,#GGZG?R<'SU>KK;
M1=ZKMG:SL*(,-,?%;%(W(DOE=X7]^IW5[0UT&0P7\& ;DX%ROENQBD? I:32
M!4\SB^R?]+!-"_5WG]Z?_O-_7CGAU2]S;*< WPPM."0P$Y[UHF$&7S/*2*,0
ME!>@U$XN@N=/GL,XMO;EQ;E"/S<[GJ3Y>QZ\JZ;Y_%_UX1E]E*[3\)9Z2N)4
M("63T:JF,]2B!=IIZXM<.(Q2GDA.0)>,:@E,B9<$IW45S=EWQN,AA7<N=TNJ
M2[\76;6'J0-T]4D\#!3%"<B;RT^L-4="B4>BK;#ZM5:IPY9&'?I:V,P0-Y!]
M>+ PVZ\";"6_-7+@/6N$JKL7TP((N12MQ7.U0=+$OYK,N\EA5BO);OB_6Y@)
MEP\[((VCAGJMH]VY]JUSGB%UR&(W+OE4S EVBZ^DX*MPSK/CFO=;148$*:N;
MX_@P@1@L-0>LZ?#G"L,P,,6%7LSA0B6&!4C]MJW+I "O.UTA6H]4.9^PX .H
M8CJ^ELCQ;)O#CP!P7M(1%OHQY!NV7$'(6@9X@Y<(QB6N8Y1.$'*_H. 'XC5J
M=[>&* Q=! -A(!9CUX/8];A=LUDTUF'"5P;DHV,ZS8UHOU&F:H2H+2ZW#$9R
M_D/3A99R ;4T0'SZ4K?H_LG2>SMX1#TB9>C?(E"C1BPQ"MN3O=!A?V#>4>+E
MK[W7%:?!@?V97"E8/<JRH;65>]S(5??+R1U\Z:&9E$8!*?SSX."#=(UR/ +1
M-OA'M,%O5"2XO[L/F]GIN9??'W)]]GS:!B+$5&%K;>LWA%XM[G[+[Q)G_9BK
MG;<5 X0U+_+ B+N]GL$' J-LKVF6A>KW:"7ETI8UE%\6+)ZY[Z$LVRD)0YH=
M5J'>Z S^L+O7[9F#\AL-T4O-?H7@Z'(Y?$X;&]H#;KW&J[!BJ.J'3:B*0U7/
M-Z&J3:CJ486JEC#(A@X[7P!DP,@>C&%45#-8'/V%CRVD'^.W+2=$2A;%1^\/
M3/,"\0W;9"*KM+M/8D<2YLT-AYRZ! <#.TI(+:@T+;W@9ILS[%,@_FPL7\-]
M) NQ1;%?8[9^@[T[PCZV!<AXM(<(TL63<(R,CGL9-LP3\N^X8.L:LP*QY,DF
M9X@8,&%&41EI.!YK'#L[IIQAN,G8C+2#03;S^[9M8I]C&BT*%;<P4UK--*FS
M <"O_5AC#!WI-RB+&J2SDMR)<Z9YY<_<>RK6AE*'*4HQY[G,;,>;JA /JW5^
MY(H;/PAV%2X6E:)FMFM)D_RX*ML=R<,@R$\S!(5K@T#&19E2&IFXAK1SP#!H
M5SY0YSH+#V40^6U2]'0&ZIW37:'-_'9(5!P!%)AR?0$$ZR^7MY%=I[?%:87T
MP$'\KU\+/(_MB]"N_;_HN $TPR)LD,P8_F@<QU 0$&KGA0/-H?6\$4.C_I"Z
M2QO]/573 8=Y)*IL&X PV@+I6@/G(3 ?D-QY*$_#>G:*'BML6)EI:$XN[\)N
M8BCFT8$QNHP+BA ;H>/.R\-+!,T[3]4<W<OL#49<6D(F1'>O^4#E0QEUA&*'
M(M7Y9"4K=?U>@JC6><%MY N^<ICMF$_,MX![3%*%N\-)L?RU;;U$ U<(J^NO
M3*=)JC6]8H'6:!+(0W&N(ZQ(%A%[R2EV0=W[4B\&H14^[P7UD)E5+^![3< -
M%-)0# O3!<=$8) @!(?2<TH'6SI-%<2.;:.X"BK<]AJ#V CX\*VU)HW6NS7I
M_SUE[(G1_UO_5./;WIK!9FO6=6N&Z[TUA])ED?(S7V/5O\OI3&KHJ;)U0=X%
MUV)Q/-1]':WWOIY=1;-^[S#31=/DJB.-%S2^U2H+ZZTP9U%1@HF, $-#;,(L
MY89DSH(HKJ0]W*S*L;(>%"!XTP7B Y#I!7(4BZ85(\\R_GH>%Y_1VZ#SEVAH
M4KZ6:XABTTM4=\SDG]:?XE9TTO^X<=*SD_[%QDF_<=(_#B?];0LCM=["R.RX
M#_UC$=K3)5TE?)0/ZOQA=9:@H;)L!UO6?CO2;UADOC&@_I;7'-W3;Z1C!(&7
MB?@92Y]S'$JJ2IO"!D.W2)D(7#]#I$O"O4>W.S5=P)II5J64](C ?V; K=$?
MXK]CI,8JXJPTN*G" _+%&6?KY$*;H^K/0\.2N,U^=''%$-/M$OQ/JM-H,:5T
M)A^V/,L;SJONK^:ON]XYWZ/8;D)38M^_5AJH(%7!@_5PE1Z7Z1AQ9UN&CC-O
MSX+KM@Q?Z0V/,IVE7X(H8BUYOE^VG9TDWOBO;=<SX2CD_=XBZ@YKD'Q;>YJ]
MC@5U9\0!NAI"%ZWI0I6?\5#0]:>+KQ!<%G,]=1<1*2]K>ZKW)(:>I!55O,Q8
M].,N^,BL],@L[DB:0#!L+7QODLBES &[EU,-.V&L$'A!-!PBHN<HP,9VBC%G
M3:*/==4MG/,H$U1<V&ZE1H'WIF#IBV <_IM:*.(O+4"P-4NJ0F?#YDS[&@0B
M;;R.:_MIVWC8TC1[3$Y-U,[=;$E=)>?&=D'T%EEJ4FTM3, L5].XFA8A%V]=
M87XD7(]#Y21=G@#."^O!"O;[Q2 7,0B$Q]9<&];Q'S58&!F<J)1LL\KP5).T
ME)Y'MO784CDA:@6I*J5J6W6S*7KY]5$?>6=]9 ^[/D[+K64RF*3;?'"-_<U(
MFJ"4%6/TFK8!]DGLHL"E<#+!N<K"Y)8VZ^8>K>4^7F]ER3^KPJ8I.MX"79=$
M5X(M#)JP1DX6A[</H*R]X*'!7;;?&&AE78_PS@!\D.CO]PCAC+X-:V>>+\V5
M8'(/*)#N@!E9.&<?[]F\TVEOBY#!7#1LE3]'7P%CA&0U^A)C N/*\3C@[7P*
M#1H7G.J$S^9@[@9AJ/)9UREXI4I^F8(;=PB=J@3-:I@S<6_$E4&AK_>IH%*D
M3S!G"4Q9ZF"Z#4) XY>1DY\QS; U(BEF;**-HCF]9SE.^V),Y\?'#29WSPV^
M@@TXB$G!+,L0]5N <RBQZDJIF2V%P6M(ZQ;)(9#@0"]$1WDTQKYMB,N#CY*T
M%EW&YH(;UK ,D=Z_GKH?'VE==(*T_%AJLR+?FE/7\;>Q6%A"B+:%YA)>^_BH
M(NZ2^N$3!P%#3:J(I#NNUW*0593(K3"JFM<@X%=>L9R_!C>5<$PVO&8A5?W1
M+:J2O1[,K^<0UE\L6TX"2^H*C9F%-QI<:&V'KL"T2(=;3DNN6]H[#DL@J]&1
M$Z,A?*&BI+S [*=" VY8A%ET;Q.KU>E/B "0@HF&AC%#6@<&T=K^XJ%A.WBU
M*AGOV$7P3N2END#@GM"HR*0 5%1(C/DY!@W$W.\ >>CC2@?XE=3;&X^I"R")
MBWV1I1GY>RBAEUB&>9)-DW*P_KC(?GBAAI]AG5 [<?01)!;-)/#'JQ2, ZQ?
M9QQPS!^+"9(22_QQT8(DXU;%;8Y!1A:2#L"Q5II?:[;RAK3G,:K<W&*7[&1M
M,=1;H7M$*M\)9:>/D05][HBZ<Q/><QM6G7="+-\1]0KLXQ&>2C"9D5]@7 M.
M(,'V\ $GZZR@)VC#-W10,T-2ZG?XW)!ICHH]9UW2_?JF]2?(U0+F^T\V 7,.
MF+_<!,PW ?/;#YBOWP;=MJ1*NJ0LKV)%UQ*B#0KB-$L5(<5Y@=?#:!9CX=X[
M"E5^\!P^B(%DNA<T@VEU^)6%D8Z[#<(VPZ[-0'Y; -P+*V, '$\8O9.B?/\N
MR$\EKWNJ^Z!5);9RP$58?Z%ZVV=G>H=GYZL<I5(FHKN2E:OW/Y6P-1&<]*^C
MNU?L?-IH@MCOV1:'3B!>0H <UD01@G:7:8OX^"@J[83=0$:J%#FU=D=TJZ"N
M$$AD2'':FJ'A<6ZN<T:)#_=';?56]E+K364[E%(NN+.B>1-I$\XX7OGY'S]9
M3:)I'..06]HNNCVZ&-^JUHT15R;T)@_S ?6&JJ_;AM]<A<#XC9O-)7F>K@\F
ME7"</"W5E>*M@;Q:YI@N4M,+MM4&RK9M4&)D,R\R>X<S*-+FK.<D<V,GH@8Z
M57;-%>>7U],6ZJO [PI-]'=I0HVT$&*1"1LQSS"]S:;HH'_$3$7G]L=3@F;D
MYDC Q4:Q+?N/J/J>= -3>"]JB/$?&3DN&07;K[1NZE*;GZ4$AFXV4;0YM%"$
M%48?O?F@8<UNHH9^<:TX3P4CL::F^..XT_P^1TU!0?6U>@I.K)Z/M-%4FG(E
M6U.Y0MQJ "<L0-MK<49E:\V&&\77'J@_JM%D*M"+%HBQQORQ0[2?@7F%UJH5
M3E()W,JR3;J2DX[2W@?J\9'9;%W)S##R.LM;Z %MW?N%-F%P,Y,0<^WNA=<N
M,@D=7_!"7CO;V(0K'($_U_0(<)8:YJ^9CE1LJ%URF% 0= 4[=K4DAVO=_:2$
MZS=S4@1WGT"I;U+7M(OF5M[9C186*[KW]S;N?7;O_[!Q[V_<^YMZN*\12/EZ
M._@IE]*F"B"O]ZONW8BQDPO=" 6T*FRL]M/][$K"MM8ZG0$-?.P>)/9"O^=W
M3 HIJ84\G1(DL)=C-DN6C/#@A(&*\G0'E9Y%N:,KCM4M\F+?BIEN/0U[B6>J
MZ3YJ0+C[0] @/XR6;#I/8<,522'7/K;U[V* GDIV7%^2'7=!NBEU9&Q0UE2I
MDEG),(^)T]32R%&A%3,2&=XDT]DM[75\H8O\/XUH7<FA!E*6BWER)>V($H1.
M&E.[;?TW;Q/:J+SW.&1RY#4P**YB=!!AO=G 5,!(!1W:'LJM9Z+R)F24VH=8
MLW[<.5)/ 5UUM\81T.LAFA9V<6Y!Z'?AL?>6=8 .=*F8!=->VB^Z?F!UAZID
MSN+(HBSU>]*6B)S)7TJ]J9W>!.G,<1C-FFCETM0&.*[7S<,'RZ?"1 -<I>T2
M. )83AB/G&TXTLU:@6US5Q[T/Z?!034!=LW/?[H7!OM/]I]Y=24-U/0E[S=>
M1AG(7QS' ]A:W72E!5=OC/8=U85R><Z(G?3,'SF5ZUQAE[;:Z:L]&8]<R&V4
M"<!N*BJH,"R[\H=)1DK"&^[(YF[K?N.I-SF:P<,]F<O (!? X;_H>DL*/7<D
MOI@1G(EF%L@%4.R2F'$=/4;%X RI]LI9=Z"F6R'0)CT3V&(RMUX6<1XSC\&8
M>>+>V>\!__18EC&0XD5G  VO;,CJ86BQ).Q;&"=:WN\?P'KS#"WS;)>.9A<.
MO^<8%I./2VR/VL+TZLTHW"%3:=\UP\9(T4KC[C")GD5CK!<YR="9U>2M'-^%
M98#9(J-%KX.7HUT8C&HT!C!+G/OW@(W"/8#D52,@;K36RRS7+Y!Z)VT/H/D"
M>YOR2!#!DD86)6 3L >/HY1R 1D6+/_$N9UQ50M!78WJ[:+:6^.)?=0*?>W6
M_:$7'IXS059%WBS4;WE\F0?*C<$D>+98E@3OVGFDZ;.CP_8.,&=<'Q$K 38X
MTJ&%0X-DT.5IF]D%!\-%W83\BW#/]WY\^K33L\;SLABSN>36J"J:=KM-CS3-
M1(\C\[)EW;(\K>3Y[AY(YXY-?:7V<K(FO\)5LR5->QB I9,4<)-E.-;>.R0"
M,KE]^7@=EOE+H).UUEY7# KM;X)"'!3Z<1,4V@2%'D=0Z%KI"5M'8C-U\V1;
M&Y#XL0?'9<W-18Q3O+491N&\IS /,APXA<-:8G$M3Q_,OM/*?-AYLH]/$MV>
M$D//=OZ/ WECU-6#;JOG,S4D*16\40D8J[#0-1^#WHRVDENVGNO>A[CN?:#-
M<C8/3Q9845+.R]; T2&95V_AE,H6/-GY+R1[[YO_'9+_V0*SA0:\(IY.U0@-
MLX3PS(:$BQ,<8J^J$5B/_U6!$&9;SCV*7(Q.6"J(TT/#-7U^;CZ8,OK,F$)H
M]@F:!MIQE/?$Z;A,0CA?YV'[@YW]YUTFH\7'6'<.@K5*$F!B^2S+M?$OO4B*
MBWB&.%,Q,%H@"IN:S=F5E!#^1P:+&F"@K,JE+@3K[$L#>"?]R8 ]DD%%?4/0
M.8IM3>:FC8BMCL=.4-NU%MB<O,^>59W*3U")#,I&\:><HFZ<_4D4AX&V7=Q,
M@Z =<#YUZ/@0\#Y^"0Z=&3[ECD\C#(V%-E-SA%%41N#B*2!PE%VGQ<LT]Q;%
MUNZ;;"1:F[F.%/"X:#WLP#QB_NK5<&8#_V0D:V$6T^@/=HY@I5O+C!"M[.NF
M1, "W*\$RX4"%ZB/)2<M)$Z;"JP9W)#;VE!5D30=EU%1*),XP&TN?)>/]U4T
M"S0F??.$N\V'V)F#:X]H[T&!=Z)24["[K<#V.P4H0/@#PE9R,3VP1-1S,%3E
M7PR\^ H+[>EA_D^(>)F-<!OTL\P7V8ROH9YM=+_]37,"N 'C(^R$D[]P ;[P
MXV@;9WK(B.^8,9 &YUN83^VW4/=Q>?6 :CEJ7]BG>-_RT_QY>LCZ=DSZ/C0-
M0-&QJ;FU5:JO/ZQ)DJ',K"UF@HD@M2\U@G_++@YS.&H[YHI%FVTN,.,N9EGI
M;((%Y_ @2]RGF,*5;#K0@1#QCYHV]1J'UVTOE9JW4AHP+J-(YI8[M[']T 57
MMK C.3 HQ<Y@4,_G&D2#F>B YW+?K )?9-)APF9K+7U"_$GRC$!_&(46ZC67
MCG"D_(L!@QYRDV)=@^YE)$:"DP!ZBO6C0UL[2>-FES::1)1&4ALR"+)!$A<7
M4F? 0+1PA6DC>D;DCF]Y8PYN$1Q8)AAJ@.CA;BCYV^[];X5FC1+]GD=@>T$%
M+E7T>XT16@CIYGK7*I32N5G%8@AS B4?]0=M)=1?;3&8?5+B6B@O4\KB[Z#&
MP8H=7EI_9(<Y_WGTQ>7W,&7O-\^II:.1N 2?=L]V@[$:H5AEN#%0*% 52#1I
MY$!@PO^(%F"ULRE<-$'&PC&_64E:X1"!C E7!14ZW7..]QJX7HP_%@IH6XK,
M,3(WDZ0Y093"[GGI:(R';I9GC,:DTLLXSZ26.)3,;[#_JY)4&)U'!]]BWMR8
MXG?T+O,$I"_,K..>:3[L$XS#A7MR@:0PDRI*'$2G&=4K>E]% SA=&1Y6^QTA
M4V.='P8=HT0.U"5)$?AV![C3%*S@*4X70V)3]G$8?:2,OKA<!IA(5!89+ER=
MUK7(P:&E&FM*UZ78@D+-+S%CKY(&L< XUY_<Q7N$"9+Q>'[M&5!Y3I ]+;1.
M5O'Z3WCQW"[BO*7?J#W(7$M+28;DY**B&FLQZ8I;^F0:]MD@:9>7QD3L*5K_
M@50)WX>/]2F^$[\]#V7X #SY3S>>?/+D[S_9>/(WGOQ'Y<F_H;BT?)-3II9$
M@YOL\FD7 ^1P2"N] HWI+W*H-Y/S_#PQ?3LEFCT,0>HG+5]'%TWBV =9VD'B
M:%\*R0*L4\=-M(H'M1"2#GESJEA[#>M&B]&J:#9SG1_T,MRH*L:& %=)X,^I
M/*;,3&G$\JS^A[&<BXL@O#6D.H.VB*FNT)*<[ZS6A>HJRY/1%5:#V?3R$U4&
M9_"H0F\'.>N:#Y]621G/DEA\C4]W7S[_VP-8]/V;&(TMQQB4S_5?A:_3"_>_
M6B]<ZX2X&ZQ)4UDT:]+OM6J+P7)E<;]SRN+7DHXN6WNTM-.V*%JM[O?J>O6U
M>:;[7:^2:JGU646C?FPL5R\.)B/7U>PV(GG ZN7^#;3LCI-)HL;EZLLB6K?D
MJR]4NW7=[ U*7=%I=@,EO=];JJ4WJV1;-J2Y# ]BBW2IY?)ZYCO4Y/N]%E4^
M6*+)/[2-T8DA;\3;W!81]QNC&P!7#LLBY!XFW\R=] 8_/\=ZLBV"KRY2=!_\
MB%;[2-H;+RB&MM3K]$IV,F_T@F+,NBIWLO'.+!MB'2HV4_;Z)]NFR7,/@)'1
M$@;J(DK&.L%F%L4@.TRB)*;9V)+@!> W7@Z0M[T891_,W=#\*(;%HF"33@]*
MU20K8YOK,(LXMU8RB-07-:SJK+E!L*%Y7!LWOVZ %JX488:N.)V VQ]3QDQS
M13DULP&"&[JY3##IG& @2<I,*RQ%=\^'BW:A1\\9K6LLG%>,M#[;1%HYTKJW
MB;1N(JV;2.M"@8A)=CO'F-R8(K0/S']^([_(B]V]IYV(I]U\68+WA"M!'K4#
M;)E]&24W\8L\ITCC0[/U/AT>+E"8/J4Q90,C^(+**9/Q,$,S@(#7U'B,<ID/
M,PR(# ?\5PJZSTHZ;V,:^#^S_+.K%.!I17PJSI=T6RM0#K+%]Z<L4:W^#N:B
M>6G5C1Y8F%1I4Z<2)-%5J"W+L:A78FO*N+'>Q/LMS=(=]QO6)I A[E0S!/N5
MUITF]5ZRD1&$R&1 PET3:JCKPU"W^=CVMH:6C;GIXTN6GFK+[-HCFC<<@#PN
M@!&[HX;;<0BT!46];T9C8VBE4IW$"_30=#,WQ]/OK4@+9!GR$+RACMWB*!FW
MOY\++"2+2&Z(P^^ISE4ZWN:NMND/W%;Z;X)[.\1FMMZ)9]T;-_LGKVR'^]Y*
M)Q.!Q,%-J%)0VPFS\6-4,JH\X3::3JSLP*&?R%%4:.7?*/FVEY(&^4'S)(EF
M!>4QZT1GS(J^S#[C'T-,Y$XXGQBA*'%H^#U\O$ (H3AE-#OX#.-#+66HB!50
MYUK$X0:&\ZO;*>J(*K#"P%0@,/".H.S/>/P9-J55MGXK0KD!R@0>H4$VFO/$
M4,6ACL%TCT?F=$9':DAD+8VGD((364IXH(H2&BD-G3^;M625ALX2ELU=*7::
M\56O:F4DSH9ADC;9A[(/PAME2-=L5Z 3>[D@EPHU>>0P>62$[3VSS%+@#M/F
MTD01A,YDKF>Y^3)7:-@)37'\RJB*>O1C.J-<3X@,3)<<SU6$<.RYM"D>"4>3
MJEWA)EQ_#)RZ90V 3? KA5DL7"SN_<R(B.T%>W? (F[M%346L7=S.&9/BNWM
M[M\7-K->JA40FH'UB?F"S3- >L]R5=+NDJMH%TN.%*S.%4IP=$F >"^ 0$F\
MC&QEL#%MG)(DKA?#DXGTDV,=$8^,>IB[[R*JFNNF%*"!ZH?\M!"4^'%1%HB>
M]>P\(1*46Y49J8E<2WZQ"'18?2=.K*0J"&757B9\-]07^U\7YAGU.X"RZL^G
MLF-2D/'JECKQ@29+JU->9?FHT$]&UI]5\B"B3WG%XH8GCXP:!VM.C=38TIKU
M@J)UD:.#5*[Q>F"VY(XH9$%6%$;&V6K+PRZ0K7&''O$)L\#D]QA,87PHUNG.
M$ S:4.]X0U,^30W7FZ8$HL(05>!\7V9UOH7?QFD+U\(?J/#5_8VY#V(H2#4W
M$ M8SBAT4VX%U9"NV.L)"WUU'R?'%$04[:L+A*7'9TM3)[+&*4Q=X0N,,=FT
M)=>_J],M$-MH38F-=A6=]@5MK6G$BK(M2HJ,0CU@A,Q,DP)@.=BY,LNEY5.!
M*$[%H]A$M::;:,&U$),+=\XZWT3L8)8''<0(6]N"@B)0Y+.D0EP5]"<5IJT#
M813<X8ZNDU08KW>#F_IY-9Y"#97&7-X ,VL+L0$/<,31'OT#/5>PD#W4-;C#
MLS(EDAYAA)^?P#!=68C>$=\>0_Y@!TQ/-^,2H(?&^SG*G:,3.F,_ $H1[45X
M@\ZFK*B QO43'@7GF:PIYZF1HVSNOSOD9@UV^'W$(#:<\E'XFYY$5^,J<?!H
M6KSG#ZH=W_--%@%G$>QOL@@V602/*HO@KXB"BVZ(@@@9NFDB1JE]0#HC'3U&
MK+>QX_\GO1/OT(%%QWO+:H3&>36=Y4MCVEJ@&VYTIU]$T#K>FX"\IM%(D0J#
MC]&M'.B^):_DJITP8'9#"I!!5M7QCD:JYYJ+J39V4:-&NH#R"Y%%_!14,[ #
M$16S29<'I^?'A^^.)*!^VY._W;'ZX8KU'*.,[N.GT\/?#LZ.0+L^.WAW%!R<
MO D.SLZ.?SUY?W1R'GQX&YS_=A2<'OWWT<FGH^ C[<+QQX/SXP\GP>GQK[^=
MKSW]W5;X:W]WKQOA+UT,AEL:B=/L@+PHNNRG,[RC8P&FFXBS U$]FG ?E"HP
MXR0C!\ZQAO/HH3NV1BH%=YCC185"X#QF#50(0@3!T7YXU*6:ZP=32C6G:F',
M*%?2UGQ+<> T*IRHJ4[R"M@_O&TSR3DSFU^N.]6&W.DU9YJ,AO0\'=?';CC<
M;*E6D+^L;>488QH$=IE@ARA,AH#WO8L5UL'(@,>2NX7?^OGK#-@("XLN $*Q
MA3.S-8!9;(WQ/Q.9S];G;1/G70@V;]NLTNO%1-T-CAU8<K.M161=9[Q27L,I
MPA]>>1F\[#.BA/84M BG \N3N?C/!K(MYQ4MXU)XALY]HW@3;6MV@S'QSI?2
MNDZ%IO*"5:%%+Y/[L*.7SBVD]7D4+.L>HI!_A67M;UA6&\NZIM/N8V%92Y=A
M598UN%V6M7Q,&Y;5B2#W35C6<4E%$-0>),7$""=O>L9-N0(.> >F1PD2>I/O
MF*QD9CUDV"\OQJ2N#D0H"'(>P1,K%7*+1T74-2BRI"J%F'),?N60VNH#\$Z@
M?SB%K[0>'"FO;B5F_^ L.2Z[0&2QY(V8(:22=Z\K'BF59'D5H2",>RM'.4VA
M@$-SJ)^3QP-@R@@;#\3\+TPF)1SO)(M2FQ[*KY;QV]X;40#+/IK@N@>-]'[X
MLM^SJ>9NY2W=.LCRG)+^@#>2O_%&!#50*7!?RNMO+#-M@+_8K>7WQF\EK!ND
M&%9.FCRR+9!Q)K;:;+H8?#H\W#95"S8U>Z"\\%>=3!1E1>IGX/#,I3;[%M./
M2Q8M7!8;43>.TMT "XW^.DH_Y]6L'()TBZZ*W> (*]6]]_L"N=_C,M/@*B*0
M^2TJ;7=+;S&!0"5CIF.O0^MVJ-=V&GU!7&Q)CW+2#3!CO%9*0NY!C3] I%K4
MVL;@D51YJ;?8HUV3)H6UM+ N=,)OZ_!KS>>OG/XEDFSEPX_8YB/.D/>6CG/+
M:*=$D_JJ'0"R=+/Z6PB*1CH'WF')B1OX9LDEA??D@%"BKM>*=Q[\BH[^+-\-
M#H;#+,=+DGF+_DF1@)M)!*,$+5,S*)^)M"DNMI 3+=VBG-"F"69+IV[<IRB=
MQ ,;UM[BCCVZ2F&;UH5FQ<,Q5>9P_JVB*].4<Q5QS^)_J<+GGU@/T%9_@UHG
MSQH6M>*9.3_6:[RD"+SM.90.9O=^.TBCJ<8$T:Q 9R\.8,>^;^,/^A)BZEB*
MA5#FWYN2>V<DI+$OEV@9G0&@[&SBU<#;_B).C=K8$0,+9(".;"$603X*-0X*
MVU%N011;)61+"<H^AJZ*HJ*>!O[A]M@Q%]>-8):Q-"!?-J"PC9ZQT&PE%4<(
M)N:G<82"ZG%LV0V^=D%QC"3N84\H)G_;PH.F0DJ2+6 Z58ZLY\TXNO1QBX"]
MDS"0 \VL5P8YR8UU80Q$E)%:]!LT&MT7?JS3!B0'L=;FGK_R\6N]9C.H6B.
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M'.K[@PX^X?!C)Z ^$M?9EYA&.\Y@W]:!>E)>_#Z/2CA^GU,ZWN?6(X9W-8;
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MZ6#O1(;MFS-"L8X&?O4^*; =\N%U1)!X9,9#\U*Q8'!U3!VI>39X(/O1.)G
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MS&Y&([ K%KE  M=-,V>+5GUPT_C=#DT=NFVFD^/PG@;7=$+SX#K)AI&+G].
MFQ=O(^ <F><\#Y8N9,'@MP,!;\XDD@,WM99G;0( .*PK;OC6UA)PVLO2]AG#
MPUQM9)9,/'<"2:>A64"'K2O0W4BB$6T3!)=2.(+ ?.V6$Y@Y$ZC;)Q57%:ZA
MK[ &+AV2"+&*V*(^Q+;06>18]=;=<A+TD[Z0]=!]8$K8O<N(RP1W0+^,'3XN
MV2U<FW:MD&]K@-F1-K(WC1 ,(4=3^8CHSG!("L,E0Z1G(&&K X9WEZDRVS2T
M03?G%K4K/2"Z\!XO.F/,C8WQ>LU(58[;6@GTBMY=!=(([;1#7".PHI*Y9BU
MK6GG]V+?W=W9W0V5%<S-=#-H&L^5[6@J/=]KO%(B/U0N$>9G2[ E;D,7KXW+
M]NS@IB7NNHJIO)_3L*;W;TZO.G,<)M=D^@#C14Y2JFK+.9%A0V/4!04G%./,
M1X]<!;G/0K]=3?1D0B0H%3%6.Y@43B71$[II59N>,=*7CRZ:3LT,;:HK;5<(
M6ZCF=QS3\C:4*A710>K+)W/D1"#5F16A+A]H\B&"GR3"9,LAYA"U<2I16!]9
MC2J'4M,NHV05 Y=(760&+%;)X:E^X>FM]S.H*#U'WLXR6(1HJVJP^'*39H3B
MNDHS(5CNK]'4]+UHV-+K+"??K("<O(B^M5L7AM23NG_[5I_J28'^5(D"O2,S
MK=F,QK6BH]H<$:Y:HF0*^9R_R ;5_[LL)B[]XJ<R[UTA+O!3CF'L*H/RPM.)
MX?$G5C1YC\"ZGSU@W?[IR?NC@\.3BZ/.\='%7RL_ [<-7_V\$L"Z?=_!I*/5
M;EGCQ##S>,RZ_O*%S59+I8142G6<[*9$-,:,V C=/T3+F?Y+X%Z UBQSU1M8
M*=-43"/4U!S1I80):;+05:"5O.P9^12-25E1+%_B>-QNN:XXF_.V37Q)N&7_
M??N@GX99$5=^B^%B=;]$/@1.,6Q4(4.J03W /=:T./EEA624D):C,&WBU0QD
M0Q$!TQC]=OK(NX$$(SBW17#:4+F0/;);E$PD/XJ!)=MKO9HZK\SO <]#\P3/
M(5S?$E_.#"9T;NIN6P2%FA\Y=]>Q50>P;=)QS$<%'J3#]U5]*OU@]<&D2^;<
M=M<MY_;S)N>V(:-:C;3;JEDCCY*O^8IUZ-$0)KH_%722H:CU]'#H:D5#Q.JC
M,2K1\3#0[B,P3?B]J& !H/BZ0) ;OZV\9'\B&&5:V$LNT\#JI.LH&;K%260C
M]7P3">T%U=+R?3\;$9F.OY 8*786LWG'/,NE? P*&12OV'GE_E:30I:51;2E
M<G3$)U<YHBJ5GXEN3;%RXE<?-"TXZ@Z;*FL.NU5(HI[E'GF,*E;NB=./QS$-
ME(A$KN-A-K:9ZNIJZ8H,*@4(5+&HQ/!T-3J(DQBCB3VP,PNFD$?H/MZV9"\G
MRRVBU&P0URT('*\ ?('\.:Y\_$@KCP6IG)3"A1='MS]#+B.</ +?-WWAN=#=
MJ$#C#4Y[4 794I6&XZ V),*Y/-4D"#A<\&2B9K>/&:U"M4.'FR[\&RWY R/0
MGRK>:27-Y,.$<4T<4<&*!Q-.FB7CFL#%CKJE9C[-+<0Y$3,<4D?FH$@F)9^[
MU8]ZT']W[YL5(GF0!5]JW<=YAK1I3%I$* ,LZ<-E :DG\G#U;9@'6I:'69?Y
M3R7"+4;Z<_=J+TU32).:2^D-5+BD=<['5+=1#B^52DRH\3#0'7_K76'_]&)]
ME_6>U_6&"QI<@T71%S95HN?K925[,OC;F*3IW[!<13\Q2"EV*QH:&*[M*EY_
MST4DHF8Y7UD^#2G;BK$Z(F0K3.)U75?CGA=C^37A%J:V<W!#RSMPZI)Q(BG^
MF<;,"%82,^]=?'D4F99KCT6N*3N<[RAPO3HZ'^@W&I9% TZQ%M+:[I7O*G[M
M?!,$K8&*X,R!7UUS*V#P'N.X_V*2O<"(,7N.C7N+EO1&&ZS=LCLL8Q19R<!E
MN/T@IO@3_CW?&W7W6$1=?@J&]DTP8RTTC^ T8<YB-"9?N1Q+E;5DO!W(UV:;
M-F[3^]JG\Q^$Z\*)(5X%C45I=^092>4U7I8[K\N-)<8XF\B)9O AGM@D!6'!
MG"5.:P?J<EFX^/U^W)W4?[$=TCE,B>F$"-FZV$5#.Q)PM["<^PC0[DARAY*6
M.A^6(+&(^E]NCNG'_G52X#ULK-N3*KDOZJQ("UFF57UX [I%"!M6FPVG%:]?
MM63B4KYQ[]>B'(TDI>GUO&5LB.(><!*9L,3.D4-H:V;I*AF[$Z5=4-U6*XSQ
MO3>UO[P(1BZ%IRQ E\1R[*T;EN.7#99C@^58!RS' [GHWQ[!*T140%+X\>9J
M]5OD(*&=CLTN-K 98/HLTPV/ =ZH-8VIU&9(DH!+Z1HS\85G5% !7>2:+C/,
M9E.B.,LB %T^=QO\O+.W%6V#Q! 0,DH(^\_$M&+0CZZQI]F$BD@,#)1;>(!C
M)BTUJ&OY)5<Q:9BAW0)CC@"T0E4C=E?UA0R$M()T0!'7T# /2Q8Q%AQ[HHF%
MEY9!5!&I.PAXM7UGZ^W*46R"2\UUWN.("? X;DV'CNNFR &%B2D+!57/M,JH
M%Q[7CZG/;9S59WD&5ZMQDU<@6.455/W(3H9J7EXWM]"M@<H J;*I+2#Z3Y^H
M/1ULX#.&CC/+FC@97HJ?S'P4YTV--XA($HRH/(VG4B2'(4'RRS2UKWW@?$27
M1>OX$2#3Q(0>\F2VVWT4QOSB%<9<')Y]/#IYWFS3OZQ$4<Q':HX$,T[]6$Q=
MP0X"55R,F3 13N1G?!ZXLY*)&[F< I6S8H_DD]G5MU_7%0&N9*C2>@U+^YG[
M6\51/DP0DVC7M%(%5;=!8-.&#H"BN33;VSBLIS'@G*1ES&3_)7P"XD!8\*0;
M90F_8!H:'1CVH%4RF5KK6S(5"#0;>:R_U!TM&&;I)=[![7 WTIZ80D: L&BI
MDYQ5S6PZ.[AT#<Y\:IWP1 @2QV!#3OQ>KC,F)-+U0= I"'U= VNI-52%2ZD3
M!\PL+22HJ+S$'O,:"N*YL<-\BF?N?NI]?WE0XJR%I_"\S*_!(Q]*K6&U+'Q>
MO\H9%8B_A!4,DT,MRENBH&?&[OK7,<._MEN-S4Q>!5L6YE:H>U$A1-BJ5"LW
M_NSG8*M2<+D=SB*DA%5JM[9TLK9)*M3ON+L;;'V$P<$YC](X*XOM'>\LBM*I
MGC0F4P&!<JU>@O@NEM3*5O,3O):!UO$,L4#\GN8V3(%C.MH]I3.W9.SUU9K%
M7M^\W,1>-]R5SS[P>H^^V^Y+SWD[_./PY.(\.'T?'!R^[WP^O@C.#C\>'AP=
MGJ_\;-S6YM]]^3#.W$(#@VB6"%+Q&6-<A]?B?1W$@Z@<3@PW/VJLZI>BWGI#
M.ANF6ZNR)\:#)$V\GKQXTI2"G",@A1KVRN5FVN=(:]$1#@\.!M([1U./]0S)
M(+<,&Z3EFI2>&%I=I29ZK0M+E12RPC#6;A'YB=<IV#>0D1]RV_^!D A4*.5B
MC-/'L0GJ@/%#W0LD=,/!*8F58BDF?4W0R4&[U4^*JRS-<LW:R@M)F[?"N[+A
M(V)75\P[QJ+@[9E7*8:%RR-%:=HKS(_D&^I,R]$F_5'N7\W;XTN"[R13+WSO
M>:SD2_$W?-MB.%72(:]O*S']17VFTU+N/0EQ5;<=]T18L(]D/:@:@(;*MIOP
MX%26_%8[R>S4Q5LI6&XGN9L=.?JH?U\TI2 X\8_)8)B)D!H8%$IV3T>,PM38
M@7?VC<+;;,)@X1YLMQY^$P:+]V"[=9=-N.W7:!J>$+R;>,Z,IV21Z5=Z)FZ/
MBW;+YUFI$!;5Z+T6^G%N<QS#:2='()4PB$/Y(H=!L28X-W7IC6217BMMYWZ$
M[3Z+>U<1YGE W_V;I_EP=A;%YX4T/3(TAD?,:40^/,&Y,M>%SCS;" 7QDG*V
MIX\=+BDL;B8X#C[O[[L%L7*513EFF"@5HJE<]A.=%_*V>/=B* D6X#*!92DJ
MIYCY3.4&_::K ^?BU7?5[M-8V_6,M8]'Y_N'Q\>=D\/3S\_8/MM])/OLGW&$
M$J*0 - %NA/:D8::C"J_(IM<V )G3+'4*[E0=5(17U/;U Y27@\%/RSOV-!4
MQMSSD%T@^7WO*NZ70SS(*%4'[*V 3$A8:J38VKY/C8((1L>M8O LFGKWVD.L
M!"&IES%0D4*ZH4-'R$)G%$>I,,*B3LE!G$^LE'OZC;YNNBD?)%.P9 LOW9,=
M7C[\Q %O]K+1J$PEP#<C$F8PF@[1F=T276(B 3,DD?Y)GP[>8[XTZET)ZC+J
M%<DH0:,&RY 2+ +%%LAB'H#X*@@Z*E2A!O]I8Y]@<:(]@.OC6&/"@Z#?!6Y7
M9K;E(QLFP 0"WA?_GPJTQ]R#2*A'<0/WL#*?\!!"8-T8P\35?#I5I#_\#DZA
MERIW>W'3=':NP>H=!D>864>C;)+]NNKOM;/W!E]-1KY_<AY\PL:042\N*=,"
M%Q\?[S_,0WL_9CIEE8<&GQ[FF7,R)+L__?3Z9;!_A:VO\P%&"X,/8%RA:Q/U
MP=H_+^%GO 1[+U]^Y\&YPPJ#CZ?!3Z]>OGS#YDAG(I[&KSRZ^?\]!C]O" 8Q
MGEF4*1)_0I'S*X<+5W?'+AE]?[UNT??=3?1]@WQ>AP"\5<6"#.YEX^D3TK(?
MLJP/5ABBZ3#$ )KU$\O?W9<O@Y.,<&\IJ$1LU<-?O,N*"88'/W:"EWM[NR^K
M(A]&T$5&]L.=X%.9C6%_>@+]3#[\GY?\9 S%@)FZZM/E&UL43@DEXD1LJZL]
M>EGLLXL_35CTZ"@XZ#R0%;4'Y__],$,*JX>X_:=H. *W G9A\,\,!-+#/.4@
M3O^=@$T='$?I0ST"2>?28.^![OYR+_CSX-7;A[F[>!0/<_.'/ 3W.>B'/ZY'
MIL 1W9Y/#_,@\#)V7X+V8C$?\MD-'FCCX"5_9?F7,#CY"V[U<O?U _F/DPDI
M(S"8$["2_\PDKG&1I=/@Y!(D>/HP#WX:GLN3-UR2;H%FR$&92NSF/Z/1^+=@
M/R\GO2NQ9![DR6_>O D^,M%G< ZV:SQYF.><1VGP/L>2YJ*7A<%^)_CE]2ZX
MV ]U6HS]-H4'?RQS<#0NLCX<F#R:8 GU YV6%WQ<\A$\\7]>TJKV84W1* 3O
M9R(/KWRSNIL4IK(2BKU1$):;J!%Q *&"R27KE\,IU7>EUN'Z>H5?:/\EC'I>
M48 O&9B8*W&<R@]"QR&C2PN*$,*O"X%#.H%<E@@I-BTWW?M,<9?0NW5CP:WV
MRY[-X>JWYF8P.;VK)(WI^<T#F!]?9MY,;#11'PMUUQM/9HS%%/ ;# @_1O*(
M%![%^CH!S*1HUA<PU*((#J*I2S 82X$3CD4J"S^GU*GI?$(T,-AE IFUJ'>I
MB71?)Q$M/F96D?HAC5_T(_>7$C /)%Z^PF[NW9,D#X+@7J*7W3A."Y,E^9,7
MD$,@[FH7"\LA#&B)CVH>)Z-NF1>QDUX?"/#HPJ&?T $@S1Y#92C;3P><&I,T
M/&XG(!B8Y8GF6X)6"W:#?2G>U,-N40VA]\L]_>6\P3MU:J;'B\&X4 )FB7<)
MS*M0XD8'R&]B&_,XO-MN36:2ALBO/PP&<4Q4)H6D.6-]FL.%@N,;8K@XU%.L
MV:INE'XAP0-WV;8#;"C>9J8<C#9'C'-*XTN0UOQ'NQ5_(SI+H0,Q9WE&;M8C
M*J$HEYTOAD/%H_&0,E6"?C&2?APE?;>CD&F4QX,G@4,3.FMB5C^UNF1T_,VZ
M1<?W-M'Q371\':+C=S<;'J0A[N*Z2T/J86J^@@^X&AFC69GT@Y Q7Z^PERPW
M/D,Q7JT4#-T> K;+66,[L[#2<D!^CO"%=NL3F;<3E[ 7?RH?2Q6\WWG 1T W
MT\-QUS+]2YJJ=K$UK,.^C3>]HD2O:;?+'4NEJ?3VPF:I%I;@3"!/E2TXQK,Y
MX4;<H D-M;YCI<Q_F9 QARX[?R-[RSX1& NO%Z*=JMR,A.%5F@R<H':KX1KG
MG>CH%VP N8^'\8@) 8]5=(V?1,!26N0SD][&.(&]V*4^1Q3N>,*<'K5+I;4>
M6EA@AJ#':;'2%0(R&:J'@&YR1IW>W^ZKJ.'2;DFC;VK^)Z!Z>:(\HNFNW/^4
MH-W76=+7UG[]K.Q.]-VEKS."NKUZQK<$8R9LKDKF>N]&-6V1PI([+*C12[(:
MC&2PFII/C<?<@T?-L/L<TU6Q=+-F8&:<&XCOQRC_$M.:=L:X@Q GHG:TQ\!,
M^U)N%C=O2O/0=DM^2,V;<]V"W@U#ECAB*/(KF4%C86<7_H'.S0YV>+7HXIH?
M4<7I\XKBB?.,W09!1V9_2I^,LMQT/;+DJ+CBKD_5X)G@W08"INZ4EV4QX05]
MM0N6^-[+O=<S?!K2QRBKM "!?I=6G+@E7[9JV#OO2H7N^K(RR11UM#)8OG!/
MBKA$\^?F8D8 J)NP_$01A,]1&DD<>3=.XT$BS:K[#/:F"GP"HW:G31U);>=R
ME__1\E?!UD)J%"5]Y"DI=G@=@@["^8D=.:^07<'$7"?9T #_9P/J7MN72Y$S
M !^#(F#U_9>[FR\/TJ=ZL?D"*]1G=#U.]I]89I%OVIW<XR1?5.I+A%@EPHE'
M:33*^LD@81NI*,?C(?T,_T9V(C3HC#5 &I0B 6[ IXETY;< UE8-%5Q.<1@H
M:J-+KL\6ZBSO^;.)Z686]>,>)CG=^-6NGFU0?!D2W!.C&@UY!@VQ0E.KN%2O
MNDA,[1T4/Y8:H2$&(],N=40RMS A#9-;"[-<XD.,<J5;/$M:FT?BYVNW!E$R
M)"8]<1,TV*EE")9_P<*TI0Q);1IR@, XS[YR62=5?4VMPR2[#XG T#&F@B5>
M22UWI:(X_1V1Z\*]V8XA/0G^>+45-7.R-S]YG,?4Q-K9K/"E\H.9.VFMK5B\
M^KE4@>F5S<] 5XHR X64 $9#SK=,OF( HD'#&_4:FS RZGV4""(-P#*P4H!X
MCVF6> EFGZ_5/PY+1AA_6K<(XZM-A''#?K$"X<5;[_I'5YM54^>GQ\E?4BC,
ML32;:/W":HU@"@JG7_'_ LL(92H(W?) TE/T- [?F$">HWBXO9^C>:KT9@0!
MD#@.;$ATZT43<H0'D0EQ/W;RB]ZSV 5U\G%%Y0G2-5-X,FRJKJ:Y>$H\?ECG
M_1T:*'FY!JB=F3@U6:UVC0IFF!U/XE$WSF6/O.&8Q1Z>3TGV.:1\52[1*G->
M:*>'[-4F+J[F)"1-IA/JBT:9,B+K<KF\JM4^!,9ZN"1@P@V>OOKFP=V/_=M'
MJNW$*F,;47I'@9]>$N6)8!FJ\:.D,/"# F-73JC(B816Z !,9&A6. A<*8X'
M"><$QV Y;:\\#NSD)J/Q$/U=WDW$10V?=D7$$+$A^EQJFSJA-*^E=F/TB@/P
MS8&JT&("\('H@')IMN1.G-R*4#)2@!^?9/CO8IYF?*HY#!.:?79/NN[LF];-
M,L,.X<& @Z-U3_GMSNXZG)6?'^6L<$]#@DL<1U\;#T>3B L%FZ>[LUXCS#J$
MFF;J*9H((8UBF(U4OV1N>1;E%*_%;=F[RJ0,&H7N,&%:"[BCZW2!WP>J6 E*
MD80T*X=]SBAQOL1A0I>!Z*"L+^DF!]9AK_WR*'OM7\XL_]9N_4%549NXZOW-
M\6%G_Y_MUNG[X.*?A\$G-$ .SX-_'IX=7IS2_[W[*S@Z.SO\XW2_\^[XKZ!S
M<A!\/MD_/3DX0I;QSC%\=O[YW<>CB_,P>']Z%L _#H_?T^_@G\'9X?FGP_V+
MHS_@YF>GGP[/+O@>G?/S0[P$GH(//OQ?^\>?S^%7[=:_/I\=G1\<[>/MD0RO
M<_)7<'+X9_#7Z=E_!><7G8O#8/_T\]E%  ][?WAP>-8YU@_X)3Z?'%T<'O!/
MB4ZO\_'P[&B_$YP?75P<G7P(CD[L#>'*DXN_0O-!R*,[^0L\@$^?D.'%/.\"
MI^/T?<C[!&Z"(^O(.,_P]?8/#P_P 1UX _S_T\\T*/CR[!!NA!_1^QZ=!YT/
M9X>''P]/+D)Z#_K)_NF'DR.]W>$)?+A//Z'EP8?]Z_/!!_P WT FUHR*QHVO
M_^[S7X=GH2XG_EJ_@84Y/CQ;=E5IA'!=!VYP#%-\W#GZ>-YN.8^649U_WO]G
M\SQ\[/S%D_7N$)[:.3N@!QT<,DT]K)%,(MUAQAJ;+?+^,XS^_ *VR@7-R2>\
MR06N-+P,K-7Q$;[+87#<^=,N$=W9VR4[-YHD=Q*"]T<P,]XBT#Z9_?[G_\29
M>X<O<R+[FY[CSHNL,\W%*2YFX!Z <WRY\\]',!,G-#SS=#QJ/'MT5;OUL7-R
M<DB/_^/HH&E6=@(\ZWI*EIT!.=RU@QK _)^?\H38\<*I@;O\<7CR^1 ?U+2P
M^ -O1<Z77!):BQG;(9BQ&\!"@>W "T@+<W[NS?[YX=D?<(U,;GT(,,O."([X
M9^<@4 *9;KKSR2FX;8?^G3_ ')T$GSZ?G7_NX':%89\?TAQ)[0S:K$A^$O !
M?I8*[3$2(?>@T/[LP.*=S]IJ<!C-0A\??F!A"7<Y?/^>-1W\?0"K?1KB:8#S
M^>Y?O/"\6=S+3T[_Q"V&P^J\O\!#UX&3)8\][OQ%2N2]/4^WTSBP^3R5HX*C
M<C"K^O1V\L*=6W\>VZWESFP@1_80>7 /3\[ES6'4L$HP%4=X+0C-SQ]UICYV
MCD[@CIV3?2MU&J?)$]G\DBM_[)9,N+Q=MX3+ZTW"90/I7HV<R\KIW>_?G$P&
MV4RD>1AA./&301YTI\'?V/%ER+5/PM&H]+2%5Q1%447*=-"Z=PGF.56&1*F3
MXE[LO3BF_(G?TZS2FX;!.QS",3O35G5:H .'%AW4*'[%42J!SKA-CZ.<,12T
MI7EOX75"RII.-8YD -H[[=:A@S[Z9/(&0DQ<:-@4QB\ "_@7%F0BG&(:4G]"
M^2?C^X;87IK:.E/AJBJVN3ME]=7?/3"8OKR?P["X:PWM8^Z-(E4,0B&/62G9
MI#.151PR52PSH]$Q@HI5 %(AD*37(*:Q"G%HXN]EZB)2Y5@4R:14T<P$T3Z4
M&:&[8:4ON(G2Q[!W04+W:%OQ<RQ*7K;KPJ*[A-'"3&@JP5ZDEH=3D?.CDL)(
M<Y0#_>N8:CNS($[H<+I I=#)7^)<<D+":>$S:SI37!*XC%C.<ZQ&3N>TTM)D
MC9G1Q/0-IXE/)N8<9W"%E%W4UM8CA_9FP$@>LT $#5JW4/+N/9$*+SZ1X[B'
MR$PJ,"![!?8P)RQ<X:L9,*?@75)>1-]MCT;F[$Q.&B"!0#0" P\6..<:U^YP
MZG?#M>(?V\[/V;-(+HS;9LR#;<R12/ZPD#>3X^ QN.-MI!<390H9-1[W=X(.
MW8NU1KL5-TV!?6-;V33."M*GW4RH\2V08!)],3!_;W82 <A9;G30\_$7K&%)
MTK_+5!4W'D?]DYK=@OZC63/=I,P;V%F+YY]]*12FYZ% X>-LYHP$CG\)P[9)
MLC6)%X%4>$8'P@>2B9T.QP!)%.-A3CVB"TUJV&<R$(%?X%]DMTK/$$IO>24M
MF: L[6+)F 7XD=A>$GZW5(%2(GQ$BY<$QZO+0[WX,$U&5@]L#<SJ3IM/B>(I
MO*WB;7C)DXEIA"K-;->Q/8=-W/.\Z/BG67+8J-*-F35*42#7W81;K5#1#AW/
M2-]27L0<SZ@/+X.5\>L@6.^)&'NA8-U')H XQRUA.=J;@.*,&+('(2T1O\,T
M[O867%PS];:9A2@73!T0>Y>$!KS/>YH93C*E$XC[5887L:$B%#H)3+HXD5*]
MQS<!:8:XJ^PR9BVM/3@5LH451GKHB@A[:-IBN_ULC,.&>^D(VBWO'<EF$L^7
MD$K#&!F@'$)O*TSH[R@GXG>^)S9ASK,4)3[?A^B0W+JH_QSVL5+ST\'[\#]S
M^B>_0+LEH!#P=7/2"/+Z9J;\>37H"B5[T</IO0WWGADDJ*;6XFC=$YW*$JVI
M1-5=)6,#?1'W4+$6L?BX_"L/J=Y4QH*+A1@E4GL1+:CM$L(>.%.9,Q@P$7R0
MWBPE]A1[-XSCX%D>)/T2,3I39]^BG(^&_O ,"8AK(/AUUW/J]-23H.O >Y!Y
ML6<D\LMH%3.%7@F8^X;TI$D>5-"8C7-')0[.LT,IP\UZAL$DXG!&@,I/ZB^L
M\L76/'2"4=72>[-/127(ZNY1P1\1\ONUYA?1-_,=+WSS&'$*I,L,?#QU7)")
M=N^%&Z,,*,C9@QLFMA36P9-R"UR,EFG-813@TL!XA*-J&C#^AWK(#X-#>JW5
MEP!+AM%_7K<P^IM-&'T31M^$T9<R >Z)&F4QP+*,<+JG3P/HQO_=>4O=*[PY
M?KDSOZ/%*L+A*%4A"T!TA7(V)*Y9IH:/A<((E_Q+=H1CVW80(QHE'#!MFX8?
M#K06?P*3B9T]'5_8]%S4_HJ&=\4K-!!RRX2+)F:0B>"!#I89KT2USF)B(>8,
M3=)+QBR.B*G#!') ;_71MR:ORU#B58*_W6I<104,#$B#24,PVR8UOAK&KA.F
MF'Y O##T"J&^BL8=D*,CC2A#DE'4I<QYTEGFB4F$P6TT?;AKI(:7\)7%,TUC
M!+>+]0H7PNH0$PJ6;6;Y1'H+#C%V Z\7BXE86;,[KY4U]R@:,I2@,(S>9]]Q
M2V8=HJ(9&P".V9 K9S ]!'N8-T7H+ =%(]5GK,@<<1^WQ1;7KU"78/@NS^/K
MC-LZ7NI7Z%(X6]V=IBVQRH._RV+"GC^/+DNWN>3!^-G8O9'B0A*03^L-(SE=
MH4!NO_)^X$3P&@J4*":%I#UCMW\KUSJ8<]'W%E&:UC<Y+AP#ZU$$D,->O+OH
MU-A@K%<IW5 UT4\*;#=Y:4N5C?"1\)L51G(0-$L*<^9L!3+>NWG&0S<)23QR
MIO1[*DE0;WVZ.@?V0<ZVTL5G[Z-"<!37Q^=6B6.XI0N"@YKAP2;PA%'H]#SC
M7 DX4IHLZ4[%LD!)001'6'X&&D%1^S'($9C#ON%<@'FD)_'*AEH(/HIA:G.Y
M&=G>9J^(H"!3BQOK99PKZV7(OA(9UA_:)1&'9Y20"$<H-]#FNKFIK]=#"L()
M)EKV3%'$&%W9ZCKO@!R:>3F>]."44K3E6GQ,C(K#:&%;\5=9?AFEVHW4\7UM
MT!E)RZ[A"I&E/)/XA[8I0V76DV?C0-VC@_FU2:RO;)@MR,TV(66IKN>DH<,R
MM7"38@7@9$JA  G9F@#[S$[.TH=W@*$'9[/"%^",7L;T3Z=MKGL@:?=SU@45
MK03U,$1A@V_&BPX#N!FC#SC)R \VY5?$*8U:.2924G+F&RE.G:/".WN.:I I
MLC*'K^ 8)"DL.YV@K:0-->=V./P=74:89.#WJ(KIBCCEN*>MI<R<XXF!$<H\
MX!#8A$'(ANA(IKN=\*F@N9PA0G0)&EG0Y)@TLG GF)4M>F@P4F9I1"K"O"V-
ML(!IH&^1[F12:L&DT*F-A>/"/2_V6#')@W]Z!L[!-8^J;6,O%TB27>+-[!0Q
M)*,(X%#C)H4MH'Z:JRVI 39M$++]S!U50&!!'1U";69,W"WL@A<B,K7W;R_)
MP0'D-'SA#P(3?H:^+M:M:]LIHYV$C4]ZP1@D8&]J6MMC9!=)<?5&Z&;&7$)K
M N;N74B#&OIC,-4X8^3=/'3I78HFJ@QBC?'!![8<$E96>T5[]'.$KZAQX:"U
M(D%NIMUP]R$9DK(/O75"PB;N!ZNN4/G[VR:+095(]"T9E<AHIY" 2I$GW;_=
M\C>":WFX209D[E%Z%)C+J6D;+4(=/J&1AQ7UVB1*UM@[? QL.9-0&:.WG\42
MG)9UY-)8LTL: #:)5AN"7,-NY)(W-;<T$6EBI,->7>B7#)(4NU)@P*; $"[*
M (\<WS0(QG8!K)=^WM-=>@2F(/ALX,; CV#$'39:R9@&&^H:3)MZPW8G^VUE
MD%N:R5EL<%?K:6RQQPPM)&:T5W^GWD. Z)[(YZRL:[=>O_PEZ)3@.L,BTIE'
M8;6ZDWC[XP[&?5!!1.JV]*G+#,3,^*'3NG<Q!(LEXFG[MX,H)8F*;D O027O
M4;]MX3_%(?:=[W.]0#]1!YF<+B2T)/]"P@1;7Z\X?6QSMCP>U][8#@C=!UI@
ML/B%F6:5F-XP5]<K<Y0N%"V@-"W'9Q5L,2KLCUF%6W@K!CB8IT.%P9E[]>E@
M@!:U.Q/[9Z?F;6=P^[^#)7WQ>8P,L3RR(PQ^@]TF::HF;,X@0?MAQE0%_DSQ
MHA%'6/55[2!@G"L<?+[#L>ANPWQJN3O3-\N^%G<M7N;0P&E@N [MIYIMFV;V
M5/S8&V(/%S^'&W]+L!M"+=-</R,6EB2#J?7$5K!5U,29[=R'VO' R!RSBRE5
M,8_IJ]A9CS()5J7&HZ3O:"P,VWP8_("1-[L(*\DEB*BW0".Y5%(--E*S<H+H
MBH#3)<80)],Y&WIBIN%%5WC?+IDU_67=LJ8_;;*F&[:W%4B9KAC;FS<2V+7)
M[__G'#Z)"!6#.Y$?RRSEQ?_]QX_)"INRR\F^5R_73?:]W<B^#6)D-<3?=PT(
MD*7^P^]')\&?1Q<GR"3QIW*O-."6R7BE.>W7>CM(1%[AMT[;,\.<[3</,%6!
MT82R*A/.M&&O$\Q0&T>W+T2)!$7 R1XD.;IAW>P:XT5,$/Z ,\XIS5X\'!;C
MJ >6\?_XX>4/]/<8TTCRMSST:]*?7.%37_['36P%D9.81([&!<@2_=</) +^
M,<GU 5CZA0ZE'C&0,S^HF)CTS=CAG^9#O!D,/?T?/^Q5)>YMO;Z?=MZ\,4):
M]](+_O2'WYD\X5<68S 2^$]^W^_A_. A;C\_1M;YHW-P>!SLGYP'G_[9.?O8
MV3_\?'&TWSD^#X/CXWT3%;S5X"I;Z<W+__BA>;S^[UXM][/7;__C(29OX8?W
M]9SY"_-N^JL[^;5)6&2/_%C\&'Q ]$X^#0Z2ZZ007IN5^>_#K]D"1GXRG+PI
MNMMNO[>176#-UZ^!1)L_@6HA;=P\NA])J/^^B@IZHW_NK'^$RV=+J&QY(-7_
M*2)/*Q%\ E8NK]A^TCI,M%1%0P6?4$%M---&,VWTU@KIK?VK)!X$A\Q%#]X1
M9ZWRC?I:/_75.0\ZP8?/G;/.R<7I6;/V4MVV!FKL_7'G(ZBQ(R3_.SD(CB\.
M-NKK2:JO,]B?(V2_#R[*X7#ZV(*754)]5*ND%5; C?D.2;!*/@5#B9^DE)O3
MZN<(5#>AQO^[NM'5)=,KNT\NI[*>29!- GB3 =ED0#8F_(U->"*6_I4GD,;P
M'9[IBLU'R8I@][.ST[\ZQQ=_!4='P4%GDPAYXO8Z_"2!S__,D WOX\[!SF.;
MQ<9F;QC9*MGM'2NZ.S##>1K/<"Q6.)+3#']JQ#XY!GOP'.WUO8V]OK'7-_;Z
MZLBA>15VW=^EARV/H_./'[LK#,B< 3+M_G[\^>/97_][M0>_I/A\M1&?&_&Y
M$9]/%.]>D:?O5ELDS7R)=PG7JZ-M^B"O\#BR]?5&MCX)V;K!TZ^/=5H7FOO/
M2.*\^2TX);*QXM?@."HF3UX ?3]I\..[TX._,-CSXS\O/A[#/_X?4$L! A0#
M%     @ ;3!^5A,J3HY" P  *0P  !$              ( !     &%V9&PM
M,C R,S S,CDN>'-D4$L! A0#%     @ ;3!^5FSRHQK_"@  ;(<  !4
M         ( !<0,  &%V9&PM,C R,S S,CE?;&%B+GAM;%!+ 0(4 Q0    (
M &TP?E;$+H:]4P<  +U8   5              "  :,.  !A=F1L+3(P,C,P
M,S(Y7W!R92YX;6Q02P$"% ,4    " !M,'Y6MA5I@30I  !FSP  $P
M        @ $I%@  =&TR,S$P-S4R9#)?.&MA+FAT;5!+ 0(4 Q0    ( &TP
M?E9W!1;G3>8  /5L!@ 6              "  8X_  !T;3(S,3 W-3)D,E]E
?>#$P+3(N:'1M4$L%!@     %  4 2@$   \F 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
